I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692605] u d y Title: A n O pe n -la bel E xte nsi o n St u d y i n Patie nts 6 5 Years or Ol der wit h 
C hr o nic L y m p h oc ytic Le u ke mia ( C L L) or S m all L y m p h oc ytic 
L y m p h o ma ( S L L) W h o Partici pate d i n St u d y P C Y C - 1 1 1 5- C A 
(I br uti ni b vers us C hl ora m b ucil) 
St u d y N u m ber: P C Y C -1 1 1 6 -C A 
Ori gi n al Pr ot oc ol D a te: 2 8 Se pte m ber 2 0 1 2 
Pr ot oc ol A me n d me nt 1 D ate: 2 8 Ma y 2 0 1 4 
Pr ot oc ol A me n d me nt 2 D ate: [ADDRESS_692606] o ber 2 0 1 6 
Pr ot oc ol A me n d me nt 3 D ate: 1 2 J ul y 2 0 1 8 
Pr ot oc ol A me n d me nt 4 D ate: [ADDRESS_692607] o ber 2 0 2 2 
I ha ve caref ull y  rea d Pr ot oc ol P C Y C - 1 1 1 6-C A A me n d me nt 4e nt it le d “A n O pe n -la b el  E xte nsi o n  
St u d y  i n Patie nts 6 5 Years or Ol der wit h C hr o nic L y m p h oc yt ic Le u ke mia ( C L L) or S m all 
L y m p h oc y ti c L y m p h o ma ( S L L) W h o Partici pate d i n St u d y  P C Y C - 1 1 1 5- C A ( I br uti ni b vers us 
C hl ora m b ucil ). ”   I a gree t o c o n d uct t his st u d y as o utli ne d herei n a n d i n c o m p lia nce wit h G o o d 
Cli nical Practices ( G C P) a n d all a p plica ble re g ulat or y  r e q ui re me nts . F urt her m ore, I u n dersta n d 
t h at t he Sp o ns or , P har mac yclics L L C , a n d t he I nstit uti o nal  Re vie w B oar d/ Researc h E t hi cs 
B oar d/I n de pe n de nt Et hics C o m mittee (I R B/ R E B/I E C) m ust a p pr o ve a n y c ha n ges t o t he pr ot oc ol 
i n writ i n g bef ore i m ple me ntati o n. 
I a gree n ot t o di v ul ge t o a n y o n e, ei t h er d uri n g or after t he ter mi nat i o n of t he st u d y , a n y  
c o nfi de nt ial i nf or mati o n ac q uire d r e gar di n g t he i n vesti gati o nal pr o d uct a n d pr ocesses or met h o ds 
of  P har mac yclics L L C . All data pertai ni n g t o t his st u d y  will be pr o vi de d t o P har mac yclics L L C . 
T he p olic y of P har mac yclics L L C ,re q ui res t hat a n y  prese ntati o n or p u blicati o n o f st u d y  data b y  
cli nical i n vest i gat or s be re vie we d b y P har mac yclics L L C , b ef ore rel ease, as s pecifie d i n t he 
pr ot oc ol .
Pri nci pal I n vesti gat or’s Si g nat ure Date 
Pri nt Na me 
T he f oll o wi n g P har mac yclics L L C re prese ntati ve is a ut h orize d t o si g n t he pr ot oc ol a n d a n y 
a me n d me nts: 
Me dical M o nit or’s Si g nat ure Date 
 M D 
Cli nical Scie nce, P har mac yclics L L C 1 5- N o v- 2 0 2 2 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692608] u d y i n Patie nts 6 5 Years or Ol der wit h C hr o nic 
L y m p h oc ytic Le u ke mia ( C L L) or S m all L y m p h oc ytic L y m p h o ma ( S L L) 
W h o Partici pate d i n St u d y P C Y C - 1 1 1 5- C A ( I br uti ni b vers us C hl ora m b ucil) 
Pr ot oc ol N u m ber P C Y C - [ADDRESS_692609] u d y ( ie, St u d y P C Y C - 1 1 1 5- C A) .
I n vesti g ati o n al Pr o d uct I br uti ni b oral ( P O) har d gelati n ca ps ule 
Refere nce T her a p y N o ne 
O bjecti ves T o m o nit or pr o gressi o n -free s ur vi val ( P F S) 
T o c o nti n ue treat me nt a n d safet y assess me n t of patie nts ra n d o mize d t o 
Ar mB ( i br uti ni b ) i n St u d y P C Y C - 1 1 1 5- C A (t he pare nt st u d y) w h o ha ve 
n ot pr o gresse d at t he ti me of pare nt st u d y cl os ure 
T o f oll o w patie nts f or l o n g -t e r m  o utc o me 
T o ca pt ure o verall res p o nse rate ( O R R), d urati o n of res p o nse ( D O R), 
P F S, a n d o verall s ur vi val (O S ), a n d ti me t o ne xt t hera p y 
T o f ulfill l o n g -t e r m  f oll o w -u p re q uire me nts of ra n d o mize d patie nts after 
cl os ure of t he pare nt st u d y, i ncl u di n g O S 
St u d y Desi g n St u d y P C Y C- [ADDRESS_692610] u d y 
P C Y C - 1 1 1 5- C A (t he pare nt st u d y) ,a n d it will r u n c o nc urre ntl y wit h t he 
pare nt st u d y . A patie nt will be tra nsferre d t o P C Y C - 1 1 1 6 -C A after 
I n de pe n de nt Re vie w C o m mittee (I R C) c o nfir mati o n of diseas e pr o gressi o n 
( P D) i n t he pare nt st u d y or at cl os ure of t he pare nt st u d y b y t he Sp o ns or , 
w hic he ver c o mes first . 
After P D, selecti o n of s e c o n d -li ne t hera p y , w he n cli nicall y i n dicate d, is at t he 
discreti o n of t he i n vesti gat or a n d ca n i ncl u de sec o n d -li ne i br uti ni b (f or 
patie nts ra n d o mize d t o c hl ora m b ucil i n t he pare nt st u d y w h o als o meet t he 
criteria f or sec o n d -li ne i br uti ni b t hera p y [ Secti o n 4. 2 ]‡)sec o n d -li ne 
c hl ora m b ucil (f or patie nts ra n d o mize d t o i br uti ni b i n t he pare nt st u d y), or 
ot her t hera pi[INVESTIGATOR_014]. 
Tra nsfer of patie nts fr o m t he pare nt st u d y a n d treat me nt i n t he e xte nsi o n 
st u d y are descri be d i n Ta ble 1. 
Assess me nts i n t he e xte nsi o n st u d y var y de pe n di n g o n t he treat me nt t o w hic h 
t he patie nt was ra n d o mize d i n t he pare nt st u d y, t he disease -pr o gressi o n stat us 
P har mac yclics, I nc. Pr o prietar y a n d C o nfi de ntial Pa ge 3of 9 7 
                                                  
‡N ote: sec o n d -li ne i br uti ni b is n ot a p plic a ble after i m ple me nt ati o n of Pr ot oc ol A me n d me nt 3 .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692611] u d y; assess me nts are s u m marize d i n t he sc he d ules of assess me nts 
(A p pe n di x A, A p pe n di x B, A p pe n di x Ca n d A p pe n di x D). 
Patie nts will be f oll o we d f or l o n g -t e r m  o utc o me , i ncl u di n g P F S, O S, O R R, 
a n d w he n a p plica ble, res p o nse t o ne xt treat me nt. 
After I m ple me nt ati o n of Pr ot oc ol A me n d me nt 3: 
Patie nts ra n d o mize d t o c hl ora m b ucil w h o ha ve n ot pr o gresse d o n t he 
st u d y a n d ha ve n ot starte d s u bse q ue nt a ntica ncer t hera p y ,a n d patie nts 
ra n d o mize d t o i br uti ni b will b e  f oll o we d o n t he st u d y. 
Patie nts ra n d o mize d t o c hl ora m b ucil w h o pr o gresse d will e xit t he st u d y. 
Sec o n d -li ne i br uti ni b patie nts will be gi ve n t he o p p ort u nit y t o e nr oll i nt o 
a se parate l o n g -t e r m  i br uti ni b e xte nsi o n st u d y if t he y meet t he eli gi bilit y 
criteria of t hat st u d y .
P o p ul ati o n T his st u d y will e nr oll patie nts [ADDRESS_692612] meet all of t he f oll o wi n g 
criteria: 
1. Ra n d o mize d i n t he pare nt s t u d y ,P C Y C -[ADDRESS_692613] u d y 
A d diti o n al Criteri a f or 
Recei vi n g Sec o n d -li ne 
Ibr uti ni b ‡
( Sec o n d -li ne i br uti ni b will 
n o l o n ger be i nitiate d 
f oll o wi n g i m ple me ntati o n of 
Pr ot oc ol A me n d me nt 3) T o recei ve sec o n d -li ne i br uti ni b , patie nts m ust meet all of t he f oll o wi n g 
criteria: 
1. I R C- c o nfir me d disease pr o gressi o n i n t he pare nt st u d y 
( P C Y C - 1 1 1 5- C A) ,or f or patie nts w h o di d n ot pr o gress i n t he pare nt 
st u d y, i n vesti gat or -deter mi ne d disease pr o gressi o n i n t he e xte nsi o n 
st u d y ( P C Y C -1 1 1 6- C A )
2. Recei ve d at least 3 c ycles of c hl ora m b ucil t hera p y 
3. D oc u me nte d, pr ot oc ol -defi ne d reas o n f or c h l ora m b ucil disc o nti n uati o n :
N o e vi de nce of res p o nse i n ra di o gra p hicall y assesse d disease 
para meters at C ycle 5 c o m pare d t o baseli ne; n o f urt her res p o nse 
( defi ne d as fail ure t o reac h at least a P R, or a platea u of res p o nse 
wit h n o f urt her i m pr o ve me nt of di s e as e  para meters) after at least 
6c ycles; c o ul d n ot t olerate treat me nt (a sit uati o n defi ne d b y t he 
r e c urre nce of t o xicit y of at least Gra de 3 des pi[INVESTIGATOR_040] a p pr o priate d ose 
re d ucti o ns a n d o pti mal s y m pt o matic ma na ge me nt); or ma xi m u m 
treat me nt of 1 2 c ycles wit h c hl ora m b ucil 
4. De m o nstrates co nt i n ua ti o n of a de q uate or ga n f u ncti o n, perf or ma n c e 
stat us , a n d ot her criteria, as f oll o ws :
Easter n C o o perati ve O nc ol o g y Gr o u p ( E C O G) stat us of 0- 2 
A de q uate he ma t ol o gic f u ncti o n, defi ne d as A N C ≥0. 7 5 x 1 0 9/ L 
(i n de pe n de nt of gr o wt h fact or s u p p ort i n t he prece di n g 7da ys) a n d 
platelet c o u nt ≥3 0 x 1 0 9/ L (i n de pe n de nt of tra nsf usi o n or gr o wt h 
fact or s u p p ort i n t he prece di n g 7 da ys) 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692614] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5A de q uate he patic f u ncti o n, defi ne d as ser u m as partate tra nsa mi nase 
( A S T) a n d ala ni n e tra nsa mi nase ( A L T) < 2. 5x u p per li mit of n or mal 
( U L N) , a n d t otal bilir u bi n ≤1. 5 x U L N ( u nless d ue t o Gil bert's 
s y n dr o me) 
A de q uate re nal f u ncti o n, defi ne d as a n esti mate d gl o mer ular 
filtrati o n rate ≥ 3 0 m L/ mi n usi n g t he C o c kcr oft -Ga ult e q uati o n 
Patie nts m ust ha ve rec o vere d fr o m ac ute t o xicities d ue t o pri or 
c he m ot hera p y, ra di ot hera p y, i n vesti gati o nal dr u gs or e x peri me ntal 
treat me nts ( n o n -he mat ol o gic t o xicities ha ve res ol ve d t o a 
N CI C T C A E [versi o n 4. 0 3 ] Gra de of ≤ 2) pri or t o rece i vi n g ne xt li ne 
i br uti ni b o n t his st u d y 
5. Meets at least 1 of t he I nter nati o nal W or ks h o p o n C hr o nic L y m p h oc ytic 
Le u ke mia (I W C L L) criteria f or acti ve disease re q uiri n g tr e at me nt 
(Halle k 2 0 0 8 ): 
E vi de nce of pr o gressi ve marr o w fail ure as ma nifeste d b y t he 
de vel o p me nt of, or w orse ni n g of, a ne mia ( he m o gl o bi n < 1 0 g/ d L) 
a n d/ or t hr o m b oc yt o pe nia ( platelets < 1 0 0, 0 0 0/ L) 
Massi ve ( ≥6 c m bel o w t he left c ostal mar gi n), pr o gressi ve, or 
s y m pt o matic s ple n o me gal y 
Massi ve n o des (at least [ADDRESS_692615] dia meter), pr o gressi ve, or 
s y m pt o matic l y m p ha de n o pat h y 
Pr o gressi ve l y m p h oc yt osis wit h a n i ncrease of m ore t ha n 5 0 % o ver a 
2- m o nt h peri o d or a l y m p h oc yte d o u bli n g ti me ( L D T) of <6m o nt hs . 
L D T m a y be o btai ne d b y li near re gressi o n e xtra p olati o n of a bs ol ute 
l y m p h oc yte c o u nts o btai ne d at i nter vals of 2 wee ks o ver a n 
o bser vati o n peri o d of 2 t o 3 m o nt hs . I n patie nts wit h i nitial bl o o d 
l y m p h oc yte c o u nts of < 3 0, 0 0 0/ L, L D T s h o ul d n ot be use d as a 
si n gle para meter t o defi ne i n dicati o n f or treat me nt . I n a d diti o n, 
fact ors c o ntri b uti n g t o l y m p h oc yt osis or l y m p ha de n o pat h y ot her t ha n 
C L L (e g, i nfecti o ns) s h o ul d be e xcl u de d. 
A ut oi m m u ne he m ol ytic a ne mia a n d/ or i m m u ne t h r o m b o c yt o pe nia 
(see defi niti o ns bel o w) t hat is p o orl y res p o nsi ve t o c ortic oster oi ds or 
ot her sta n dar d t hera p y 
(D e fi niti o ns : A ut oi m m u ne he m ol ytic a ne mia is defi ne d b y at least 
1ma r ker of he m ol ysis [i n direct bilir u bi n a b o ve t he U L N n ot d ue t o 
li ver disease, i ncrease d lactate de h y dr o ge nase [a b o v e U L N] wit h o ut 
alter nati ve eti ol o g y, or i ncrease d a bs ol ute retic ul oc yt osis [a b o ve 
U L N] or b o ne marr o w er yt hr o p oiesis i n t he a bse nce of blee di n g] ,
A N D at least 1ma r ker of direct or i n direct a ut oi m m u ne mec ha nis m 
[ p ositi ve direct a nti gl o b uli n f or I g G or C 3 d, c ol d a g gl uti ni ns] 
[Di n g 2 0 0 7 ]. A ut oi m m u ne t hr o m b oc yt o pe nia is defi ne d b y platelets 
≤ 1 0 0, 0 0 0/ L a n d i ncrease d me ga kar y oc ytes o n t he b o ne marr o w 
e xa mi nati o n.) 
C o nstit uti o nal s y m pt o ms, defi ne d as 1or m ore of t he f oll o wi n g 
disease -rel ate d s y m pt o ms or si g ns, d oc u me nte d i n t he patie nt’s 
r e c or d pri or t o ra n d o mizati o n: 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692616] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 6U ni nte nti o nal wei g ht l oss > 1 0 % wit hi n 6 m o nt hs pri or t o 
Scree ni n g 
Si g nifica nt fati g ue (i na bilit y t o w or k or perf or m us ual 
acti vities) 
Fe vers > 1 0 0. 5° F or 3 8. 0° C f or 2 or m o r e  wee ks pri or t o 
Scree ni n g wit h o ut e vi de nce of i nfecti o n 
Ni g ht s weats f or m ore t ha n 1 m o nt h pri or t o Scree ni n g wit h o ut 
e vi de nce of i nfecti o n 
6. O btai ne d t he Sp o ns or ’s a p pr o val f or sec o n d -li ne i br uti ni b t hera p y 
T o recei ve sec o n d -li ne i br uti ni b, p atie nts m ust meet N O N E of t he 
f o ll o wi n g criteri a: 
1. Disease pr o gressi o n i n v ol vi n g t he ce ntral ner v o us s yste m ( C N S )or 
tra nsf or mati o n t o a n ot her hist ol o g y 
2. I nter ve ni n g c he m ot hera p y, i m m u n ot hera p y, or i n vesti gati o nal a ge nt 
s pecificall y t o treat C L L if a d mi nistere d bef ore da te of I R C c o nfir me d 
pr o gr essi ve disease 
3. I n t he 4 wee ks bef ore d osi n g: ra diati o n t hera p y, maj or s ur ger y, or 
r e cei pt of a n i n vesti gati o nal dr u g 
4. Re q uir e me nt f or treat me nt wit h a str o n g C Y P [ADDRESS_692617] u d y 
E n d p oi nts T he e n d p oi nts of P C Y C - 1 1 1 6 -C A are as f oll o ws: 
P F S o n first -li ne t hera p y 
P F S af ter  i nitiati o n of s u bse q ue nt a nti ca ncer t hera p y ( P F S 2) 
O verall s ur vi val 
Ti me t o ne xt treat me nt 
O R R a n d D O R 
Safet y as meas ure d b y all A Es a n d s e ri o us a d verse e ve nts ( S A Es )
Disease o utc o me f oll o wi n g cessati o n of i br uti ni b t hera p y after 
attai n me nt of mi ni mal resi d ual disease ( M R D) -ne gati ve re missi o n i n 
t h ose patie nts recei vi n g i br uti ni b as sec o n d -li ne t hera p y 
Tr a nsfer fr o m 
P are nt St u d y t o 
P C Y C - [ADDRESS_692618] u d y are descri be d bel o w. 
O n g oi n g i br uti ni b 
(first -li ne t her a py) Patie nts w h o recei ve d i br uti ni b i n t he pare nt st u d y a n d ha ve n ot pr o gresse d at 
t he ti me of pare nt st u d y cl os ure will be tra nsferre d t o St u d y P C Y C - 1 1 1 6 -C A 
t o c o nti n ue o n t heir c urre nt t olerate d d ose of i br uti ni b . Treat me nt will 
c o nti n ue u ntil P D, u nacce pta ble t o xicit y, start of s u bse q ue nt a ntica ncer 
t hera p y or ot her reas o n f or treat me nt disc o nti n uati o n. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692619] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7Alte r n ative a ntic a ncer 
tre at me nt ( sec o n d -li ne 
t her a py )At t he i n vesti gat or ’s discreti o n, alter nati ve a ntica ncer treat me nt is a 
t hera pe utic o pti o n f or patie nts w h o e x perie nce P D d uri n g i br uti ni b t hera p y or 
d uri n g or after c hl ora m b ucil treat me nt . Alter nati ve treat me nt ca n als o be 
c o nsi dere d if dr u g is disc o nti n ue d f or ot her reas o ns (e g, i nt olera bilit y or 
a d verse e ve nt [ A E]). 
Selecti o n of t he dr u g(s) a n d treat me nt re gi me n(s) is at t he i n vesti gat or ’s 
discreti o n. 
F or patie nts ra n d o mize d t o i br uti ni b i n t he pare nt st u d y, c hl ora m b ucil ca n be 
use d f or sec o n d -li ne t hera p y. 
Sec o n d -li ne i br uti ni b t hera p y ‡is a treat me nt o pti o n f or t h ose patie nts w h o 
e x perie nce P D d uri n g o r after c hl ora m b ucil treat me nt a n d meet criteria f or 
c hl ora m b ucil disc o nti n uati o n i n t he pare nt st u d y . The patie nt sm ust meet t he 
criteria descri be d a b o ve (i n “ A d diti o nal Criteria f or Recei vi n g Sec o n d -li ne 
i br uti ni b ”). 
I br uti ni b d osi n g is i nitiate d at 4 2 0 m g ( 3 x 1 4 0 -m g ca ps ules), orall y, o nce 
dail y . If necessar y, t he d ose ca n be decrease d as descri be d i n t his pr ot oc ol. 
At t he i n vesti gat or ’s discreti o n, patie nts recei vi n g sec o n d -li ne i br uti ni b 
t hera p y ‡w h o ac hie ve a n d retai n M R D -ne gati ve re missi o n f or 6c ycles 
(i ncl u di n g [ADDRESS_692620] o ne b o ne marr o w as pi[INVESTIGATOR_337] ) ca n ha ve t heir i br uti ni b 
disc o nti n ue d . If sec o n d -li ne i br uti ni b is disc o nti n ue d, t he patie nt will be 
f oll o we d f or M R D rec urre nce b y peri p heral bl o o d m o nit ori n g a p pr o xi matel y 
e ver y 6c ycles; i br uti ni b t hera p y ma yb e  rei nitiate d i n t he e ve nt of rec urre nce 
of M R D p ositi ve s tat us or cli nical pr o gressi o n .
N o a ntic a ncer tre at me nt Patie nts ca n elect t o f ore g o f urt her a ntica ncer t hera p y , or patie nts ma y n ot 
ha ve met I W C L L criteria f or acti ve disease re q uiri n g a ntica ncer t hera p y .
S afet y Pl a n: AP har mac o vi gila nce C o m mittee will c o m pare a d verse e ve nts i n t he st u d y 
wit h safet y data fr o m t he e ntire cli nical trial data base f or i br uti ni b . All 
e nr olle d patie nts will be e val uate d cli nicall y a n d usi n g sta n dar d la b orat or y 
testi n g d uri n g t heir partici pati o n i n t his st u d y. 
Safet y assess me n ts will c o nsist of m o nit ori n g a n d rec or di n g A Es a n d S A Es; 
meas ure me nts of pr ot oc ol -s pecifie d he mat ol o g y, cli nical c he mistr y, a n d 
ot her la b orat or y varia bles; meas ure me nt of pr ot oc ol -s pecifie d vital si g ns; a n d 
ot her pr ot oc ol -s pecifie d tests t hat are dee me d c ritical t o t he safet y e val uati o n 
of t he st u d y dr u g(s). 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692621] atistic al Met h o ds All statistics will be descri pti ve; n o i nfere ntial h y p ot hetical tests will be 
c o n d ucte d. 
Eac h efficac y e n d p oi nt will be descri pti vel y a nal yze d b ase d o n c o m bi ne d 
data fr o m t he p ar e nt st u d y a n d St u d y P C Y C - [ADDRESS_692622] u d y P C Y C -1 1 1 6- C A, al o n g wit h O S . Me dia ns 
f or P F S a n d O S a n d t heir 9 5 % c o nfi de nce i nter vals will be esti mate d usi n g 
t he Ka pla n -Meier met h o d f or all patie nts ra n d o mize d i n S t u d y P C Y C- 1115 -C A .
T he o verall r e s p o nse rate will be descri be d b y cr u de pr o p orti o n of patie nts 
ac hie vi n g a c o m plete res p o nse ( C R )or partial res p o nse ( P R ). F or patie nts 
r e cei vi n g sec o n d -li ne i br uti ni b w h o ac hie ve M R D -ne ga ti ve re missi o n, cr u de 
pr o p orti o n, d urati o n of M R D ne gati vit y, a n d t he pr o p orti o n of patie nts w h o 
r e c ur after cessati o n of treat me nt will be calc ulate d. 
Ver bati m descri pti o ns of A Es will be c o de d t o a preferre d ter m a n d ma p pe d 
t o S yste m Or ga n Class usi n g t he c urre nt versi o n of t he Me dical Dicti o nar y 
f or Re g ulat or y Acti vities ( Me d D R A) . A Es t hat starte d d uri n g treat me nt a n d 
u p t o [ADDRESS_692623] u g are c o nsi dere d treat me nt -
e me r ge nt a n d will be ta b ulate d. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692624] u dies ................................ .................................. 1 9 
1. 5. 3. Ris ks ................................ ................................ ......................................... 2 0 
1. 5. 3. 1. Bl ee di n g -relate d E ve nts .............................................................. 2 0 
1. 5. 3. 2. Car di ac Arr h y t h mias a n d Car diac Fail ure .................................... 2 0 
1. 5. 3. 3. Ras h ................................ ............................................................ 2 0 
1. 5. 3. 4. N o n -me la n o ma s ki n ca ncer ......................................................... 2 1 
1. 5. 3. 5. I nfecti o ns ................................ .................................................... 2 1 
1. 5. 3. 6. C y t o p e ni as ................................ .................................................. 2 1 
1. 5. 3. 7. I ntersti ti al  L u n g Disease (I L D) .................................................... [ADDRESS_692625] u d y ........................................................ 2 7 
4. S E L E C TI O N O F P A TI E N T S................................ ........................................................ 2 8 
4. 1. Eli gi bilit y Cri t eri a................................ ................................ ................................ . 2 8 
4. 2. A d dit i o nal Cri t eri a f or Recei vi n g Sec o n d -li ne I br uti ni b ‡....................................... 2 8 
5. T R E A T M E N T S ................................ ................................ .............................................. 3 0 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692626] i o n, or Disc o nt i n uat i o n................................................. 3 2 
5. 2. 4. Treat me nt -relate d L y m p h oc yt osis ............................................................. 3 3 
5. 2. 5. D ose M o dificat i o n f o r He pati c I m paire d S u bjects ...................................... 3 4 
5. 2. 6. War ni n gs, Preca uti o ns, a n d A d verse Effects .............................................. 3 4 
5. 2. 6. 1. War ni n gs a n d Preca uti o ns........................................................... 3 4 
5. 3. N o n -i br uti ni b T hera pi[INVESTIGATOR_014] ................................ ........................................................ 3 5 
5. 4. Treat me nt C o m plia nce ................................ .......................................................... 3 5 
5. 5. C o nc o mita nt Me dicati o ns D uri n g I br ut i ni b T hera p y ............................................. 3 5 
5. 5. 1. Per mi tte d C o nc o mita nt Me dicati o ns .......................................................... 3 5 
5. 5. 2. C o nc o mita nt Me dicati o ns t o be Use d wit h Ca uti o n .................................... 3 6 
5. 5. 2. 1. C Y P I n hi bit i n g/I n d uci n g Dr u gs ................................................... [ADDRESS_692627] u gs T hat Ma y  Ha ve T hei r Plas ma C o nce ntrati o ns Al tere d b y 
I br uti ni b ................................ ...................................................... 3 6 
5. 5. 3. A nt i p latel et A ge nts a n d A nt ic o a g ula nts ..................................................... 3 6 
5. 5. 4. Pr o hi bite d C o nc o mit a nt Me di cat i o ns ......................................................... 3 7 
5. 6. G ui deli nes f or I br uti ni b Ma na ge me nt wit h S ur geries or Pr oce d ures ...................... 3 7 
5. 6. 1. Mi n or S ur gical Pr oce d ures ................................ ........................................ 3 7 
5. 6. 2. Maj or S ur gi cal Pr oce d ures ................................ ........................................ 3 7 
6. S T U D Y P R O C E D U R E S A N D A S S E S S M E N T S .......................................................... 3 7 
6. 1. I nf or m e d C o nse nt a n d Assess me nt of Eli gi bilit y................................................... 3 8 
6. 2. Ra n d o mizati o n a n d Bli n di n g ................................ ................................................. 3 8 
6. 3. Assess me nts a n d Pr oce d ures b y  Visi t................................ .................................... 3 8 
6. 3. 1. P C Y C - 1 1 1 6- C A Assess me nts Bef ore P D i n Ar m A Patie nts (ie, i n patie nts 
o n c hl ora m b ucil i n pare nt st u d y )............................................................... 3 8 
6. 3. 1. 1. Eli gi bilit y Visi t................................ ........................................... 3 9 
6. 3. 1. 2. D a y  1 of  E ver y  4 t h M o nt h ............................................................ 3 9 
6. 3. 1. 3. S us pecte d -P D Vi si t................................ ..................................... 3 9 
6. 3. 2. P C Y C - 1 1 1 6- C A Assess me nts Bef ore P D or e n d of i br ut i ni b t hera p y f or 
ot her reas o ns i n Ar m B Patie nts (ie, i n pat ie nt s ra n d o mize d t o I br uti ni b i n 
pare nt s t u d y )................................ ............................................................. [ADDRESS_692628] u d y  Visi t......................................................... 4 0 
6. 3. 2. 3. D a y  1 of  Desi g nate d C y cles –Efficac y Assess me nts ................... 4 1 
6. 3. 2. 4. S us pecte d -P D Vi si t................................ ..................................... 4 1 
6. 3. 2. 5. E n d -of -Treat m e nt Visi t............................................................... 4 2 
6. 3. 2. 6. Pre -P D F oll o w -u p Visi ts ............................................................. 4 2 
6. 3. 3. P C Y C - 1 1 1 6- C A Assess me nts After Disease Pr o gressi o n –Sec o n d -li ne 
I br uti ni b T hera p y ‡................................ ..................................................... 4 3 
6. 3. 3. 1. Eli gi bilit y Visi t................................ ........................................... 4 3 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692629] C ycle o n I br uti ni b ( m ust be c o m plete d wit hi n 1 4 da ys 
of  esta blis hi n g eli gi bilit y) ........................................................... [ADDRESS_692630] u d y  Cl os ure ..... 4 5 
6. 3. 3. 5. S us pecte d -P D Vi si t................................ ..................................... 4 5 
6. 3. 3. 6. E n d -of -Treat m e nt Visi t............................................................... 4 6 
6. 3. 3. 7. Pre -P D F oll o w -u p Visi ts ............................................................. 4 6 
6. 3. 4. P C Y C - 1 1 1 6- C A Assess me nts After Disease Pr o gressi o n –N o n -i br uti ni b 
S u bse q ue nt T hera p y  or N o S u bse q ue nt T hera p y ........................................ [ADDRESS_692631] or y ................................ ......................................................... 4 8 
6. 4. 3. A d verse E ve nts ................................ ......................................................... 4 8 
6. 4. 4. P h ysical E xa mi nat i o n................................ ................................................ 4 9 
6. 4. 5. Vi t al  Si g ns ................................................................................................ 4 9 
6. 4. 6. E C O G Perf or ma nce Stat us ................................ ........................................ 4 9 
6. 4. 7. C o nc o mita nt Me dicati o ns ................................ .......................................... 4 9 
6. 4. 8. P ati e nt -re p orte d O utc o mes ................................ ........................................ 4 9 
6. 4. 8. 1. E Q - 5 D- 5 L ................................ ................................................... 4 9 
6. 4. 8. 2. F A Ci T -Fat i g ue ................................ ............................................ 4 9 
6. 4. 9. H e m at ol o g y ................................ ............................................................... 5 0 
6. 4. 1 0. Se r u m  C he mistr y ................................ ....................................................... 5 0 
6. 4. 1 1. Di sease Assess me nt ................................ ................................................... 5 0 
6. 4. 1 1. 1. C o m p ute d T o m o gra p h y ( C T) Sca ns ............................................ 5 0 
6. 4. 1 1. 2. B o ne Marr o w Bi o ps y  a n d/ or As pi r at e ......................................... [ADDRESS_692632] or at or y  I n vesti g ati o ns of  Pr o g n osti c a n d Pre dicti ve Bi o mar kers a n d 
Mec ha nis m of Treat me nt Resista nce ......................................................... 5 1 
6. 4. 1 4. Alt er nat i ve A nt ic a ncer Treat m e nt .............................................................. 5 1 
7. M AI N E F FI C A C Y E V A L U A TI O N S ................................ ............................................ 5 1 
7. 1. S us pecte d Disease Pr o gressi o n ................................ .............................................. 5 2 
7. 2. G ui deli nes f or Di sease E val u ati o n ................................ ......................................... 5 2 
7. 3. S ustai ne d He mat ol o gical I m pr o ve me nt ................................ ................................ . 5 3 
7. 4. Res o l ut i o n of Pretr eat m e nt Disease -Relate d S y m pt o ms ........................................ 5 3 
7. 5. Treat me nt -Relate d Defi nit i o ns ................................ .............................................. 5 3 
7. 5. 1. C o m p ute d T o m o gra p h y Sca ns ................................ ................................... 5 3 
7. 5. 2. B o ne Marr o w As pi[INVESTIGATOR_337] a n d/ or Bi o ps y  a n d Mi ni mal  Resi d ual Disease ........ [ADDRESS_692633] a n ................................ ......................................................... 5 5 
8. 2. Defi nit i o ns ................................ ................................ ............................................ 5 5 
8. 2. 1. A d verse E ve nts ................................ ......................................................... 5 5 
8. 2. 2. S eri o us A d verse E ve nt ................................ .............................................. 5 6 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692634] it uti o nal  Re vie w B oar d (I R B), Researc h Et hics B oar d ( R E B) a n d 
I n de pe n de nt Et hics C o m mittee (I E C) A p pr o val .................................................... [ADDRESS_692635] u d y  M o ni t ori n g/ A u di t R e q ui re me nts ................................ .................................. 6 9 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692636] u d y  Disc o nt i n uat i o n................................ ........................................................... 7 1 
1 2. R E F E R E N C E S ................................ ................................ ............................................... 7 2 
1 3. A P P E N DI C E S ................................ ................................ ................................................ 7 6 
LI S T O F I N -T E X T T A B L E S 
Ta ble 1: P ati e nt Tra nsfer t o St u d y  P C Y C - 1 1 1 6- C A a n d Assess me nts wit hi n 
P C Y C -1 1 1 6- C A ................................ ................................ ................................ . 2 5 
Ta ble 2: P ati e nt Ha n dli n g after I m ple me ntati o n o f Pr ot oc ol  A me n d me nt 3 ...................... 2 6 
Ta ble 3: Dr u g Disc o nt i n uat i o n Act i o ns f or I br uti ni b f or E ve nts n ot S pecifie d i n 
Ta ble 4. ................................ ................................ .............................................. 3 3 
Ta ble 4: I br uti ni b D ose M o dificat i o ns f o r Car di ac Fail ure or Car diac Arr h yt h mias .......... 3 3 
Ta ble 5: E val ua ble Para meter Re q uire me nts ................................ .................................... 5 3 
LI S T O F I N -T E X T FI G U R E S 
Fi g ure 1: C ha n ges i n Peri p heral Bl o o d L y m p h oc y te C o u nts a n d B ur de n of 
L y m p ha de n o pat h y  i n Patie nts wi t h  C L L/ S L L, St u d y  P C Y C - 1 1 0 2- C A ............... 2 3 
LI S T O F A P P E N DI C E S 
A p pe n di x A. Sc he d ule of Assess me nts:  P C Y C -1 1 1 6- C A Assess me nts Bef ore P D i n Ar m A 
P ati e nts (ie, i n pat ie nt s o n c hl ora m b ucil i n pare nt st u d y )................................ . 7 7 
A p pe n di x B. Sc he d ule of Assess me nts:  P C Y C - 1 1 1 6- C A Assess me nts Bef ore P D i n Ar m B 
P ati e nts (ie , i n pat ie nt s o n I br uti ni b i n pare nt st u d y) ........................................ 7 9 
A p pe n di x C. Sc he d ule of Assess me nts:  P C Y C -1 1 1 6- C A Assess me nts After P D – Sec o n d -
li ne I br ut i ni b T hera p y ‡................................ .................................................... 8 1 
A p pe n di x D. Sc he d ule of Assess me nts:  P C Y C - 1 1 1 6- C A Assess me nts After P D – 
S u bse q ue nt T hera p y  ( N o n-i br ut i ni b) or N o S u bse q ue nt T hera p y ..................... 8 4 
A p pe n di x E. Defi nit i o ns of Res p o nse ( Halle k 2 0 0 8) ............................................................ 8 5 
A p pe n di x F. Cri teria f or Res p o nse Cate g ories ................................ ..................................... 8 9 
A p pe n di x G. I n hi bit ors a n d I n d ucers of C Y P 3 A ................................ .................................. 9 0 
A p pe n di x H. E C O G Stat us Sc ores ................................ ....................................................... 9 1 
A p pe n di x I.  H e m at ol o gi c A d verse E ve nt Gra di n g Sc he me ( Halle k 2 0 0 8) ........................... 9 2 
A p pe n di x J. E Q - 5 D- 5 L ................................ ................................ ....................................... 9 3 
A p pe n di x K. F A Ci T -Fat i g ue ................................ ................................ ................................ 9 6 
A p pe n di x L. C hil d -P u g h Sc ore f or S u bjects wit h Li ver I m pair me nt *................................... 9 7 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692637] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 1 4 LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N S 
A b bre vi ati o n Defi niti o n 
A E a d verse e ve nt 
A L T ala ni ne a mi n otra nsferase 
A N C a bs ol ute ne utr o p hil c o u nt 
A S C O A mer ica n S ociet y of Cli nical O nc ol o g y 
A S T as partate a mi n otra nsferase 
A U C ar e a u n der t he c ur ve 
B C R B- cell r e ce pt or 
B T K Br ut o n’s t yr osi ne ki nase 
B U N bl o o d urea nitr o ge n 
C B C c o m plete bl o o d c o u nt 
C E R T Ce nter f or E d ucati o n a n d Researc h o n T hera pe utics 
C F R C o de of Fe deral Re g ulati o ns 
c G V H D c hr o nic graft vers us h ost disease 
CI c o nfi de nce i nter val 
C L L c hr o nic l y m p h oc ytic le u ke mia 
C N S ce ntral ner v o us s yste m 
C R c o m plete re missi o n (res p o nse) 
C R F case re p ort f or m 
C Ri C R wit h i nc o m plete b o ne marr o w rec o ver y 
C T c o m p ute d t o m o gra p h y 
C T C A E C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts 
C Y P c yt oc hr o me P [ADDRESS_692638] u g A d mi nistrati o n ( U nite d States) 
FI S H fl u oresce nce i n sit u h y bri dizati o n 
G C P G o o d Cli nical Practice 
HI P A A Hea lt h I ns ura nce P orta bilit y a n d Acc o u nta bilit y Act 
HI V h u ma n i m m u n o deficie nc y vir us 
I B i n vesti gat or’s br oc h ure 
I C 5 0 half ma xi mal i n hi bit or c o nce ntrati o n 
I C F i nf or me d c o nse nt f or m 
I C H I nter nati o nal C o nfere nce o n Har m o nisati o n 
I E C I n de pe n de nt Et hics C o m mittee 
I L D i nterstitial l u n g d isease 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692639] o ge nase 
L D T l y m p h oc yte d o u bli n g ti me 
L N l y m p h n o de 
Me d D R A Me dical Dicti o nar y f or Re g ulat or y Acti vities 
M R D mi ni ma l resi d ual disease 
M RI ma g netic res o na nce i ma gi n g 
M Z L ma r gi nal z o ne l y m p h o ma 
N C C N Nati o nal C o m pre he nsi ve Ca ncer Net w or k 
N CI Nati o nal Ca ncer I nstit ute 
N H L n o n- H o d g ki n’s l y m p h o ma 
n P R n o d ular partial re missi o n (res p o nse) 
O R R O verall r e s p o nse rate 
O S o verall s ur vi val 
P D pr o gr essi ve disease 
P F S pr o gr essi o n -free s ur vi val 
P K p har mac o ki netic(s) 
P R partial res p o nse 
P R O patie nt -r e p orte d o utc o me 
Q T c c orrecte d Q T i nter val 
R E B Researc h Et hics B oar d 
R/ R r e la pse d/refract or y 
S A E seri o us a d verse e ve nt 
S A P statistical a nal ysis pla n 
S C A Rs se ver e c uta ne o us a d verse reacti o ns 
S E E R S ur veilla nce E pi [INVESTIGATOR_32450] o g y a n d E n d Res ults 
SJ S Ste ve ns -J o h ns o n s y n dr o me 
S L L s ma ll l y m p h oc ytic l y m p h o ma 
S O P sta n dar d o perati n g pr oce d ure 
S P D s u m of t he pr o d ucts of dia meters 
T L S t u m or l ysis s y n dr o me 
T N treat me nt nai ve 
U L N u p per li mit of n or mal 
U S U nite d States 
W B C w hite bl o o d cell 
W H O W orl d Healt h Or ga nizati o n 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692640] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 1 6 1. B A C K G R O U N D A N D R A TI O N A L E 
1. 1. I br uti ni b O ver vie w 
I br uti ni b (I M B R U VI C A ®) is a fir st -i n -class, p ote nt, orall y  a d mi nistere d c o val e nt l y -bi n di n g 
i n hi bit or of Br ut o n’s t y r osi ne ki nase ( B T K) c o -de vel o pe d b y P har mac yclics L L C a n d Ja nsse n 
Researc h & De vel o p me nt L L C (c ollect i vel y refer re d t o as t he S p o ns or) f o r t he treat me nt of 
B- cell mali g na ncies. 
I br uti ni b has bee n a p pr o ve d i n ma n y re gi o ns, i ncl u di n g t h e U nite d States ( U S )a n d E ur o pea n 
U ni o n ( E U ), f or i n dicat i o ns i ncl u di n g treat m e nt of  p ati e nts wi t h  m a nt le cell l y m p h o ma ( M C L) 
w h o ha ve recei ve d at l e ast 1 pri or t hera p y , p ati e nts wi t h  c hr o nic ly m p h oc y ti c le u ke mia 
( C L L) /s mall  l y m p h oc y ti c l y m p h o ma ( S L L) i ncl u di n g C L L / S L L wi t h  a del et i o n of t he s h ort ar m 
of  c hr o m o s o m e 1 7 ( del 1 7 p), pati e nts wi t h  Wal de nstr ö m’s macr o gl o b uli ne mia , p ati e nts wi t h 
mar gi nal z o ne l y m p h o ma ( M Z L) w h o re q uire s yste mic t hera p y a n d ha ve recei ve d at least o ne 
pri or a nti -C D [ADDRESS_692641] disease (c G V H D) 
af t er f ail ure of o ne or m ore li nes of s yste mic t hera p y .
F or t he m ost u p t o date a n d c o m pre he nsi ve n o ncli nical a n d cli nical i nf or mat i o n re gar di n g 
i br uti ni b bac k gr o u n d, safet y,  efficac y , a n d i n vi tr o a n d i n vi v o precli nical act i vit y a n d t o xi c o l o g y  
of  i br uti ni b, r ef er t o t he l atest versi o n of  t he i br ut i ni b I n vesti gat or’s Br oc h ure a n d/ or t he 
a p plica ble r e gi o n al  la beli n g i nf or mat i o n. 
1. 2. C hr o nic L y m p h oc ytic Le u ke mi a a n d S m all L y m p h oc ytic L y m p h o m a 
C L L is t he m ost c o m m o n f o r m  of  a d ul t l e u ke mia i n t he de vel o pe d w orl d . T he esti mate d 2 0 1 0 
pre vale nce i n t he U nite d States ( U S) was a p pr o xi matel y 1 0 6, 0 0 0 i n di vi d uals ( S E E R 2 0 1 0 ). T he 
me dia n a ge at prese ntati o n is t y p icall y bet wee n 6 5 a n d 6 8 y ears; a p o p ul at i o n- base d st u d y  f o u n d 
t h at m ore t ha n half o f t h e cases prese nte d at o ver 7 0 years of a ge ( Bre n ner 2 0 0 8 ). C L L is 
c haracterize d b y  a n  acc u m ulati o n of m o n ocl o nal mat ure B cells ( C D 5 +/ C D 2 3 +) i n t he bl o o d, 
b o ne marr o w, a n d sec o n dar y  l y m p h or ga ns . T hese cells are c o nsta nt l y bei n g sti m ulate d b y t heir 
B C R, as well as b y  i nt eract i o ns wi t h  t h ei r micr oe n vir o n me nt ( C hi orazzi 2 0 0 5 ). Acc or di n g t o t he 
W o rl d Heal t h  Or ga nizat i o n ( W H O), S L L , a di sease wi t h  si milar pat h ol o gical fi n di n gs b ut 
wi t h o ut t he l y m p h oc y t osi s, is c o nsi dere d t o be a ma n ifestati o n of  t he sa me u n derl yi n g dis or der 
as C L L ( Ca m p o 2 0 1 1 ). 
O nce dia g n ose d wit h C L L or S L L, patie nts ca n ha ve a varia ble c o urse —s o me n ot re q uiri n g 
treat m e nt f or m ore t ha n a deca de a n d ot hers re q uiri n g m ore ur ge nt treat me nt, par ti c ularl y  t h ose 
wi t h  cli nicall y s y m pt o mat ic disease ( Gri b be n 2 0 1 1 ). Acc or di n g t o t he I nter nati o nal W or ks h o p o n 
C hr o nic L y m p h oc y ti c Le u ke mia (I W C L L) g ui deli nes, t he f oll o wi n g feat ures are i n dicat i o ns f or 
t h era p y : pr o gressi ve m arr o w fail ure ( ma nifeste d b y a ne mia or t hr o m b oc y t o p e ni a), m assi ve or 
pr o gressi ve s ple n o me gal y ( 6 c m or greater), massi ve l y m p h n o des ( [ADDRESS_692642] di a meter), pr o gressi ve l y m p h oc y t osi s wi t h  a ra pi d l y m p h oc y te d o u bli n g ti me occ urri n g 
i n less t ha n [ADDRESS_692643] it ut i o n al  s y m pt o ms ( Halle k 2 0 0 8 ). 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692644] i ne, a n d ale mt uz u ma b as si n gl e a ge nts ha ve s h o w n i m pr o ve d efficac y  
c o m pare d wi t h  c hl ora m b ucil  w he n e val uate d i n pati e nts wi t h  a m e dia n a ge of less t ha n 6 5 y ears 
(Rai  2 0 0 0 ; Hill me n 2 0 0 7 ; C hes o n 2 0 0 9 ; K na uf 2 0 0 9 ). H o we ver, i n t he o nl y P hase 3 st u d y 
c o m pari n g fl u dara bi ne wit h c hl ora m b ucil i n a ra n d o mize d fas hi o n i n C L L pat ie nt s 6 5 y ears or 
ol der ( Ei c h h orst 2 0 0 9 ), t here was n o be nefit i n pr o gressi o n- free s ur vi val ( P F S) ( 1 8 vers us 
1 9 m o nt hs, res pecti vel y) or i n o verall s ur vi val ( O S) ( [ADDRESS_692645] i vel y). 
T he a d dit i o n of c ycl o p h os p ha mi de t o fl u dara bi ne f urt her i m pr o ve d res p o nse rates a n d P F S 
c o m pare d wi t h  f l u dara bi ne al o ne, b ut at t he c ost of i ncrease d t o xicit y (Fli n n 2 0 0 0 , O' Brie n [ADDRESS_692646] 2 0 0 6 ; Fli n n 2 0 0 7 ). I n a lar ge P hase [ADDRESS_692647] -li ne treat me nt of C L L, 
t h e a d di ti o n of  ri t u xi ma b, a n a nt i- C D 2 0 m o n o cl o n al  a nt i b o d y , t o fl u dara bi ne a n d 
c y cl o p h os p ha mi de i n t he fr o nt -li ne setti n g res ulte d i n si g nifica nt i m pr o ve me nt i n P F S a n d O S 
c o m pare d wi t h  f l u dara bi ne a n d c ycl o p h os p ha mi de al o ne, wi t h  a hazar d rati o f or pr o gressi o n of  
0. 5 1 ( 9 5 % CI: 0. 3 9, 0. 6 7) f or patie nts less t ha n 7 0 years o f a ge ( N =7 3 6) ( Halle k 2 0 1 0 ; 
Casa k 2 0 1 1 ). H o we ver, t he treat me nt effect i n pat ie nts 7 0 y ears or ol der ( N = 8 1) was decrease d, 
wi t h  a hazar d rati o of 1. 1 7 ( 9 5 % CI: 0. 5 1, 2. 6 6) . T his tre n d of di mi nis h e d efficac y  ( P F S hazar d 
r ati o > 1. 0 0) was als o see n i n patie nts [ADDRESS_692648] u d y  c o m pari n g t he 
sa me c o m bi nat i o n re gi me ns (R o ba k 2 0 1 0 ). El derl y pati e nts e x perie nce d greater t o xicit y t h a n 
y o u n ger pati e nts i n ge neral a n d wit h ri t u xi ma b —p arti c ularl y c y t o pe nias ( Casa k 2 0 1 1 ). 
T h us, des pi[INVESTIGATOR_040] t hese a d va nces, a d dit i o n al  tr e at m e nt o pti o ns are desira ble —es peciall y  i n t he 
el derl y  p o p ul at i o n i n w hic h t olera nce t o c he m ot hera pe utic a ge nts ca n be a c halle n ge. 
1. 4. S u m m ar y of N o ncli nic al D at a 
1. 4. 1. P h ar m ac ol o g y 
I br uti ni b was desi g ne d as a selecti ve a n d c o vale nt i n hi bit or of t he B T K ( Pa n 2 0 0 7 ). I n vit r o, 
i br uti ni b is a p ote nt i n hi bit or of B T K act i vit y (I C 5 0 = 0. 3 9 n M) . T he irre versi ble bi n di n g o f 
i br uti ni b t o c ystei ne -[ADDRESS_692649] i vit y o ver ot her ki nases t hat d o n ot c o ntai n a c ystei ne at t his p ositi o n . 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692650] i vat i o n of B -cells (I C 5 0 =8 0 n M) as assa ye d b y a nti -I g M st i m ulat i o n fol l o we d b y 
C D 6 9 e x pressi o n ( H er m a n 2 0 1 1 ). 
I br uti ni b arreste d cell gr o wt h a n d i n d uce d a p o pt osis i n h u ma n B -cell l y m p h o ma cell li nes 
i n vit r o a n d i n hi bi t e d t u m or gr o wt h i n vi v o i n xe n o graft m o dels ( H er m a n 2 0 1 1 ). I br uti ni b als o 
i n hi bite d a d hesi o n a n d mi grati o n o f M C L cells i n c o -c ult ure a n d re d uce d t u m or b ur de n i n l y m p h 
n o de a n d b o ne marr o w i n a m uri ne m o del of M C L disse mi nat i o n a n d pr o gressi o n ( C ha n g 2 0 1 3a , 
C ha n g 2 0 1 3 b ). 
F or m ore detaile d a n d c o m pre he nsi ve i nf or mat i o n re gar di n g n o ncli nical p har mac o l o g y , please 
refer t o t he c urre nt I B .
1. 4. 2. S afet y P h ar m ac ol o g y a n d T o xic ol o g y 
No treat me nt -r el ate d effects were o bser ve d i n t he ce ntral ner v o us s yste m  or res pi [INVESTIGATOR_1305] y  s yste m  i n 
rats at a n y  d ose teste d . F urt her, n o treat me nt -relate d c orrecte d Q T i nter val ( Q Tc) pr ol o n gati o n 
effect was o bser ve d at a n y  teste d d ose i n a car di o vasc ular st u d y  usi n g tel e metr y -m o nit ore d d o gs . 
Base d o n data fr o m rat a n d d o g i ncl u di n g ge neral t o xicit y st u di es u p t o [ADDRESS_692651] p ote ntial f or h u ma n t o xicit y wi t h  i br ut i ni b is pre dicte d t o be i n l y m p h o i d tiss ues 
(l y m p h o i d de plet i o n) a n d t he gastr oi ntest i nal tract (s oft feces/ diarr hea wit h or wit h o ut 
i nfla m ma ti o n) . A d dit i o nal t o xicit y fi n di n gs see n i n o nl y o ne s pecies wit h n o o bser ve d h u ma n 
c orrel ate i n cli nical st u dies t o date i ncl u de pa ncreatic aci nar cell atr o p h y  (rat), mi ni mall y 
decrease d tra bec ular a n d c ortical b o ne (rat) a n d c or neal d ystr o p h y  ( d o g) . I n st u di es i n pre g na nt 
rat s a n d ra b bits, ibr uti ni b a d mi nist r ati o n was ass ociate d wit h malf or mat i o ns (terat o ge nicit y)  at 
ibr uti ni b d oses t hat res ult i n a p pr o xi matel y 1 4 a n d 2 ti mes t he e x p os ure ( A U C) i n pat ie nt s 
a d mi nistere d t he d ose of [ADDRESS_692652] Met a b olis m 
F o ll o wi n g oral  a d mi nistrati o n of  i br ut i ni b at d oses ra n gi n g fr o m 4 2 0 t o 8 4 0 m g/ da y, e x p os ure t o 
i br uti ni b i ncrease d pr o p orti o nall y  wi t h  s u bsta nt ia l i nt er -s u bject varia bilit y. T h e m ea n ter mi nal 
pl as ma eli mi nat i o n half -life (t 1/ 2 ) of i br ut i ni b ra n ge d fr o m  4 t o 1 3 h o urs, wit h a me dia n ti me t o 
ma xi m u m plas ma c o nce ntrati o n ( T ma x ) of  2 h o urs . Des pi[INVESTIGATOR_040] t he d o u bli n g i n mea n s yste mic 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692653] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 1 9 e x p os ure w he n d ose d wit h f o o d ,t h e fa v ora ble safet y  pr ofile of i br ut i ni b all o ws d os i n g wi t h  or 
wi t h o ut f o o d . I br uti ni b is e xte nsi vel y meta b o lize d pri maril y b y c yt oc hr o me P 4 5 0 ( C Y P) [ADDRESS_692654] yi n g n o n -cli nicall y  rele va nt acc u m ulat i o n. Less t ha n 1 % of i br uti ni b is e xcrete d i n t he uri ne . 
I br uti ni b e x p os ure is n ot altere d i n patie nts wit h creati ni ne cleara nce ( Cr Cl) > 3 0 m L/ mi n . 
P ati e nts wi t h  se vere re nal i m pair me nt or patie nts o n dial ysis ha ve n ot bee n st u die d . F o ll o wi n g 
si n gle d ose a d mi nistrati o n, t he A U C of i br ut i ni b i ncrease d 2. 7 -, 8. 2 -a n d 9. 8 -f o l d i n s u bjects wi t h  
mil d ( C hil d - P u g h class A), m o derate ( C hil d- P u g h class B), a n d se vere ( C hil d -P u g h cl ass C) 
he pat ic i m pair me nt c o m pare d t o s u bjects wit h n or mal li ver f u nct i o n. A hi g her pr o p orti o n of 
Gra de [ADDRESS_692655] i o ns were re p orte d i n patie nts wit h B -cell  m ali g na ncies ( C L L, 
M C L a n d W M) wit h mil d he pat ic i m pair me nt ba se d o n N CI or ga n d y sf u nct i o n w or ki n g gr o u p 
( N CI -O D W G) criteria f or he patic d ysf u nct i o n c o m pare d t o patie nts wit h n or mal he pat ic 
f u nct i o n. 
F or t he m ost c o m pre he nsi ve i nf or mati o n re gar di n g p har mac o ki netics ( P K) a n d pr o d uct 
meta b o lis m, please refer t o t he c ur re nt versi o n of t he I B .
1. 5. 2. S u m m ar y of Cli nic al S afet y 
A br ie f s u m mar y  of  safet y data fr o m  m o n ot hera p y  st u di es is pr o vi de d bel o w. F or t h e m ost rece nt 
a n d t he m o re c o m pre he nsi ve safet y i nf or mati o n ,please refer t o t he c urre nt versi o n of t he I B . 
A d dit i o nal safet y i nf or mat i o n ma y be a vaila ble f or a p pr o ve d i n dicat i o ns i n re gi o nal prescri bi n g 
la bels w here t he st u d y  i s c o n d ucte d (e g, U S PI, S m P C). 
1. 5. 2. 1. M o n ot her a p y St u di es 
I nte grate d safet y data are s h o w n f o r 1, [ADDRESS_692656] ete d pri mar y  a n al ysis or fi nal a nal ysis as o f 
t h e 3 1 J ul y 2 0 1 7 c ut off date f or t h eversi o n 1 1 I n vesti gat or’s Br o c h ure u p date .
T he m ost f re q ue ntl y re p orte d treat m e nt -e mer ge nt a d verse e ve nts ( T E A Es) i n s u bjects recei vi n g 
i br uti ni b as m o n ot hera p y  ( N = 1, 5 2 3 ): 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692657] fre q ue ntl y re p orte d T E A Es 
1 5 % aM ost fre q ue ntl y re p orte d Gra de 
3 or 4 T E A Es 3 % aM ost fre q ue ntl y re p orte d 
Seri o us T E A Es 2 % b
Diarr hea Ne utr o pe nia P ne u m o nia 
Fati g ue P ne u m o nia Atrial fi brillati o n 
Na usea T hr o m b oc yt o pe nia Fe brile ne utr o pe nia 
C o u g h A ne mia P yre xia 
P yre xia H y perte nsi o n 
A ne mia Diarr hea 
Ne utr o pe nia Fati g ue 
U p per r e s pi[INVESTIGATOR_1305] y tract i nfecti o n Atrial fi brillati o n 
T hr o m b oc yt o pe nia 
Oe de ma peri p heral 
M uscle s pas m 
aTa ble 5 of i br uti ni b I B ; bTa ble 6 of i br uti ni b I B .
1. 5. 3. Ris ks 
1. 5. 3. 1. Blee di n g -rel ate d E ve nts 
T here ha ve bee n re p orts of he m orr ha gic e ve nts i n s u bjects treate d wit h i br ut i ni b, b ot h wit h a n d 
wi t h o ut t hr o m b oc y t o p e ni a. T he se i ncl u de mi n or he m orr ha gic e ve nts s uc h as c o nt usi o n, e pi[INVESTIGATOR_227146] ,
a n d petec hiae; a n d maj or he m orr ha gic e ve n ts , s o me fatal, i ncl u di n g gastr oi ntesti nal blee di n g, 
s u b d ural i ntracra nial he m orr ha ge ,a n d he mat uri a. Use of i br ut i ni b i n s u bjects re q ui ri n g ot her 
a nt ic o a g ul a nts or m e dicat i o ns t hat i n hi bit platelet f u nct i o n ma y i ncrease t he ris k of blee di n g . 
S u bjects wit h c o n ge nital blee di n g diat hesis ha ve n ot bee n st u die d . See Secti o n 5. 5. 3 f o r g ui da nce 
o n c o nc o mita nt use of a ntic oa g ula nts, a nti platelet t hera p y a n d / or s u p pl e me nts . See Secti o n 5. [ADDRESS_692658] or y  of  car diac 
arr h y t h mia . P eri o di call y  m o ni t or s u bjects cli nicall y  f or car di ac arr h y t h mia . S u bjects w h o 
de vel o p arr h yt h mic s y m pt o m s (e g, pal pi t ati o ns, li g ht hea de d ness , s y nc o pe, c hest disc o mf o rt or 
ne w o nset of d y s p nea )s h o ul d be e val uate d cli nicall y , a n d if i n dicate d, ha ve a n E C G perf or me d . 
F or car diac arr h yt h mias w hic h persists, c o nsi der t he ris ks a n d be nefit s of i br ut i ni b t hera p y ,a n d 
f o ll o w t he pr ot oc ol d ose m o dificati o n g ui deli nes (see Secti o n 5. 2. 3 ). 
1. 5. 3. 3. R as h 
Ras h has bee n c o m m o nl y re p orte d i n s u bjects treate d wit h eit her si n gle a ge nt i br uti ni b or i n 
c o m bi nat i o n wi t h  c he m ot h era p y . M ost ras hes were mil d t o m o derate i n se verit y. Is ol ate d cases 
of  se vere c uta ne o us a d verse react i o ns ( S C A Rs) i ncl u di n g Ste ve ns -J o h ns o n s y n dr o me ( SJ S) ha ve 
bee n re p orte d i n s u bjects treate d wit h i br ut i ni b . S u bjects s h o ul d be cl osel y m o ni t or e d f or si g ns 
a n d s y m pt o ms s u g gest i ve of S C A R i ncl u di n g SJ S . S u bjects r ecei vi n g i br ut i ni b s h o ul d be 
o bser ve d cl osel y  f or ras hes a n d treate d s y m pt o maticall y, i ncl u di n g i nterr u pti o n of t he s us pecte d 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692659] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 2 1 a ge nt as a p pr o priate . I n a d dit i o n, h y perse nsit i vit y- r el ate d e ve nts i ncl u di n g er y t h e ma, urti caria, 
a n d a n gi oe de ma ha ve bee n re p orte d. 
1. 5. 3. 4. N o n -mel a n o m a s ki n c a ncer 
N o n -me la n o ma s ki n ca ncers ha ve occ urre d i n s u bjects treate d wit h i br uti ni b . M o ni t or s u bj ects 
f o r t he a p peara nce of n o n -me la n o ma s ki n ca ncer. 
1. 5. 3. 5. I nfecti o n s
Infecti o ns (i ncl u di n g se psis, bacterial, viral, or f u n gal i nfect i o ns) were o bser ve d i n s u bjects 
treate d wit h i br ut i ni b t hera p y . S o m e of  t hese re p orte d i nfect i o ns ha ve bee n ass ociate d wit h 
h os pi [INVESTIGATOR_1314] o n a n d deat h . Alt h o u g h ca usalit y has n ot bee n esta blis he d, cases of pr o gressi ve 
m ult if o c al  l e u k oe nce p hal o pat h y  ( P M L) a n d he pat itis B react i vat i o nha ve occ urre d i n s u bjects 
treate d wit h i br ut i ni b . S u bjects s h o ul d be m o nit ore d f or s y m pt o ms (fe ver, c hills, wea k ness, 
c o nf usi o n, v o mit i n g a n d ja u n dice ) a n d a p pr o pri ate t hera p y  s h o ul d be i nst it ute d as i n dicate d. 
1. 5. 3. 6. C yt o pe ni as 
Treat me nt -e mer ge nt Gra de 3 or 4 c yt o pe nias ( ne utr o pe nia, t hr o m b oc yt o pe nia, a n d a ne mia) were 
re p orte d i n s u bjects treate d wit h i br ut i ni b . S u bjects s h o ul d be m o nit ore d f or fe ver, wea k ness, or 
eas y  b r uisi n g a n d/ or bl ee di n g .
1. 5. 3. 7. I nterstiti al L u n g Dise ase (I L D) 
Cases of i nterstit ial l u n g disease (I L D) ha ve bee n re p orte d i n s u bjects treate d wi t h  i br ut i ni b . 
M o ni t or s u bjects f o r p ul m o nar y  s y m pt o m s i n dicat i ve of I L D . S h o ul d s y m pt o m s de vel o p ,f o ll o w 
t h e p r ot oc ol d ose m o dificat i o n g ui deli nes (see Secti o n  5. 2. 3 ). 
1. 5. 3. 8. T u m or L ysis S y n dr o me 
T here ha ve bee n re p orts of t u m or l ysis s y n dr o me ( T L S) e ve nts i n s u bjects treate d wit h 
si n gle -a ge nt i br uti ni b or i n c o m bi nat i o n wi t h  c he m ot hera p y . S u bjects at ris k o f T L S are t h ose 
wi t h  c o m or bi di ti es a n d/ or ri s k fact ors s uc h as hi g h t u m or b ur de n pri or t o treat me nt, i ncrease d 
uri c aci d ( h y per uri ce mia), el e vate d l actate d e h y dr o ge nase ( L D H), b ul k y disease at baseli ne, a n d 
pre -e xist i n g ki d ne y a b n or malit ies .
1. 5. 3. 9. Di arr he a 
Di arr hea is t he m ost fre q ue nt l y re p orte d n o n -he mat ol o gi c A E wi t h  i br ut i ni b m o n ot hera p y a n d 
c o m bi nat i o n t hera p y . Ot her fre q ue nt l y re p orte d gastr oi ntesti nal e ve nts i ncl u de na usea, v o mit i n g, 
a n d c o nst i pat i o n. T hese e ve nts are rarel y se vere . S h o ul d s y m pt o ms be se vere or pr ol o n ge d ,
f o ll o w t he pr ot oc ol d ose m o dificati o n g ui deli nes (see Secti o n 5. 2. 3 ). 
1. 5. 3. 1 0. H y perte nsi o n 
H y perte nsi o n has bee n c o m m o nl y  re p orte d i n s u bjects treate d wit h i br uti ni b . M o ni t or s u bj ects 
f o r ne w o nset of h y perte nsi o n or h y perte nsi o n t hat is n ot a de q uatel y  c o ntr olle d after starti n g 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692660] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 2 2 i br uti ni b . A d j us t e xisti n g a nt i- h y perte nsi ve me dicati o ns a n d/ or i nit iate a nti -h y perte nsi ve 
treat m e nt as a p pr o pri ate. 
1. 5. 3. [ADDRESS_692661] asis 
T here were i s o lat e d cases of le u k ostasis re p orte d i n s u bjects treate d wit h i br uti ni b . A hi g h 
n u m ber of circ ulat i n g l y m p h oc y tes ( > 4 0 0, 0 0 0/ µ L) ma y c o nfer i ncrease d ris k . F or s u bject a n d 
i br uti ni b ma na ge me nt g ui da nce, refer t o Secti o n 5. 2. 3 .
1. 5. 3. 1 2. L y m p h oc yt osis 
U p o n i nit iat i o n of treat m e nt, a re ve rsi ble i ncrease i n l y m p h oc y te c o u nts (i e, ≥ 5 0 % i ncrease fr o m 
baseli ne a n d a n a bs o l ut e c o u nt > 5 0 0 0/ µ L), ofte n ass ociate d wit h re d ucti o n o f l y m p ha de n o pat h y, 
has bee n o bser ve d i n m o st s u bjects wit h C L L/s mall l y m p h oc y ti c l y m p h o ma ( S L L) treate d wit h 
i br uti ni b . T his effect has als o bee n o bser ve d i n s o me s u bjects wit h M C L treate d wit h i br ut i ni b . 
T his o bser ve d l y m p h oc y t osi s (i ncrease i n t he n u m ber of circ ulat i n g l y m p h oc y tes e g, 
> 4 0 0, 0 0 0/ µ L) is a p har mac o d y na mic effect a n d s h o ul d n ot be c o nsi dere d pr o gressi ve diseas e i n 
t h e a bse nce of ot her cli nical fi n di n gs . I n b ot h disease t y pes, l y m p h oc y t osi s t y p icall y occ urs 
d uri n g t he firs t f e w wee ks of i br ut i ni b t hera p y a n d t y pi[INVESTIGATOR_1306] y  res ol ves wi t h i n a me dia n of 
8. 0 wee ks i n s u bjects wit h M C L a n d 1 4 wee ks i n s u bjects wit h C L L/ S L L. T his 
p har mac o d y na mic effect was less pr o mi ne nt or n ot o bser ve d i n ot her i n dicat i o ns. 
F or s u bject a n d i br uti ni b ma na ge me nt g ui da nce, refer t o Secti o n 5. 2. [ADDRESS_692662] t hat t he bl oc ka de 
of  t he B C R -si g nali n g pat h wa y  b y i br ut i ni b i n C L L res ul ts i n 3ma j o r effects: ( 1) direct i n d uct i o n 
of  a p o pt osi s, ( 2) i n hi bit i o n of cell h o mi n g a n d mi grati o n t o c he m o ki nes wit h s u bse q ue nt 
a d hesi o n t o cell ular s u bstrates, a n d (3) i n hi bit i o n of pr o liferat i o n ( Her m a n 2 0 1 1 ; 
P o na n der 2 0 1 2 ). O wi n g t o t he descri be d mec ha nis m o f act i o n of B T K i n hi bit i o n, a d mi nistrati o n 
of  i br uti ni b t o pati e nts wi t h  l y m p h o pr oliferat i ve diseases has bee n ass ociate d wit h m o bilizati o n 
of  t u m o r cells fr o m ti ss ue t o peri p heral bl o o d ( C ha n g 2 0 1 1 ; B ur ger 2 0 1 0 ;P oll yea 2 0 0 9 ). 
T his effect be gi ns i n s o me cases wit hi n h o urs of t he first a d mi nistrati o n a n d t y p icall y reac hes 
pea k m a g ni t u d e wi t hi n t he fi rst 3 m o nt hs of treat me nt . C o i nci de nt wit h t he i br uti ni b 
treat m e nt -relate d l y m p h oc y t osis i s a ra pi d a n d s u bsta nti al decrease i n l y m p h n o de a n d/ or s plee n 
size ofte n o bser ve d wit h or wit h o ut a n i m pr o ve me nt i n he mat ol o gic p ara m eters a n d/ or 
s y m pt o m at ic i m pr o ve me nt of disease -relate d s y m pt o m s. T his effect was n ote d i n C L L/ S L L 
pati e nts treate d o n b ot h P C Y C -0 4 7 5 3 a n d P C Y C - 1 1 0 2- C A ( Fi g ure 1). 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C -[ADDRESS_692663] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 2 3 Fi g ure 1: C h a n ges i n Peri p her al Bl o o d L y m p h oc yte C o u nts a n d B ur de n of 
L y m p h a de n o p at h y i n P atie nts wit h C L L/ S L L, St u d y P C Y C -1 1 0 2 -C A 
A L C =a bs ol ute l y m p h oc yte c o u nt; R/ R = rela pse d/refract or y; S P D =s u m of pr o d ucts of l y m p h n o de di me nsi o n ; 
T N =treat me nt nai ve 
T his p he n o me n o n is a p har mac o d y na mic effect of i br uti ni b , i n w hic h t he i n hi bit i o n of 
B T K -me diate d cell ular h o mi n g a n d a d hesi o n res ults i n a m o bilizat i o n of C L L cells fr o m t he 
l y m p h n o de t o t he peri p heral bl o o d c o m pa rt m e nt . T his patter n of res p o nse ha d pre vi o usl y bee n 
n o te d wi t h  ot her a ge nts k n o w n t o i n hi bit B C R si g nali n g ( Fr ie d ber g 2 0 0 8 ; F ur ma n 2 0 1 0 ). T his 
treat m e nt -relate d l y m p h oc y t osis res ol ves o ver a vari a ble p eri o d of  ti me ( m e dia n 6 m o n t h s) wi t h  
t h e maj ori t y  of  pat ie nt s meet i n g I W C L L 2 0 0 8 criteria f or res p o nse wit h c o nt i n ue d i br ut i ni b 
t h era p y  ( O’ Brie n 2 0 1 1 ). As s uc h, a n i ncrease i n t he n u m ber of circ ulat i n g l y m p h oc y tes i n t he 
p eri p h er al  bl o o d i n t he a bse nce of s y m pt o ms or ot her i n dicat ors of pr o gressi ve disease has n ot 
bee n c o nsi dere d a n i n dicat or of pr o gressi ve disease b y t he i n vest i gat or s i n cli nical st u dies wit h 
i br uti ni b . T his is c o nsiste nt wit h t he rec o m me n dat i o n of c urre nt Na ti o n al  C o m pre he nsi ve Ca ncer 
Net w or k ( N C C N )N H L 2 0 1 6g ui deli ne a n d t he clarificat i o n of t he I W C L L 2 0 0 8 criteria b y  i ts 
a ut h ors ( Halle k 2 0 1 2 ). 
1. 6. R ati o n ale f or Tri al 
I br uti ni b has de m o nstrate d pr o misi n g act i vit y i n st u di es e nr o lli n g ol der patie nts wit h treat me nt -
nai ve or rel a pse d/refract or y  C L L a n d ol d er p ati e nts wi t h  S L L . The pare nt st u d y , 
P C Y C -[ADDRESS_692664] u d y .  
             
       
  
  
     
  
    
   
 
                
   
  
   
  
  
  
            
             
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692665] u d y  of  i mati ni b, I RI S, i n c hr o nic p hase C M L 
(O’ Brie n 2 0 0 3 ), p ati e nts i n P C Y C - 1 1 1 6- C A will be all o we d t o recei ve t he i n vesti gat or’s c h o ice 
of  sec o n d -li ne t hera p y if cli nicall y i n dicate d a n d I R C P D has bee n c o nfir me d, i ncl u di n g a n 
o pti o n f or i br uti ni b f o r rel a pse d C L L/ S L L patie nts . Patie nts a ge d [ADDRESS_692666] d ose of c hl ora m b ucil ha ve a hi g her ris k of earl y deat h 
c o m pare d t o t h ose wi t h  l o n ger re missi o ns ( Cat o vs k y  2 0 0 7 ). Patie nts w h o ha ve ac q uire d a 
d el et i o n of t he s h ort c hr o m os o me of 1 7 ( del 1 7 p) d uri n g or f o ll o wi n g treat m e nt wi t h  
c hl ora m b ucil w o ul d als o n ot be c o nsi dere d a p pr o priate f or fl u dara bi ne or al k ylat i n g base d 
t h era p y . I n t hese hi g h -ri s k p o p ul at i o ns, t he use of i n vesti gati o nal a ge nts is j ust ifie d d ue t o t he 
pa uci t y  of  data t o s u p p ort safe a n d effect i v e c o m merci all y  a vaila ble t hera pi[INVESTIGATOR_014] i n t he rela pse d 
el derl y  or f r ail  C L L pati e nts, ei t h er wi t h  m o n ot hera p y  ( Hill me n [ADDRESS_692667] 2 0 0 9 , 
K na uf 2 0 0 9 ) or wit h c o m bi nat i o n t h era pi [INVESTIGATOR_014] ( Casa k 2 0 1 1 , Fisc her 2 0 1 1 ). I n C L L pat ie nt s wi t h  d el  
[ADDRESS_692668] i ve treat me nt o pti o ns are e ve n m ore li mite d; ale mt uz u ma b has de m o nstrate d efficac y, 
b ut t he safet y pr ofile wi t h  se vere c y t o p e ni as a n d i nfect i o us c o m plicat i o ns has precl u de d its safe 
use i n t he el derl y p o p ulat i o n ( L oza ns ki 2 0 0 4 ). 
2. S T U D Y O B J E C TI V E S 
T o m o ni t or P F S 
T o c o nti n ue treat me nt a n d safet y assess me nt of patie nts ra n d o mize d t o Ar m B ( i br ut i ni b ) i n 
St u d y  P C Y C - 1 1 1 5- C A (t he pare nt st u d y ) w h o ha ve n ot pr o gresse d at t he ti me of pare nt st u d y  
cl os ure 
T o f o ll o w pati e nts f or l o n g -t er m  o ut c o m e
T o ca pt ure o verall res p o nse rate ( O R R), d urati o n of res p o nse ( D O R), P F S, a n d O S , a n d ti me 
t o ne xt t hera p y 
T o f ulfill l o n g -t er m  f ol l o w- u p re q uire me nts of ra n d o mize d pat ie nt s after cl os ure of t he pare nt 
st u d y , i ncl u di n g O S 
3. S T U D Y D E SI G N 
T his o pe n -la bel e xte nsi o n st u d y  pr o vi des o n g oi n g treat m e nt a n d f o ll o w- u p f or el d erl y pat ie nt s 
wi t h  C L L or S L L w h o were pre vi o usl y e nr olle d i n t h epare nt st u d y , P C Y C - [ADDRESS_692669] u d y w he n t he y
e x perie nce i n de pe n de nt re vie w c o m mittee (I R C)- c o nfir me d pr o gressi ve disease (P D )or w he n 
t h epare nt st u d y is cl ose d b y t he S p o ns or , as descri be d i n Ta ble 1.
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692670] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 2 5 T a ble 1: P atie nt Tr a nsfer t o St u d y P C Y C- [ADDRESS_692671] u d y, P C Y C -1 1 1 6 -C A 
P C Y C - 1 1 1 5- C A Ar m A or B Patie nts :  
I R C -c o nfir me d P D i n pare nt st u d y 
    Sc he d ule of assess me nts is base d o n ma na ge me nt decisi o n: 
  N o t hera p y:  See A p pe n di x D
  Sec o n d -li ne i br uti ni b (if eli gi ble) ‡:  See A p pe n di x C
  Sec o n d -li ne n o n -i br uti ni b t hera p y :  See A p pe n di x D
P C Y C - 1 1 1 5- C A Ar m A Patie nts :  
C o m pleti o n of [ADDRESS_692672] u d y     Bef ore P D, sc he d ule of assess me nts is i n A p pe n di x A;
After P D, sc he d ule of assess me nts is base d o n ma na ge me nt decisi o n: 
  N o t hera p y:  See A p pe n di x D
  Sec o n d -li ne i br uti ni b (if eli gi ble) ‡:  See A p pe n di x C
  Sec o n d -li ne n o n -i br uti ni b t hera p y :  See A p pe n di x D
P C Y C - 1 1 1 5- C A Ar m B Patie nts :  
O n g oi n g treat me nt wit h i br uti ni b , a n d 
n o P D at cl os ure of pare nt st u d y 
O R 
Disc o nti n uati o n of ra n d o mize d 
treat me nt f or a reas o n ot her t ha n P D, 
a n d n o P D at cl os ure of t he pare nt 
st u d y     Bef ore P D, sc he d ule of assess me nts is i n A p pe n di x B; 
After P D, sc he d ule of assess me nts is as f oll o ws: 
  N o t hera p y:  See A p pe n di x D
  Sec o n d -li ne n o n -i br uti ni b t hera p y :  See A p pe n di x D
Ar m A =c hl ora m b ucil i n P C Y C -1 1 1 5 -C A; Ar m B = i b r uti ni b i n P C Y C -1 1 1 5 -C A; I R C =I n de pe n de nt Re vie w 
C o m mittee; n o n -i br uti ni b =alter nati ve a ntica ncer treat me nt ot her t ha n i br uti ni b ; P D = pr o gressi ve disease 
N ote : Alter nati ve a ntica ncer treat me nt is selecte d at t he i n vesti gat or’s discreti o n. F or a patie nt ra n d o mize d t o 
c hl ora m b ucil i n t he pare nt st u d y, i br uti ni b is a n o pti o n f or sec o n d -li ne t hera p y, pr o vi de d t he patie nt meets t he criteria 
f or sec o n d -li ne i br uti ni b t hera p y ( Secti o n 4. 2 )‡. F or a patie nt ra n d o mize d t o i br uti ni b i n t he pare nt st u d y, 
c hl ora m b ucil is a n o pti o n f or sec o n d -li ne t hera p y. 
Treat me nt o pti o ns i n t his e xte nsi o n st u d y  var y  de pe n di n g o n t h e treat me nt t o w hic h t he patie nt 
was ra n d o mize d i n t he pare nt st u d y, t he disease -pr o gressi o n stat us at tra nsfer t o t he e xte nsi o n 
st u d y , a n d t he pla n ne d treat me nt i n t he e xte nsi o n st u d y . C h o ice o f sec o n d -li ne alter nat i ve 
a nt ica ncer treat me nt is at t he cli nical j u d g me nt of t he i n vest i gat or . Treat me nt ca n be wit h 
i br uti ni b (f or pati e nts ra n d o mize d t o c hl ora m b ucil i n t he pare nt st u d y  w h o f ulfill t he criteria f or 
sec o n d -li ne i br ut i ni b [Secti o n 4. 2 ]‡), c hl ora m b ucil (f or patie nts ra n d o mize d t o i br ut i ni b i n t he 
pare nt st u d y ), or o t h er t hera pi[INVESTIGATOR_014] . I n a d dit i o n, a n y pati e nt ca n elect n ot t o u n der g o f urt her 
a nt ica ncer treat me nt. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692673] u d y is as f oll o ws: 
P ati e nts c o nti n ui n g o n first -li ne i br ut i ni b t h era p y  e n ter t hi s st u d y  at t hei r c urre nt t ol erate d 
d ose . D o se a dj ust me nt , if re q uire d, is descri be d i n Secti o n 5. 2. 3 .
P ati e nts i ni ti ati n g sec o n d -li ne i br ut i ni b t h er a p y ‡start tr eat me nt at a d ose of 4 2 0 m g/ d a y . Dose 
re d ucti o n , if  r e q ui re d is descri be d i n Sect i o n 5. 2. 3 .
T he d ose (s) a n d treat me nt re gi me n(s) f o r ot her alt er nat i ve a nt ic a ncer treat m e nt   w hic h 
c o ul d be c hl ora m b ucil, f or patie nts i nit iall y ra n d o mize d t o i br uti ni b is selecte d b y t he 
i n vesti gat or i n li g ht of t he c urre nt sta n dar d of care. 
Pati e nts recei vi n g first -li ne or sec o n d -li ne i br uti ni b t h era p y ‡i n t he e xte nsi o n st u d y  will be 
f o ll o we d f or safet y,  res p o nse (i ncl u di n g di sease pr o gressi o n ), a n d s ur vi val . Assess me nts i n 
s pecific s u b gr o u p sof  p ati e nts are descri be d i n detail i n t he sc he d ule s of assess me nts: 
A p pe n di x A, assess me nts bef ore PD i n pat ie nt s ra n d o mize d t o c hl ora m b ucil ; A p pe n di x B, 
assess me nts bef ore P D i n patie nts ra n d o mize d t o i br uti ni b ; A p pe n di x C, assess me nts after P D i n 
pa ti e nts o n sec o n d -li ne i br ut i n i b ‡; a n d A p pe n di x D, assess me nts after P D i n pat ie nt s o n 
a nt ica ncer treat me nt ot her t ha n i br ut i ni b (i e, n o n- i br uti ni b ), or n o treat m e nt .
U nli ke t he pare nt st u d y , i n t hi s e xte nsi o n  st u d y , P D is esta blis he d b y t he i n vesti gat or; t here is n o 
c o nfir mat i o n of  P D b y a n I R C. 
At  t he i n vesti gat or’s discret i o n, pati e nts recei vi n g sec o n d -li ne i br ut i ni b t h era p y‡w h o ac hie ve a n d 
retai n M R D -ne gat i ve re missi o n f o r 6 c ycle s (i ncl u di n g [ADDRESS_692674] o ne b o ne marr o w as pi[INVESTIGATOR_337]) ca n ha ve t heir i br ut i ni b 
di sc o nti n ue d . If  sec o n d -li ne i br ut ini b is disc o nt i n ue d, t he s u bject will be f o ll o w e d f or M R D 
rec urre nce b y peri p heral bl o o d m o nit ori n g a p pr o xi matel y e ver y  6 c ycles; i br ut i ni b t hera p y ma y 
be rei nit iate d i n t he e ve nt of rec urre nce of M R D p osit i ve stat us or cli nical pr o gressi o n. 
F o ll o wi n g i m ple me ntati o n of Pr ot oc ol  A me n d me nt [ADDRESS_692675] u d y ( ei t h er o n 
ra n d o mize d treat me nt or d uri n g f o ll o w- u p) will  c o m plete a n e n d -of -treat m e nt visi t u p t o [ADDRESS_692676] u d y ,
P C Y C - 1 1 1 6- C A. 
If treat m e nt i s disc o nt i n ue d i n t he a bse nce of I R C -c o nfir me d pr o gressi o n (ie , f or a n A E, or 
wi t h dra wal  f r o m  treat m e nt b y  t he patie nt or i n vesti gat or’s decisi o n), pati e nts will re mai n i n t he 
pare nt st u d y  t o m o ni t or f or fi rst pr o gressi o n .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692677] i gat o r’s discret i o n. Ar m A 
pati e nts (i e, ra n d o mize d t o c hl ora m b ucil) w h o pr o gress a n d wis h t o i nit iate sec o n d -li ne treat me nt 
wi t h  i br ut i ni b i n t he e xte nsi o n  st u d y m ust m eet all s pecific criteria i n S e cti o n 4. 2 ‡.
4. S E L E C TI O N O F P A TI E N T S 
T his st u d y  i s desi g ne d t o e nr oll pat ie nt s w h o were ra n d o mize d i n t h e pare nt S t u d y  
P C Y C - [ADDRESS_692678] meet all o f t h e f o ll o wi n g cri t eri a: 
1. Ra n d o mize d i n t he pare nt st u d y , P C Y C -[ADDRESS_692679] u d y 
4. 2. A d diti o n al Criteri a f or Recei vi n g Sec o n d- li ne Ibr uti ni b ‡
(N ote: s ec o n d -li ne tre at me nt wit h i br uti ni b will n o l o n ger be i niti ate d f oll o wi n g 
i m ple me nt ati o n of Pr ot oc ol A me n d me nt 3) 
T o recei ve sec o n d -li ne ibr ut i ni b , p ati e nts m ust m eet all  of  t he f o ll o wi n g cri t eri a: 
1. I R C- c o nfir me d disease pr o gressi o n i n t he pare nt st u d y  ( P C Y C - 1 1 1 5- C A), or f or patie nts 
w h o di d n ot pr o gress i n t he pare nt st u d y , i n vest i gat or -deter mi ne d disease pr o gressi o n i n t he 
e xte nsi o n st u d y ( P C Y C -1 1 1 6- C A) 
2. Recei ve d at least 3 c y cles of c hl ora m b ucil t hera p y 
3. D oc u m e nte d, pr ot oc ol - defi ne d reas o n f or c hl ora m b ucil disc o nt i n uat i o n: 
N o e vi de nce of  res p o nse i n ra di o gra p hicall y assesse d di sease para meters at C y cle 5 
c o m pare d t o baseli ne; n o f urt her res p o nse ( defi ne d as fail ure t o reac h at least a P R, or a 
pl atea u of res p o nse wit h n o f urt her i m pr o ve me nt of disease para meters) after at least 
6c y cles; c o ul d n ot t ol erate treat m e nt (a si t u ati o n defi ne d b y t he rec urre nce of t o xicit y of  
at l east Gra de 3 de s pi[INVESTIGATOR_040] a p pr o priate d ose re d ucti o ns a n d o pti mal s y m pt o mat ic 
ma na ge me nt); or ma xi m u m treat me nt of 1 2 c y cles wi t h  c hl ora m b ucil 
4. D e m o nstrates c o n ti n uati o n of  a de q uate or ga n f u ncti o n, perf or ma nce stat us, a n d ot her 
cri teria, as f o ll o ws: 
Easter n C o o perati ve O nc ol o g y Gr o u p ( E C O G) stat us of 0 - 2 
A de q uate he mat ol o gic f u nct i o n, defi ne d as a bs o l ut e ne utr o p hil c o u nt ( A N C ) ≥ 0. 7 5 x 
1 0 9/ L (i n de pe n de nt of gr o wt h fact or s u p p ort i n t he prece di n g 7 da ys) a n d platelet c o u nt 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692680] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 2 9 ≥ 3 0 x 1 0 9/ L (i n de pe n de nt of tra nsf usi o n or gr o wt h fa ct o r s u p p ort i n t he prece di n g 
7d a y s) 
A de q uate he pat ic f u ncti o n, defi ne d as ser u m as partate tra nsa mi nase ( A S T) a n d ala ni ne 
tra nsa mi nase ( A L T) < 2. 5 x u p per li mit o f n or m al  ( U L N), a n d t otal bilir u bi n ≤1. 5 xU L N 
( u nless d ue t o Gil bert's s y n dr o me) 
A de q uate re na l f u nct i o n, defi ne d as a n est i mate d gl o mer ular filtrat i o n rate ≥3 0 m L/ mi n 
usi n g t he C oc kcr oft -Ga ult e q uati o n 
P ati e nts m ust ha ve rec o vere d fr o m ac ute t o xicit ie s d ue t o pri or c he m ot h era p y , 
r a di ot h era p y , i n vest i gat i o nal dr u gs or e x peri me ntal treat me nts ( n o n -he mat ol o gic 
t o xi ci ti es ha ve res o l ve d t o a N CI C T C A E [versi o n 4. 0 3 ] Gra de of ≤ 2) pri or t o recei vi n g 
ne xt li ne i br uti ni b o n t hi s st u d y 
5. Meets at least 1 of t he I nter nati o nal W or ks h o p o n C hr o nic L y m p h oc y ti c Le u ke mia 
(I W C L L) criteria f or acti ve disease re q ui ri n g treat me nt ( Halle k 2 0 0 8 ):
E vi de nce of pr o gressi ve marr o w fail ure as ma nifeste d b y  t he de vel o p me nt of, or 
w orse ni n g of, a ne mia ( he m o gl o bi n < 1 0 g/ d L), a n d/ o r t hr o m b oc yt o pe nia ( platelets 
<1 0 0, 0 0 0/ L) 
Massi ve ( ≥6 c m bel o w t he left c ostal mar gi n), pr o gressi ve, or s y m pt o mat ic 
s ple n o me gal y 
Massi ve n o des (at least [ADDRESS_692681] dia meter), pr o gressi ve, or s y m pt o matic 
l y m p ha de n o pat h y 
Pr o gressi ve l y m p h oc y t osi s wi t h  a n i ncrease of m ore t ha n 5 0 % o ver a 2 -m o nt h peri o d or a 
l y m p h oc y te d o u bli n g t i me ( L D T) of < 6 m o nt hs . L D T ma y be o btai ne d b y li near 
re gressi o n e xtra p olat i o n of a bs o l ut e l y m p h oc y te c o u nts o btai ne d at i nte r vals of 2 wee ks 
o ver a n o bser vat i o n peri o d of  2 t o 3 m o nt hs . I n patie nts wit h i nit ial bl o o d l y m p h oc y t e 
c o u nts of < 3 0, 0 0 0/ L, L D T s h o ul d n ot be use d as a si n gle para meter t o defi ne i n dicat i o n 
f o r treat m e nt . I n a d dit i o n, fact ors c o ntri b uti n g t o l y m p h oc y t osis or l y m p ha de n o pat h y  
ot her t ha n C L L (e g, i nfect i o ns) s h o ul d be e xcl u de d. 
A ut oi m m u ne he m o l yt ic a ne mia a n d/ or i m m u ne t hr o m b oc y t o p e ni a (see defi nit i o ns bel o w) 
t h at is p o orl y res p o nsi ve t o c ortic oste r oi ds or ot her sta n dar d t hera p y .
(Defi nit i o ns : A ut oi m m u ne he m o l y ti c a ne mia is defi ne d b y  at l east 1 m ar ker of he m ol ys is 
[i n direct bilir u bi n a b o ve t he U L N n ot d ue t o li ver disease, i ncrease d lactate 
de h y dr o ge nase [a b o ve U L N] wit h o ut alter nat i ve eti o l o g y , or i ncrease d a bs ol ute 
r eti c ul o c y t osis [a b o ve U L N] or b o ne m arr o w er y t hr o p oi esis i n t he a bse nce of blee di n g] 
A N D at least [ADDRESS_692682] a ut oi m m u ne mec ha nis m [ p osit i ve direct 
a nt i gl o b uli n f or I g G or C 3 d, c ol d a g gl ut i ni ns] [ Di n g 2 0 0 7 ]. A ut oi m m u ne 
t h r o m b oc y t o pe nia is defi ne d b y platelets ≤1 0 0, 0 0 0/ L a n d i ncrease d me ga kar y oc ytes o n 
t h e b o ne marr o w e xa mi nat i o n.) 
C o nst it ut i o nal s y m pt o m s, defi ne d as 1 or m ore of t he f o ll o wi n g disease -relate d s y m pt o ms 
or si g ns, d oc u me nte d i n t he patie nt’s rec or d pri or t o ra n d o mizat i o n: 
oU ni nte nti o nal wei g ht l oss > 1 0 % wit hi n 6 m o nt hs pri or t o Scree ni n g 
oSi g nifica nt fati g ue (i na bilit y t o w or k or perf or m us ual acti vities) 
oFe vers >1 0 0. 5° F or 3 8. 0° C f or 2 or m ore wee ks pri or t o Scree ni n g wit h o ut e vi de nce of 
i nfecti o n 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692683] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 3 0 oNi g ht s weats f or m ore t ha n 1 m o nt h pri or t o Scree ni n g wit h o ut e vi de nce of i nfecti o n 
6. O btai ne d t he Sp o ns or ’s a p pr o val f or sec o n d -li ne i br uti ni b tr e at m e nt .
T o recei ve sec o n d -li ne i br uti ni b , p atie nts m ust n ot meet a n y of t he f oll o wi n g criteri a: 
1. Di sease pr o gressi o n i n v o l vi n g t he ce ntral  ner v o us s yste m ( C N S )or tra nsf or m at i o n t o 
a n ot her hist ol o g y 
2. I nter ve ni n g c he m ot hera p y, i m m u n ot hera p y , or i n vesti g ati o n al  a ge nt s pecificall y t o treat 
C L L if a d mi nistere d bef ore date of I R C c o nfir me d pr o gressi ve disease 
3. I n t he [ADDRESS_692684] u g 
4. Re q ui re me nt f or treat m e nt wi t h  a str o n g C Y P 3 A i n hi bit or 
5. U nc o ntr olle d s yste mic i nfecti o n or re q uire me nt f or i nt ra ve n o us ( I V )a nti bi otics 
6. N o nc o m plia nce o n t he pare nt st u d y 
5. T R E A T M E N T S 
Bef ore i m ple me ntati o n of  A me n d me nt N o. 3: 
C h o ic e of  sec o n d -li ne alter nat i ve a nt ica ncer treat me nt is at t he cli nical j u d g me nt of t he 
i n vesti gat or . Sec o n d -li ne treat me nt ca n i ncl u de i br uti ni b (f or p ati e nts ra n d o mize d t o 
c hl ora m b ucil i n t he pare nt st u d y  w h o f ulfill  t he c rit eri a f or sec o n d -li ne i br uti ni b [Secti o n 4. 2 ‡], 
c hl ora m b ucil (f or patie nts ra n d o mize d t o i br ut i ni b i n t he pare nt st u d y ), or ot h er t hera pi[INVESTIGATOR_014] . I n 
a d di ti o n, a n y patie nt ca n elect n ot t o u n der g o f urt her a ntica ncer treat me nt. 
After i m ple me ntati o n of A me n d me nt N o. 3: 
P ati e nts ra n d o mize d t o c hl ora m b ucil will be f o ll o we d u n ti l pr o gressi o n . F o ll o wi n g pr o gressi o n, 
t h ese s u bjects will e xit t he st u d y a n d t h e i nit iat i o n of sec o n d -li ne treat me nt wit h i br ut i ni b will 
n ot be a vaila ble f or t hese patie nt s o n St u d y  P C Y C - [ADDRESS_692685] urer . All f o r m ulati o n e xci pie nts are 
c o m pe n dial a n d are c o m m o nl y  use d i n oral  f or m ul ati o ns. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692686] ora ge c o n dit i o n f o r i br uti ni b ca ps ules is c o ntr olle d r o o m te m perat ure . 
F or mal I nter nati o nal C o nfere nce o n Har m o nizat i o n (I C H) sta bilit y st u di es are o n g oi n g t o 
deter mi ne t he s hel f- life o f t h e pr o d uct . Refer t o t he p har mac y bi n der a n d st u d y dr u g la bel f or 
m o re detaile d i nf or mat i o n. 
Refer t o t he i br uti ni b I B f o r a d di ti o nal i nf or mat i o n re gar di n g t he dr u g pr o d uct. 
5. 1. 2. N o n -i br uti ni b T her a pi[INVESTIGATOR_014] 
S pecific a ge nt(s) a n d t he treat me nt re gi me n(s) are selecte d per t he cli nical j u d g me nt of t h e 
i n vesti gat or . F or dr u g t h era pi [INVESTIGATOR_014], refer t o t he pac ka ge i nsert. 
5. 1. 3. N o Tre at me nt 
A pat ie nt ca n elect n ot t o recei ve f urt her a nt ica ncer treat me nt. 
5. 2. I br uti ni b 
5. 2. 1. D os a ge a n d A d mi nistr ati o n 
P ati e nts c o nti n ui n g o n first -li ne i br ut i ni b t h era p y  e n ter t hi s st u d y  at t hei r c urre nt t ol erate d d ose, 
w hile t h ose i nit iat i n g sec o n d -li ne i br ut i ni b t h era p y ‡st art t reat me nt at a n oral d ose o f 4 2 0 m g/ d a y 
( 3 x 1 4 0 -m g ca ps ules). 
I br uti ni b is a d mi nistere d orall y  o nce dail y  wi t h  8 o u nces (a p pr o xi matel y  2 4 0 m L) of water . T he 
ca ps ules s h o ul d be s wall o we d i ntact a n d patie nts s h o ul d n ot atte m pt t o o pe n ca ps ules or diss o l ve 
t h e m  i n water . Eac h d ose of i br ut i ni b s h o ul d be ta ke n at least [ADDRESS_692687] 
2h o urs after a meal, at a p pr o xi matel y t he sa me ti me eac h da y . T he use of str o n g C Y P 3 A 
i n hi bit ors/i n d ucers a n d gra pefr ui t a n d Se ville ora n ges ( d ue t o C Y P 3 A i n hi bit i o n) s h o ul d be 
a v o i de d f or t he d urati o n of  t he st u d y  ( A p pe n di x G) .
If a d ose i s n ot ta ke n at t he sc he d ule d ti me , i t ca n be ta ke n as s o o n as p ossi ble o n t he sa me da y 
wi t h  a ret ur n t o t he n or mal sc he d ule t he f oll o wi n g da y . T he patie nt s h o ul d n ot ta ke e xtra 
ca ps ules t o ma ke u p t he misse d d ose. 
T he fir st d ose will be deli vere d i n t he cli nic o n Da y  1, af ter w hic h s u bse q ue nt d osi n g is t y pi[INVESTIGATOR_1306] y 
o n a n o ut patie nt basis . St u d y dr u g m a y  n ot be s hi p pe d t o t he s u bject wit h o ut a p pr o val fr o m 
P C Y C a n d ma y  n ot be dis pe nse d t o a n y o n e ot her t ha n t he s u bject . I br uti ni b will be dis pe nse d t o 
pati e nts i n b ottl es at eac h visit . U n use d i br uti ni b dis pe nse d d uri n g pre vi o us visits m ust be 
ret ur ne d t o t he site a n d dr u g acc o u nta bilit y rec or ds ( Secti o n 1 1. 8 ) u p date d at eac h visit . Ret ur ne d 
ca ps ules m ust n ot be re -dis pe nse d t o a n y o ne. 
D ose m odificat i o ns for t o xi ci t y  are descri be d bel o wi n Sect i o n 5. 2. 3 .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692688] be 
re p orte d as a S A E i n t he a p pr o priate ti me fra me a n d d oc u me nte d as cli nical se q uelae t o a n 
o ver d ose. 
T here i s n o s pecific e x perie nce i n t he ma na ge me nt of i br ut i ni b o ver d ose i n pat ie nt s. N o  
ma xi m u m t olerate d d ose ( M T D) was reac he d i n t he P hase 1 st u d y  i n w hic h s u bjects recei ve d u p 
t o 1 2. 5 m g/ k g/ da y ( 1 4 0 0 m g/ da y ). Heal t h y s u bjects were e x p ose d u p t o si n gle d ose of [ADDRESS_692689] e x perie nce d re versi ble Gra de 4 he pat ic e nz y me i ncreases ( A S T a n d A L T) 
af ter a d ose of [ADDRESS_692690] u d y  treat me nt 
s h o ul d be disc o nt i n ue d i n t he e ve nt of a t o xicit y lasti n g > 2 8 da ys , u nless re vie we d a n d a p pr o ve d 
b y t he Me dical M o nit or. 
A he mat ol o gi c A E gra di n g sc he me f or he mat ol o gic t o xicit y is i ncl u de d i n A p pe n di x I. 
T he acti o ns i n Ta ble 3,a n d Ta ble 4s h o ul d be ta ke n f or t he f oll o wi n g t o xicit ies: 
Gra de [ADDRESS_692691] i o n or fe ver 
Gra de 4 ne utr o pe nia ( A N C < 5 0 0/ µ L) f or > 7 da ys ( Ne utr o p hil gr o wt h fact ors are per mitte d 
per A merica n S ociet y of  Cli nical  O n c ol o g y  ( A S C O )g ui deli nes [ S m it h 2 0 0 6 ] a n d use m ust 
be rec or de d i n t he case re p ort f or m [ C R F ].) 
Gra de 3 or 4 t h r o m b oc y t o p e ni a ( pl at el ets < 5 0, 0 0 0/ µ L); or, i n patie nts wit h baseli ne 
t h r o m b oc y t o pe nia, a pl atelet decrease of 5 0 % -7 4 % fr o m baseli ne i n prese nce of blee di n g 
Gra de 4 t h r o m b oc y t o p e ni a ( plat el ets < 2 5, 0 0 0/ µ L); or, i n pati e nts wi t h  baseli ne 
t h r o m b oc y t o pe nia, decrease of ≥7 5 % f r o m  b aseli ne or < 2 0, 0 0 0/ µ L, w hic he ver is hi g her 
Gra de 3 or greater n o n -he mat ol o gi c al t o xi ci t y  ( N ote: Ta ble 4rec o m me n dati o ns f or Gra de 3 
or hi g her car di a c f ail ure a n d car diac arr h y t h mias) 
Gra de 2 car diac fail ure ( Ta ble 4)
A n y ot her Gra de [ADDRESS_692692] i gat or p ote ntiall y 
ma na gea ble b y d ose re d ucti o n, t hese ca n be ma na ge d wit h a o ne d ose le vel d ose re d ucti o n. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692693] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 3 3 T a ble 3: Dr u g Disc o nti n u ati o n Acti o ns f or I br uti ni b f or E ve nts n ot S pecifie d i n 
T a ble 4. 
Occ urre nce aActi o n 
1st H ol d i br uti ni b u ntil rec o ver y t o Gra de ≤ 1 or baseli ne; ma y 
r e start at ori gi nal d ose le vel b
2n d H ol d i br uti ni b u ntil rec o ver y t o Gra de ≤ 1 or baseli ne; restart 
at 1 d ose le vel l o wer ( 2 8 0 m g dail y) 
3r d H ol d i br uti ni b u ntil rec o ver y t o Gra de ≤ 1 or baseli ne; restart 
at 1 d ose le vel l o wer ( 1 4 0 m g dail y) 
4t h Disc o nti n ue i br uti ni b 
a1st , 2 n d , 3 r d , o r 4 t h occ urre nce of t he s a me t o xicit y 
bW he n res u mi n g treat me nt, restart at t he sa me or l o wer d ose base d o n be nefit -ris k e val uati o n . If t he t o xicit y re occ urs, re d uce 
dail y  d ose b y  1 4 0 m g. 
T a ble 4: I br uti ni b D ose M o dific ati o ns f or C ar di ac F ail ure or C ar di ac Arr h yt h mi as 
E ve nts Occ urre nce Acti o n 
Gr a de [ADDRESS_692694] u g u ntil rec o ver y t o Gr a de ≤ 1 or b aseli ne; 
rest art at 1 d ose le vel l o wer ( 2 c a ps ules [ie, 2 8 0 m g d ail y]) 
Sec o n d H ol d st u d y dr u g u ntil rec o ver y t o Gr a de ≤ 1 or b aseli ne; 
rest art at 1 d ose le vel l o wer ( 1 c a ps ules [ie, 1 4 0 m g d ail y]) 
T hir d Disc o nti n ue st u d y dr u g 
Gr a de [ADDRESS_692695] u g u ntil rec o ver y t o Gr a de ≤ 1 or b aseli ne; 
rest art at 1 d ose le vel l o wer ( 2 c a ps ules [ie, 2 8 0 m g d ail y]) a
Sec o n d Disc o nti n ue st u d y dr u g 
Gr a de [ADDRESS_692696] of i br uti ni b , i n w hic h t he i n hi bit i o n o f B T K -me diate d cell ular h o mi n g 
a n d a d hesi o n res ults i n a m o bilizat i o n of t u m or cells t o t he peri p heral bl o o d ( Ste ve ns o n 2 0 1 1 ). 
Up o n i nit iat i o n of treat m e nt, a tra nsie nt p has e of  i ncrease i n l y m p h oc y te c o u nts (i e, ≥ 5 0 % 
i ncrease fr o m baseli ne a n d a b o ve a bs o l ut e c o u nt 5, 0 0 0/ µL), ofte n ass ociate d wit h re d ucti o n of 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692697] patie nts ( 7 5 %) wit h rela pse d/refract or y  C L L/ S L L 
treate d wit h i br ut i ni b . T h is effect has als o bee n o bser ve d i n s o me pat ie nt s ( 3 3 %) wit h 
r el a pse d/refract or y  m a nt le cell l y m p h o ma ( M C L) treate d wit h i br uti ni b . T his o bser ve d tra nsie nt 
l y m p h oc y t osis i s us uall y n ot ass ociate d wit h a n a d verse e ve nt a n d s h o ul d n ot be c o nsi dere d 
pr o gressi ve disease i n t he a bse nce of ot her cli nical fi n di n gs as per t he I W C L L g ui deli nes 
(C hes o n 2 0 1 2 ). I n b ot h M C L a n d C L L , l y m p h oc y t osis t y pi[INVESTIGATOR_1306] y occ urs d uri n g t he first fe w 
wee ks of i br ut i ni b t h era p y a n d res ol ves wit hi n a me dia n of 8wee ks i n t he M C L a n d 1 4 wee ks i n 
t h e C L L / S L L pati e nts. 
A s u bsta ntial i ncrease i n t he n u m ber of circ ulat i n g l y m p h oc y tes (e g, > 4 0 0, 0 0 0/ µL) has bee n 
o bser ve d i n a s u bset of patie nts . T here ha ve bee n is olate d cases of le u k ostasis re p orte d i n 
pati e nts treate d wit h i br ut i ni b .
A hi g h n u m ber of circ ulat i n g w hi t e bl o o d cells ( > 4 0 0, 0 0 0/ µL) ma y c o nfer i ncrease d ris k; t hese 
pati e nts s h o ul d be cl osel y m o ni t or e d . A d mi nister s u p p orti ve care s uc h as h y drat i o n a n d/ or 
le u k o p h oresis as i n dicate d . I br uti ni b ma y be te m p oraril y hel d, a n d Me dical M o nit or s h o ul d be 
c o ntacte d .
5. 2. 5.  D ose M o dific ati o n f or He p atic I m p aire d S u bjects 
I br uti ni b is meta b o li ze d i n t he li ver .
F or s u bject s w h o de vel o p mil d he pat ic i m pair me nt w hile o n st u d y  ( C hil d -P u g h cl ass A), t he 
rec o m me n de d d ose re d ucti o n f or i br uti ni b is t o a le vel of 2 8 0 m g dail y  (t w o ca ps ul es). 
F or s u bject s w h o de vel o p m o derate he patic i m pair me nt w hile o n st u d y  ( C hil d -P u g h cl ass B), 
t h e rec o m me n de d d ose re d ucti o n is t o a le vel o f 1 4 0 m g dail y  ( o ne c a ps ule). 
S u bjects w h o de vel o p se vere he pat ic i m pair me nt ( C hil d -P u g h cl ass C) m ust h ol d st u d y  dr u g 
u nt il res o l ve d t o m o derate i m pair me nt ( C hil d -P u g h class B) or better. 
M o ni t or s u bjects f or si g ns of  t o xi ci t y  a n d f ol l o w d ose m o dificat i o n g ui da nce as nee de d (r efer t o 
A p pe n di x L). 
5. 2. 6. W ar ni n gs , Prec a uti o ns, a n d A d verse Effects 
5. 2. 6. 1. W ar ni n gs a n d Prec a uti o ns 
I br uti ni b is c o ntrai n dicate d i n s u bjects wit h cli nicall y si g nifica nt h y pe rse nsi ti vit y t o t he 
c o m p o u n d i ts elf  or t o t he e xci pie nts i n i ts f or m ulati o n . I br uti ni b has n ot bee n use d i n s u bjects 
wi t h  biliar y  o bstr ucti o n, ac ute he pati ti s, se vere li ver fail ure, or se verel y i m paire d re nal f u nct i o n; 
t h e use of i br uti ni b s h o ul d be a v o i de d i n s u bjects wi t h  t hese c o n dit i o ns . P ati e nts re q ui ri n g 
treat m e nt wi t h  w arf ari n will be e xcl u de d fr o m st u dies of i br uti ni b . T he use of str o n g C Y P [ADDRESS_692698] u d y  ( A p pe n di x G). 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692699]’s pac ka ge i nsert. 
5. 4. Tre at me nt C o m pli a nce 
P ati e nt c o m plia nce wi t h  t he i br ut i ni b d osi n g re gi me n will be assesse d b y  t he si t e p h ar m acist or 
desi g nee at eac h visit usi n g direct q uesti o ni n g, e xa mi nat i o n of patie nt diaries, a n d ca ps ule 
c o u nts. 
C o m plia nce wi t h  t he i br uti ni b d osi n g re gi me n will be verifie d b y t he Sp o ns or or desi g ne e a n d 
will be rec or de d i n t he st u d y  p har mac y bi n der . T he res p o nsi bilit ies of t he p har macist or desi g nee 
are as f o ll o ws: 
Mai ntai n rec or ds of pr o d uct deli ver y , i n ve nt or y , ret ur n, a n d destr ucti o n 
Mai ntai n te m perat ure m o nit ori n g 
Mai ntai n u p -t o -date acc o u nta bilit y of t he st u d y  dr u g i n t he st u d y  dr u g acc o u nta bilit y l o g ( or 
e q ui vale nt) 
D oc u m e nt t he use of st u d y  pr o d uct b y  eac h pati e nt 
Ret ur n or destr o y  u n use d st u d y  pr o d uct as per t he Sp o ns or ’s i nstr ucti o ns 
5. 5. C o nc o mit a nt Me dic ati o ns D uri n g Ibr uti ni b T her a p y
5. 5. 1. Per mitte d C o nc o mit a nt Me dic ati o ns 
S u p p orti ve me dicat i o ns i n acc or da nce wit h sta n dar d practice (s uc h as f or e mesis, diarr hea, etc. ) 
are per mitte d . Use of ne utr o p hil gr o wt h fact ors (fil grasti m a n d pe gfil grast i m) is per mitte d per 
i nst it uti o nal  p olic y a n d i n acc or da nce wi t h  t he A S C O g ui deli nes ( S m it h 2 0 0 6 ). Tra nsf usi o ns ma y 
be gi ve n i n acc or da nce wit h i nstit uti o nal p o lic y. 
P atie nts at Ris k f or T u m or L ysis S y n dr o me 
P ati e nts wi t h  m ore t ha n 1of  t h e f ol l o wi n g fact ors are c o nsi dere d t o be at i ncrease d ris k of t u m or 
l ysis s y n dr o me: 
ser u m  creat i ni ne ≥ 1. 5 x U L N 
W B C c o u nt ≥ 5 0 x 1 0 9/ L ( or 5 0, 0 0 0/ m m 3)
uri c aci d > U L N 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692700] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 3 6 S uc h patie nts s h o ul d be c o nsi dere d f or h y drati o n a n d treat m e nt wi t h  a uric aci d l o weri n g a ge nt 
( xa nt hi ne o xi dase i n hi bit or all o p uri n o l or Ul ori c [fe b u x ostat] +/ -ras b uricase) acc or di n g t o t he 
dr u g pr o d uct’s pac ka ge i nsert bef ore c o nti n ui n g treat me nt wit h st u d y  dr u g, as well  as f or 
fre q ue nt m o nit ori n g f or t u m or l ysis -ass o ci ate d si g ns a n d s y m pt o m s. 
5. 5. 2. C o nc o mit a nt Me dic ati o ns t o be Use d wit h C a uti o n 
5. 5. 2. 1. C Y P I n hi biti n g/I n d uci n g Dr u gs 
I br uti ni b is meta b o lize d pri maril y b y C Y P 3 A 4. A v oi d c o -a d mi nistrati o n wit h str o n g or m o derate 
C Y P 3 A i n hi bit ors a n d c o nsi der alter nati ve a ge nts wit h less C Y P 3 A i n hi bit i o n.
If a str o n g C Y P [ADDRESS_692701] be use d, re d uc ei br uti ni b d ose t o 1 4 0 m g or wi t h h ol d 
treat m e nt f o r t he d urati o n of i n hi bit or use . S u bjects s h o ul d be m o nit ore d f or si g ns of i br ut i ni b 
t o xi ci t y .
If a m o derate C Y P [ADDRESS_692702] be use d, re d uce i br uti ni b t o 1 4 0 m g f o r t he d urati o n of  
t h e i n hi bit or use . F or s u bjects w h o are alrea d y o n m o derate C Y P 3 A i n hi bit or c o nc o mita nt l y 
wi t h  i br ut i ni b wit h o ut si g nifica nt t o xi ci t y  t he i n vesti gat or m a y c o nsi der t he o verall ris k -
be nefit t o deter mi ne if a d ose re d u cti o n of  i br ut i ni b is a p pr o priate . A v o i d gra pefr uit a n d 
Se ville or a n ges d uri n g i br ut i ni b t hera p y , as t hese c o ntai n m o derate i n hi bit ors of C Y P 3 A ( see 
Secti o n 5. 2. 1 ). 
N o d ose a dj ust me nt  is re q uire d i n c o m bi nat i o n wi t h  m il d i n hi bit ors. 
A v o i d c o nc o mit a nt use of str o n g C Y P 3 A i n d ucers (e g, car ba maze pi [INVESTIGATOR_050], rifa m pi n, p he n y t oi n, a n d 
St. J o h n’s W ort) . C o nsi der a lt er nat i ve a ge nts wit h less C Y P [ADDRESS_692703] ease refer t o t he c urre nt versi o n o f t he I B a n d e xa m ples of i n hi bit ors, i n d ucers, 
a n d s u bstrates ca n be f o u n d at h tt p:// m e dici ne.i u p ui.e d u/cli n p har m/ d dis/ mai n- ta ble/ . T his 
we bsite is c o nti n uall y re vise d a n d s h o ul d be c hec ke d fre q ue n tl y f o r u p dates .
5. 5. 2. 2. Dr u gs T h at M a y H a ve T heir Pl as m a C o nce ntr ati o ns Altere d b y Ib r uti ni b 
I n vitr o st u dies i n dicate d t hat i br ut i ni b is n ot a s u bstrate of P -gl yc o pr otei n ( P -g p), b ut is a mil d 
i n hi bit or . I br uti ni b is n ot e x pecte d t o ha ve s yste mic dr u g -dr u g i nteracti o ns wit h P -g p s u bstrates . 
H o we ver, it ca n n ot be e xcl u de d t hat i br ut i ni b c o ul d i n hi bit i ntest i nal P -g p after a t hera pe utic 
d ose . T here i s n o cli nical data a vaila ble . T heref ore, t o a v oi d a p ote ntial i ntera ct i o n i n t he GI 
tract , narr o w t hera pe utic ra n ge P- g p s u bstrates s uc h as di g o xi n s h o ul d be ta ke n at l east [ADDRESS_692704] i o n a n d s u p ple me nts s uc h as fis h o il a n d vita mi n E pre parati o ns s h o ul d be a v oi de d d uri n g 
treat m e nt wi t h  i br ut i ni b . Blee di n g e ve nts of a n y gra de, i ncl u di n g br uisi n g a n d petec hiae, 
occ urre d i n pat ie nt s treate d wit h i br ut i ni b a n d t h e mec ha nis m  f or t he blee di n g e ve nts is n ot well 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692705] -s ur ger y  de pe n di n g u p o n t he t y pe of s ur ger y  a n d t he ri s k 
of  blee di n g (see Sect i o n 5. 6 ). 
S u bjects re q uiri n g t he i nit iat i o n of t hera pe utic a nt ic oa g ulat i o n t hera p y  (e g, atri al  fi brillat i o n), 
c o nsi der t he ris ks a n d be ne fi ts o f c o nt i n ui n g i br ut i ni b t hera p y . If  t hera pe uti c a nt ic o a g ul at i o n is 
cli nicall y i n dicate d, treat me nt wit h i br ut i ni b s h o ul d be hel d a n d n ot be restarte d u ntil t he s u bject 
is cli nicall y  sta ble a n d has n o si g ns of  blee di n g . N o d ose re d ucti o n is re q uire d w h e n st u d y  dr u g is 
restarte d . S u bjects s h o ul d be o bser ve d cl osel y f or si g ns a n d s y m pt o ms of blee di n g. 
5. 5. 4. Pr o hi bite d C o nc o mit a nt Me dic ati o ns 
A n y c he m ot h era p y , a nti ca ncer i m m u n ot hera p y , or e x peri me ntal t hera p y  is pr o hi bite d w hile t he 
pati e nt is recei vi n g i br ut i ni b . L ocalize d, h or m o nal, or b o ne s pari n g treat me nt f or n o n - B- cell 
mali g na ncies ma y be c o nsi dere d wit h a p pr o val  of  t he Me dical M o ni t or. 
5. 6. G ui deli nes f or I br uti ni b M a n a ge me nt wit h S ur geries or Pr oce d ures 
I br uti ni b ma y i ncrease ris k of blee di n g wit h i n vasi ve pr oce d ures or s ur ger y . T he f o ll o wi n g 
g ui da nce s h o ul d be a p plie d t o t he use of i br ut i ni b i n t he peri o perati ve peri o d f or patie n ts w h o 
re q ui re s ur gi cal i nter ve nti o n or a n i n vasi ve pr oce d ure w hile recei vi n g i br ut i ni b :
5. 6. 1. Mi n or S ur gic al Pr oce d ures 
F or mi n or pr oce d ures (s uc h as a ce ntral li ne place me nt, s ki n or nee dle bi o ps y, l u m bar p u nct ure 
[ ot her t ha n s h u nt reser v oir access], t h orace ntesis, or parace ntesis) i br ut i ni b s h o ul d be hel d f or at 
least [ADDRESS_692706] 7 da y s pri or t o t he i nter ve nt i o n(e xce pt f or e mer ge nc y pr oce d ures) a n d s h o ul d be 
hel d at least [ADDRESS_692707] u d y  
ce nter at w hic h t he patie nt was ra n d o mize d a n d is recei vi n g treat me nt. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692708] u d y  assess me nts are briefl y descri be d bel o w a n d are descri be d i n detail i n t he sc he d ules of 
as sess me nts i n t h e a p pe n dices: A p pe n di x A, assess me nts bef ore P D i n pat ie nt s ra n d o mize d t o 
c hl ora m b ucil ; A p pe n di x B, assess me nts bef ore P D i n pat ie nt s ra n d o mize d t o i br uti ni b ; 
A p pe n di x C,assess me nts after P D i n pat ie nt s o n sec o n d -li ne i br ut i ni b ‡;a n d A p pe n di x D, 
assess me nts after P D i n pat ie nt s o n a ntica ncer treat me nt ot her t ha n i br ut i ni b (i e, n o n- i br ut i ni b ), 
or n o treat me nt. 
6. 1. I nf or me d C o nse nt a n d Assess me nt of Eli gi bilit y 
T he patie nt m ust first rea d, u n dersta n d, a n d si g n t he I nst it ut i o nal Re vie w B oar d (I R B)- / Researc h 
Et hics B oar d ( R E B)- /I n de pe n de nt Et hics C o m mittee (I E C) -a p pr o ve d i nf or me d c o nse nt f or m 
(I C F) c o nfir mi n g his or her willi n g ness t o partici pate i n t his st u d y  b ef ore a n y st u d y -s pecific 
pr oce d ures are perf or me d . T he p ati e nt m u st als o gra nt per missi o n t o use pr otecte d healt h 
i n f o r m at i o n per Healt h I ns ura nce P orta bilit y a n d Acc o u nta bilit y Act ( HI P A A) , if a p plica ble . I n 
a d di ti o n, t h e patie nt m ust si g n all a p pr o ve d I C F a me n d me nts per t he site I R B/ R E B/I E C’s 
g ui deli nes d uri n g t he c o urse of t he st u d y .
T he patie nt i nit ia ll y c o nse nt st o partici pati o n i n t his e xte nsi o n  st u d y at e nr oll me nt i n t h e pare nt 
st u d y . I nf or m e d c o nse nt f or parti ci pati o n i n t h e e xte nsi o n  st u d y will  a gai n be o btai ne d bef ore 
a n y e xte nsi o n- st u d y -s pecific pr oce d ures or assess me nts are perf or me d. 
At  e ntr y  i nt o t he e xte ns i o n st u d y , all  patie nts u n der g o a n eli gi bilit y visit . T he assess me nts at t he 
visit var y  de pe n di n g o n t he treat me nt t o w hic h t he patie nt was ra n d o mize d i n t he pare nt st u d y , 
t h e disease -pr o gressi o n stat us at tra nsfer t o t he e xte nsi o n st u d y , a n d t he pla n ne d t reat me nt i n t he 
e xte nsi o n st u d y . Assess me nts at t he eli gi bilit y visi t are descri be d i n A p pe n di x A,A p pe n di x B, 
A p pe n di x C, a n d A p pe n di x D. 
6. 2. R a n d o miz ati o n a n d Bli n di n g 
T his is a n o pe n -la bel st u d y , a n d treat m e nt assi g n me nt i n t he e xte nsi o n st u d y  is n ot ra n d o mize d. 
6. 3. Assess me nts a n d Pr oce d ures b y Visit 
St u d y -visi t assess me nts var y  de pe n di n g o n t he treat me nt t o w hic h t he patie nt was ra n d o mize d i n 
t h e pare nt st u d y , t h e di sease -pr o gressi o n stat us at tra nsfer t o t he e xte nsi o n st u d y , a n d t he pl a n ne d 
treat m e nt i n t h e e xte nsi o n st u d y . Assess me nts i n t he vari o us patie nt -s u bsets are i n di vi d uall y 
liste d bel o w. 
6. 3. 1. P C Y C - 1 1 1 6- C A Assess me nts Bef ore P D i n Ar m A P atie nts (ie, i n p atie nts o n 
c hl or a m b ucil i n p are nt st u d y )
P ati e nts ra n d o mize d t o c hl ora m b ucil i n t he pare nt st u d y  ( ie, Ar m A of t h e pare nt st u d y ) w h o 
ha ve n ot e x perie nce d P D at t he ti me of pare nt -st u d y cl os ure are tra nsfer re d t o t h ee xte nsi o n 
st u d y  a n d are assesse d as descri be d bel o w. 
T he sc he d ule of assess me nts f or t hese patie nts is i n A p pe n di x A.
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692709] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 3 9 6. 3. 1. 1. Eli gi bilit y Visit 
I nf or m e d c o nse nt 
C o nfir mati o n o f eli gi bilit y f o r P C Y C - [ADDRESS_692710] u d y , t he f o ll o wi n g assess me nts occ ur 
e ver y 4 m o nt hs , o n Da y  1 of  t h e m o nt h (i e, M o nt hs [ADDRESS_692711] u d y ); starti n g f r o m  m o n t h  [ADDRESS_692712] u d y  s c h e d ul e. 
C o nc o mita nt me dicat i o ns ( o n g oi n g at t he e n d of t he c o nc o mita nt me dicati o ns re p orti n g 
p eri o d) 
I de nt ificati o n of alter nat i ve a ntica ncer treat me nt i ncl u di n g start date a n d reas o n (f or patie nts 
di sc o nti n ui n g I P f or reas o ns ot her t ha n P D) 
A d verse e ve nts ( o n g oi n g at t he e n d of t he A E re p orti n g peri o d) 
Ot her mali g na nc y 
P h ysical e xa mi nat i o n
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
P ati e nt re p orte d o utc o mes ( P R O) assess me nts ( E Q - 5 D- 5 L , F A Ci T Fat i g ue) 
Di sease assess me nt b y disease -relate d s y m pt o m s a n d o verall res p o nse assess me nt 
T he assess me nts bel o w will occ ur e ver y  [ADDRESS_692713] u d y  
is cl ose d b y t he S p o ns or. 
Di sease assess me nt b y  c o m p ute d t o m o gra p h y ( C T )/ ma g net ic res o na nce i ma gi n g ( M RI )sca n 
B o ne m arr o w bi o ps y  a n d/ or as pi r at e a n d M R D t o be perf or me d if i n dicate d 
Pr e di cti ve Bi o m ar kers 
6. 3. 1. 3. S us pecte d -P D Visit 
T his visit occ urs as s o o n as p ossi ble after P D is s us pecte d: 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
C o nc o mita nt me dicat i o ns ( o n g oi n g at t he e n d of t he c o nc o mita nt me dicati o ns re p orti n g 
p eri o d )
A d verse e ve nts ( o n g oi n g at t he e n d of  t he A E re p orti n g peri o d )
Ot her m ali g na nc y 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692714] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 0 P h ysical e xa mi nat i o n
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
C y t o ge netic, C L L fl u oresce nce i n sit u h y bri dizat i o n ( FI S H) pa nel 
Di sease assess me nt b y  C T/ M RI sca n, di sease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] t o be perf or me d if i n dicate d 
Pr e di cti ve bi o mar kers 
If P D is c o nfir me d a n d a n i n dicat i o n f o r treat m e nt is prese nt per t he I W C L L g ui deli nes, sec o n d -
li ne treat me nt p la n is deter mi ne d, a n d s u bse q ue nt assess me nts are as descri be d i n Sect i o n 6. 3. 3 
(i f eli gi ble f or sec o n d -li ne i br ut i ni b ‡) or Secti o n 6. 3. 4 (f o r n o n -i br uti ni b t h era p y  or n o treat m e nt ). 
If P D is n ot c o nfir me d, s u bse q ue nt assess me nts are as descri be d i n Sect i o n6. 3. 1. 2 .
6. 3. 2. P C Y C -1 1 1 6- C A Assess me nts Bef ore P D o r  e n d of i br uti ni b t her a p y f or ot her 
re a so ns i n Ar m B P atie nts (ie, i n p atie nts r a n d o mize d t o Ibr uti ni b i n p are nt 
st u d y) 
P ati e nts ra n d o mize d t o i br uti ni b i n t he pare nt st u d y  (ie, Ar m  B of  t he pare nt st u d y ) w h o ha ve n ot 
e x perie nce d P D at t he ti me o f pare nt -st u d y  cl os ur e are tra nsfer re d t o t he e xte nsi o n st u d y  f or 
c o nti n ue d i br ut i ni b t h era p y a n d are assesse d as descri be d bel o w. 
T he sc he d ule of assess me nts f or t h ese patie nts is i n A p pe n di x B.
6. 3. 2. 1. Eli gi bilit y Visit 
I nf or m e d c o nse nt 
C o nfir mati o n o f eli gi bilit y f o r P C Y C -[ADDRESS_692715] u d y , t he f o ll o wi n g assess me nts occ ur 
o n Da y  1 of  e ver y  o d d -n u m bere d c ycle (ie, C ycles 13, [ADDRESS_692716] u d y ); fr o m Cycle [ADDRESS_692717] u d y  i s cl ose d b y  t he Sp o ns or :
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
C o nc o mita nt me dicat i o ns 
A d verse e ve nts 
Ot her mali g na ncies 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692718] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 1 E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
Di sease -relate d s y m pt o m s
O verall res p o nse assess me nt 
Di s pe nse st u d y  dr u g u p o n c o m plet i o n of assess me nts. 
6. 3. 2. 3. D a y 1 of Desi g n ate d C ycles –Effic ac y Assess me nts 
U nt il [ADDRESS_692719] u d y , t he f o ll o wi n g assess me nts occ ur 
o n Da y  1 of  e ver y  4 t h c ycle (ie, C y cles [ADDRESS_692720] u d y );  starti n g fr o m Cycle [ADDRESS_692721] u d y  i s cl ose d b y  t h e Sp o ns or :
Di sease assess me nt b y  C T/ M RI sca n, di sease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt 
Pr e di cti ve bi o mar kers 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] a n d M R D t o be perf or m e d if i n dicate d 
6. 3. 2. 4. S us pecte d -P D Visit 
T his visit occ urs as s o o n as p ossi ble after P D is s us pecte d : 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
A d verse e ve nts ( o n g oi n g at t he e n d of t he A E re p orti n g peri o d) 
C o nc o mita nt me dicat i o ns ( o n g oi n g at t he e n d of t he c o nc o mita nt me dicati o ns re p orti n g 
p eri o d) 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
C y t o ge netic, C L L fl u oresce nce i n sit u h y bri dizat i o n ( FI S H) pa nel 
Di sease assess me nt  b y  C T/ M RI sca n, di sease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt 
Pr e di cti ve Bi o m ar kers 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] t o be perf or me d if i n dicate d 
If P D is c o nfir me d a n d t he I W C L L cri teria are met f or acti ve di sease re q ui ri n g tr e at m e nt , t h en 
t h e sec o n d -li ne treat me nt pla n is deter mi ne d, a n d s u bse q ue nt assess me nts are as descri be d i n 
Secti o n 6. 3. 4 .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692722] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 2 If P D is n ot c o nfir me d, s u bse q ue nt assess me nts are deter mi ne d b y w het her t h e pati e nt is still 
recei vi n g i br ut i ni b :
If t he patie nt is st ill recei vi n g i br ut i ni b at t he ti me of t he S us pecte d -P D Visit, s u bse q ue nt 
assess me nts are as descri be d i n Sect i o ns 6. 3. 2. 2 a n d 6. 3. 2. 3 . 
If t he patie nt is n o l o n ger recei vi n g i br ut i ni b at t he ti me of t he S us pecte d -P D Visit 
(e g ,i br uti ni b was st o p pe d b y  t he i n vest i gat or w he n P D was s us pecte d) , s u bse q ue nt 
assess me nts are as descri be d i n Sect i o n 6. 3. 2. 6 .
6. 3. 2. 5. E n d - of- Tre at me nt Visit 
T he e n d -of -treat m e nt visit occ urs wit hi n 3 0 da ys af t er t h e e n d of ra n d o mize d i br ut i ni b t h era p y . 
T he assess me nts are as f o ll o ws: 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
C o nc o mita nt me dicat i o ns 
A d verse e ve nts 
Ot her mali g na ncies 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
Di sease -relate d s y m pt o m s
6. 3. 2. 6. Pre -P D F oll o w -u p Visits 
U nt il [ADDRESS_692723] u d y , p r e -P D F oll o w -u p Visi ts occ ur 
e ver y 4 m o nt hs after t h eE n d -of -Treat me nt Vi si t f or pati e nts w h o ( 1) ha d n ot e x perie nce d P D 
a n d ( 2) ha d i br uti n i b t h era p y disc o nt i n ue d bef ore t he S us pecte d -P D Visit . Starti n g f r o m  m o nt h 
[ADDRESS_692724] u d y  cl os ure (i br uti ni b 
t h era p y is n ot t o be restarte d i n t hese pat ie nt s) . T he assess me nts are as f o ll o ws: 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
P h ysical e xa mi nat i o n
Vi t al  si g ns 
C o nc o mita nt me dicat i o ns ( o n g oi n g at t he e n d of t he c o nc o mita nt me dicati o ns re p orti n g 
p eri o d) 
A d verse e ve nts ( o n g oi n g at t he e n d of t he A E re p orti n g peri o d) 
Ot h er m ali g na ncies 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692725] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 3 S er u m  c he mistr y 
I de nt ificati o n of alter nat i ve a ntica ncer treat me nt i ncl u di n g start date, reas o n, d urati o n ,a n d 
res p o nse (f or pati e nts di sc o nt i n ui n g I P f or reas o ns ot her t ha n P D) 
Di sease assess me nt b y  disease -relate d s y m pt o m s a n d o verall res p o nse assess me nt 
T he assess me nts bel o w occ ur e ver y  [ADDRESS_692726] u d y cl os ure: 
Di sease assess me nt b y C T/ M RI sca n 
Pr e di cti ve Bi o m ar kers 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] a n d M R D t o be perf or me d if i n dicate d 
6. 3. 3. P C Y C - 1 1 1 6- C A Assess me nts After Dise ase Pr o gressi o n –Sec o n d- li ne 
Ibr uti ni b T her a p y ‡
P ati e nts w h o e x perie nce P D a n d t h e n recei ve sec o n d -li ne t hera p y i br ut i ni b thera p y are assesse d 
as descri be d bel o w. 
T he sc he d ule of assess me nts f or t hese patie nts is i n A p pe n di x C.
6. 3. 3. 1. Eli gi bilit y Visit 
I nf or m e d c o nse nt 
C o nfir mati o n o f eli gi bilit y f o r P C Y C - 1 1 1 6- C A 
C o nfir mati o n o f eli gi bilit y f o r sec o n d- li ne i br ut i ni b 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
Me dical hist or y 
C ollect a n d rec or d t he patie nt’s c o m p lete hist or y  i ncl u di n g c o nc urre nt me dical si g ns a n d 
s y m pt o ms t hat occ urre d i n t he i nter ve ni n g peri o d bet wee n st o p pi n g first -li ne treat me nt i n t he 
pare nt st u d y  a n d start of sec o n d -li ne t hera p y .
Di sease assess me nt b y  C T/ M RI sca n, di sease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt (assess me nts perf or me d i n t he 8wee ks bef ore t he start of sec o n d -li ne t hera p y ca n 
be use d) 
B o ne m arr o w bi o ps y a n d/ or as pi[INVESTIGATOR_337] t o be perf or me d if i n dicate d 
T he p h ysical e xa mi nat i o n, vital s i g ns assess me nt, deter mi nat i o n of E C O G stat us, a n d 
ce ntral -la b orat or y  h e m at ol o g y  a n d ser u m c he mistr y  tests are n ot re q ui re d at t he eli gi bilit y visit if 
t h ese assess me nts ha ve bee n d o ne i n t he 7 da ys bef ore t he visit. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692727] C ycle o n Ibr uti ni b ( m ust be c o m plete d wit hi n [ADDRESS_692728] a blis hi n g eli gi bilit y) 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
C o nc o mita nt me dicat i o ns 
A d verse e ve nts 
Ot her mali g na ncies 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
C y t o ge netic, C L L fl u oresce nce i n sit u h y bri dizat i o n ( FI S H )pa nel 
Pr e di cti ve bi o mar kers 
Di s pe nse st u d y  dr u g 
St u d y  dr u g a d mi nistrati o n: T he first d ose of i br uti ni b will be ta ke n at t he i n vest i gat i o nal si t e 
o n Da y  1 of  C y cle 1 after all pr oce d ures are c o n d ucte d 
6. 3. 3. 3. D a y 1 of 2n d T hr o u g h 6t h C ycle o n Ibr uti ni b 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) o n C ycles 3 a n d 5. 
C o nc o mita nt me dicat i o ns 
A d verse e ve nts 
Ot her mali g na ncies 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
Di s pe nse st u d y  dr u g 
T he f o ll o wi n g will be perf or me d o n C ycle 5: 
Di sease assess me nt b y C T/ M RI sca n, disease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt 
Pr e di cti ve bi o mar kers 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] a n d M R D t o be perf or me d if i n dicate d 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692729] arti n g at t he 7 t h c ycle ( 7 t h , 9 t h , 1 1 t h , etc. , c y cle of 
i br uti ni b )u nt il [ADDRESS_692730] is 
ta ki n g i br ut i ni b :
P ati e nt -re p orte d o utc o mes asse ss me nts ( E Q -5 D- 5 L , F A Ci T- Fat i g ue) 
C o nc o mita nt me dicat i o ns 
A d verse e ve nts 
Ot her mali g na ncies 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
Di s pe nse st u d y  dr u g 
Als o, e ver y 4t h c ycle of i br ut i ni b u nt il 2 5 c ycles after t he start of treat me nt (ie, C y cles 1 3, 1 7, 2 1, 
2 5) , t he n starti n g fr o m Cycle [ADDRESS_692731] u d y cl os ure , t h e f oll o wi n g 
a d di ti o nal  assess me nts are perf or me d: 
Di sease assess me nt b y  C T/ M RI sca n, di sease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt 
Pr e di cti ve bi o mar kers 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] t o be perf or me d as i n dicate d 
6. 3. 3. 5. S us pecte d -P D Visit 
T his visit occ urs as s o o n as p ossi ble after P D is s us pecte d; disease stat us is assesse d as f o ll o ws: 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
C o nc o mita nt me dicat i o ns ( o n g oi n g at t he e n d of t he c o nc o mita nt me dicati o ns re p orti n g 
p eri o d) 
A d verse e ve nts ( o n g oi n g at t he e n d of t he A E re p orti n g peri o d) 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
C y t o ge netic, C L L fl u oresce nce i n sit u h y bri dizat i o n ( FI S H) pa nel 
Di sease assess me nt b y  C T/ M RI sca n, di sease -relate d s y m pt o ms, a n d o verall res p o nse 
assess me nt 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692732] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 6 Pr e di cti ve Bi o m ar kers 
B o ne m arr o w bi o ps y  a n d/ or as pi [INVESTIGATOR_337] t o be perf or me d as i n dicate d 
If P D is c o nfir me d a n d I W C L L cri t eri a are m et f or acti ve disease re q uiri n g treat me nt , t h e n a 
ne xt -li ne treat me nt pla n is deter mi ne d, a n d s u bse q ue nt assess me nts are as descri be d i n 
Secti o n 6. 3. [ADDRESS_692733] ill 
recei vi n g i br ut i ni b :
If t he patie nt is st ill recei vi n g i br ut i ni b at t he ti me of t he S us pecte d -P D Visit, s u bse q ue nt 
assess me nts are as descri be d i n Sect i o ns6. 3. 3. 2 , 6. 3. 3. 3 , or 6. 3. 3. 4 ( de pe n di n g o n t he 
durati o n of  pri or i br uti ni b t h era p y ). 
If t he s u bject is n o l o n ger recei vi n g i br ut i ni b at t he ti me of t he S us pecte d -P D Visit 
(e g ,i br uti ni b was st o p pe d b y  t he i n vest i gat or w he n P D was s us pecte d), s u bse q ue nt 
assess me nts are as descri be d i n Sect i o n 6. 3. 3. 7 .
6. 3. 3. 6. E n d - of- Tre at me nt Visit 
T his visi t occ urs wi t hi n 3 0 da ys of t he e n d of sec o n d -li ne i br uti ni b t h era p y . T he visit s h o ul d be 
perf or m e d bef ore i nit iati o n of  s u bse q ue nt a nt ica ncer t hera p y . T he assess me nts are as f o ll o ws: 
P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
C o nc o mita nt me dicat i o ns 
A d verse e ve nts 
Ot her mali g na ncies 
P h ysical e xa mi nat i o n(i ncl u di n g f oc use d oc ular q uesti o ns) 
Vi t al  si g n s
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
Di sease -relate d s y m pt o m s
Pr e di cti ve bi o mar kers 
6. 3. 3. 7. Pre -P D F oll o w -u p Visit s
U nt il 2 5 m o nt hs af ter t he start of treat m e nt, t hese visit socc ur e ver y  4 m o nt hs after t he E n d -of -
Treat me nt Visit f or patie nts w h o ( 1) ha d n ot e x perie nce d P D a n d ( 2) ha d i br ut i ni b t h era p y 
di sc o nti n ue d bef ore t he S us pecte d -P D Visit . Fr o m  [ADDRESS_692734] u d y cl os ure (i br uti ni b t h era p y  is n ot t o be resta rte d i n t hese 
pati e nts) . T he assess me nts are as f o ll o ws: 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692735] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 7 P ati e nt -re p orte d o utc o mes assess me nts ( E Q - 5 D- 5 L , F A Ci T- Fat i g ue) 
P h ysical e xa mi nat i o n
C o nc o mita nt me dicat i o ns ( o n g oi n g at t he e n d of t he c o nc o mita nt me dicati o ns re p orti n g 
p eri o d) 
A d verse e ve nts ( o n g o i n g at t he e n d of t he A E re p orti n g peri o d) 
Ot her mali g na ncies 
Vi t al  si g ns 
E C O G f u nct i o nal stat us 
H e m at ol o g y 
S er u m  c he mistr y 
I de nt ificati o n of alter nat i ve a ntica ncer treat me nt i ncl u di n g d urati o n a n d res p o nse (f or pati e nts 
di sc o nti n ui n g I P f or reas o ns ot her t ha n P D) 
Di sease assess me nt b y  C T/ M RI sca n, b o ne m arr o w bi o ps y a n d /or as pi[INVESTIGATOR_337] a n d M R D as 
a p pr o priate , di sease -relate d s y m pt o ms, a n d o verall res p o nse assess me nt 
Pr e di cti ve Bi o m ar kers 
6. 3. 4. P C Y C - 1 1 1 6- C A Assess me nt s After Dise ase Pr o gressi o n –N o n -i br uti ni b 
S u bse q ue nt T her a p y or N o S u bse q ue nt T her a p y 
F o ll o wi n g i m ple me ntati o n of A me n d me nt 3, p at ie nt s w h o were ra n d o mize d t o a n d w h o 
s u bse q ue nt l y pr o gresse d o n c hl ora m b ucil will n ot be f o ll o we d a n d will e xit t he st u d y .
Pati e nts w h o e x perie nce P D o n fir st -li ne i br uti ni b a n d g o o n t o recei ve a n al ter nati ve a nt ica ncer 
treat m e nt ot her t ha n i br uti ni b as s u bse q ue nt t h era p y or n o s u bse q ue nt t h era p y  will be f o ll o we d 
per A p pe n di x D. U nt il i m ple me ntati o n of t he prese nt a me n d me nt, p at ie nt s w h o recei ve d n o n- 
i br uti ni b t h era p y  were p ote nti all y eli gi ble t o recei ve s u bse q ue nt treat me nt wit h i br uti ni b if t he y 
met eli gi bilit y cr it eri a o utli ne d i n Sect i o n4. 2 ‡. O nce t h e Me di cal M o ni t or a p pr o ve dne xt li ne 
i br uti ni b t h era p y ,t h e pati e nt were assesse d f o ll o wi n g t he sc he d ule d o utli ne d i n Sect i o n 6. 3. 3 
(a n d A p pe n di x C)st arti n g wit h t he eli gi bilit y visit ‡.
T he sc he d ule of assess me nts f or t hese pati e nts i s i n A p pe n di x D.
6. 3. 4. 1. Eli gi bilit y Visit 
I nf or m e d c o nse nt 
C o nfir mati o n o f eli gi bilit y f o r P C Y C - 1 1 1 6- C A 
6. 3. 4. 2. F oll o w -u p Visits 
P ati e nts starti n g n o n -i br ut i ni b s u bse q ue nt t h era p y will be f o ll o we d ev er y  4 m o nt hs fr o m t h e start 
of  s u bse q ue nt t h era p y  wi t h  a n al ter nat i ve a nt ica ncer treat me nt . Patie n ts deci di n g t o f ore g o 
s u bse q ue nt t h era p y will be f o ll o we d ev er y  4 m o nt hs fr o m t h e date of decisi o n t o f ore g o 
s u bse q ue nt t h era p y .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692736] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 4 8 Fol l o wi n g assess me nts are perf or me d at t he fre q ue nc y descri be d a b o ve :
S ur vi val stat us 
I de nt ificati o n of a lt er nat i ve a ntica ncer treat me nt i ncl u di n g start date, reas o n f o r i nit iat i n g 
t h era p y , d urati o n ,a n d res p o nse 
Ot her ma li g na ncies 
Pr e di cti ve Bi o m ar kers will  b e c ollecte d e ver y 1 2 m o nt hs. 
6. 4. Descri pti o n of Assess me nts a n d Pr oce d ures 
6. 4. 1. C o nfir m ati o n of Eli gi bilit y 
Perf or m  all necessar y pr oce d ures a n d e val uati o ns t o d oc u me nt t hat t he patie nt meets eac h 
eli gi bilit y cri t eri o n ( Sect i o n 4. 1 ). I n a d dit i o n, f or patie nts w h o are bei n g c o nsi dere d f or sec o n d -
li ne i br ut i ni b t h era p y, perf or m all necessar y  pr oce d ures a n d e val uat i o ns t o d oc u me nt t hat t he 
pati e nt meets t h e a d dit i o nal criteria f or sec o n d -li ne i br ut i ni b (Sect i o n 4. 2 )‡. Pl ease refer t o t he 
st u d y  m a n ual  f or a m ore detaile d descri pt i o n of t he pr oce d ures . Bl o o d sa m pl es f or h e m at ol o g y 
a n d ser u m  c h e mistr y  tests will be e val uate d b y a ce ntral la b orat or y  t o c o nfir m eli gi bilit yf o r 
sec o n d -li ne i br ut i ni b ‡.
6. 4. 2. Me dic al Hist or y 
C ollect a n d rec or d t he patie nt ’s c o m p lete hist or y  i ncl u di n g c o nc urre nt me dical si g ns a n d 
sy m pt o ms t h at occ urre d i n t he i nter ve ni n g peri o d bet wee n st o p pi n g first -li ne treat me nt i n t he 
pare nt st u d y a n d start of sec o n d -li ne i br ut i ni b t h er a p y ‡.
6. 4. 3. A d verse E ve nts 
T he acce pte d re g ulat or y  defi ni ti o n  of  a n A E is i n Secti o n 8. [ADDRESS_692737] u d y , 
AEs are rec or de d as f o ll o ws: 
A E data c o llecte d f o r p ati e nts o n fir st -li ne or sec o n d -li ne i br uti ni b wi t h i n A E re p orti n g 
p eri o d defi ne d i n Sect i o n 8. 3. [ADDRESS_692738] u d y  visi ts i de ntifie d i n t he 
sc he d ules of assess me nt ( A p pe n di x Ba n d A p pe n di x C), w he n v o l u nt eere d b y  t he pat ie nt , 
a n d w he ne ver t he i n vesti gat or bec o mes a ware of a n e ve nt. 
If A E is re p orte d as o n g oi n g at t he ti me of cl o s ure of t he pare nt st u d y , A E data will c o nt i n ue 
t o b e c ollecte d f or patie nt s ra n d o mize d t o c hl ora mb ucil . T hese e ve nts are rec or de d at t he 
st u d y  visi ts i de ntifie d i n t he Sc he d ule of Assess me nt ( A p pe n di x A). 
A E data a re n ot c ollecte d f or patie nts o n sec o n d -li ne t hera p y wit h a n alter nat i ve a nt ica ncer 
treat m e nt ot her t ha n i br uti ni b .
E ve nts m ust be rec or de d fr o m t he ti me t he I C F is si g ne d (fi rst -li ne i br ut i ni b) or fr o m start of 
eli gi bilit y assess me nts (sec o n d -li ne i br ut i n ib) u nt il [ADDRESS_692739] (see Secti o n 8. 3. 4 f o r details) will be re p orte d t o t he 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692740] i o n8. 3 .
6. 4. 4. P h ysic al E x a mi n ati o n 
P h ysical e xa mi nat i o ns s h o ul d i ncl u de wei g ht, a n d e xa mi nat i o n of t he s ki n, e yes ( wit h s pecific 
q uesti o ns f oc use d o n oc ular s y m pt o ms f o r i br uti ni b patie nts o nl y ), ears, n ose, t hr oat, l u n gs, 
heart, a b d o me n, e xtre mities, a n d l y m p hat ic s yste m . T he l y m p hat ic s yste m e xa mi nat i o n will 
i ncl u de bi -di me nsi o n al  m eas ure me nts of pal pa ble l y m p h n o des a n d meas ure me nt of s plee n a n d 
li ver sizes b y ce nti meters bel o w t he c ostal mar gi n o n t he res pect i ve si de. 
T he e xa mi nat i o n s h o ul d als o i ncl u de i n q uir y  of  o c ul ar s y m pt o ms a n d pat ie nt s s h o ul d be referre d 
t o a n o p ht hal m o l o gist f or a f or mal e xa mi nat i o n if a n y Gra de ≥ [ADDRESS_692741] u d y .
6. 4. 8. P atie nt -re p orte d O utc o mes 
T w o P R O i nstr u me nts t h e E Q -5 D- 5 L ( A p pe n di x J) a n d t he F A Ci T -fati g ue ( A p pe n di x K) will  
be a d mi nistere d i n t his st u d y . T hese q uest i o n naires are t o be c o m plete d b y  t he pat ie nt  pri or t o 
a n y ot her st u d y  pr oce d ures at t he desi g nate d visit s. 
6. 4. 8. 1. E Q - 5 D- 5 L 
T he E Q - 5 D- 5 L is a sta n dar dize d i nstr u me nt use d t o meas ure of healt h o utc o me 
(E ur o Q o lGr o u p 1 9 9 0 ) a n d c o nsists of a 5 -it e m  q uesti o n naire a n d a “t her m o meter” vis ual 
a nal o g ue scale ra n gi n g fr o m 0 ( w orst i ma gi na ble healt h state) t o 1 0 0 ( best i ma gi na ble healt h 
state) . T he sc ores f or t he [ADDRESS_692742] i vit ies, pai n/ disc o mf o rt, a n d a n xiet y/ de pressi o n. 
6. 4. 8. 2. F A Ci T -F ati g ue 
T he F A Ci T -F q uest i o n naire is a meas ure of fat i g ue -relate d q ualit y of  l ife i n pat ie nt s wi t h  ca ncer 
a n d ot her c hr o nic diseases ( Yelle n 1 9 9 7 ). T he 1 3 -ite m F A Ci T -Fat i g ue Scale meas ures eac h ite m 
o n a 5 -p oi nt Li kert scale . T he F A Ci T -Fat i g ue Scale has bee n vali date d i n t he ge neral p o p ulat i o n, 
as well as i n pat ie nt s wi t h  ca nce r (Cella 2 0 0 2 ) or r he u mat oi d art hri ti s. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692743] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 0 6. 4. 9. He m at ol o g y 
H e m at ol o g y  will be e val uate d b y  a ce ntral  l a b orat or y  a n d will  i ncl u de a c o m plete bl o o d c o u nt 
( C B C) wi t h  w hi t e bl o o d cell differe nt ia l. A n y missi n g ce ntral la b orat or y  bl o o d s a m ples s h o ul d 
be re dra w n as s o o n as p ossi ble . I n t he e ve nt t hat t he missi n g ce ntral la b orat or y  sa m ple is 
u nrec o vera ble, l ocal la b orat or y  res ul ts will be c ollecte d, if a vaila ble, a n d e ntere d i n t he cli nical 
data base f or res p o nse or pr o gressi o n c o nfir mat i o n. 
6. 4. 1 0. Ser u m C he mistr y 
S er u m  c he mistr y  will be e val uate d b y  a ce ntral  l a b orat or y  a n d will i ncl u de al b u mi n, al kali ne 
p h os p hatase, A L T, A S T, bl o o d urea nitr o ge n ( B U N), calci u m, creat i ni ne, gl uc ose, lactate 
de h y dr o ge nase ( L D H), p h os p hate, p otassi u m, s o di u m, t otal bilir u bi n, a n d uri c aci d . A n y missi n g 
ce ntral  l a b orat or y  bl o o d s a m ples s h o ul d be re dra w n as s o o n as p ossi ble. 
6. 4. 1 1. Dise ase Assess me nt 
6. 4. 1 1. 1. C o m p ute d T o m o gr a p h y ( C T ) Sc a ns 
C T sca ns will be p erf or m e d as descri be d i n t he sc he d ules of assess me nt . M RI ma y be use d t o 
e val uate site s of disease t hat ca n n ot be a de q uatel y i ma ge d usi n g C T (i n cases w here M RI is 
desi ra ble, t he M RI m ust be o btai ne d at baseli ne a n d at all s u bse q ue nt re s p o nse e val uat i o ns) . 
If M RI i s re q ui r e d f or a n y  ot her reas o n, t hi s m ust first be disc usse d wit h t he st u d y’s Me dical 
Mo ni t or. 
6. 4. 1 1. 2. B o ne M arr o w Bi o ps y a n d /or As pir ate 
A b o ne marr o w as pi[INVESTIGATOR_337] a n d /or bi o ps y s h o ul d be o btai ne d t o c o nfir m C R, C R i or t o c o nfir m 
c y t o p e ni c pr o gressi o n a n d disti n g uis h a ut oi m m u ne a n d treat me nt -relate d c y t o p e ni as 
(Secti o n 7. 5. 2 ). Marr o w c ollecte d t o c o nfir m C R s h o ul d ha ve M R D assesse d b y  fl o w c y t o m etr y  
o n t he as pi[INVESTIGATOR_337] . A n a d dit i o nal t u be of b o ne marr o w as pi[INVESTIGATOR_533435] c ollecte d f or bi o mar ker 
assess me nts a n d 2sli des of t he as pi[INVESTIGATOR_337] s mear s u b mitte d. 
6. 4. 1 1. 3. Dise ase -rel ate d S y m pt o ms 
Di sease -relate d s y m pt o m sie, fat i g ue, ni g ht s weats, fe ver, wei g ht l oss, s y m pt o ms of 
s ple n o me gal y  (a b d o mi nal  pai n/ disc o mf ort i ncl u di n g earl y satiet y), a n d a n ore xia will  b e 
assesse d a n d rec or de d. 
6. 4. 1 1. 4. O ver all Res p o nse Assess me nt 
O verall res p o nse assess me nt will i ncl u de e val uat i o n of p h ysica l e xa mi nat i o ns, rec or di n g of 
s y m pt o ms, he mat ol o gical e val uati o ns, a n d ra di o gra p hic e val uat i o ns per t he sc he d ule of 
assess me nts (see Secti o n 7a n d A p pe n di x A, A p pe n di x B, a n d A p pe n di x C). F or a n y s us pecte d 
case of disease pr o gressi o n, refer t o Secti o n 7. 1 .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692744] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 1 6. 4. 1 2. C yt o ge netic, C L L FI S H P a nel 
As descri be d i n t he sc he d ules o f assess me nts, patie nts at s us pecte d P D a n d i n t he 8 wee ks bef ore 
Cycle 1 D a y  1 of  sec o n d -li ne i br ut i ni b t h era p y ‡will ha ve a b o ne marr o w bi o ps y a n d/ or as pi [INVESTIGATOR_20325] i o n 
perf or m e d l o c all y  t o assess t he c y t o ge neti c pr ofile b y  usi n g t h e sta n dar d C L L FI S H pr o bes t o 
detect a b n or malit ie s i n c hr o m o s o m es 1 3 q, 1 2, 1 1 q, a n d 1 7 p . If b o ne marr o w f or FI S H is n ot 
a vaila ble, a peri p heral bl o o d sa m ple i n a pat ie nt  wit h a pretreat me nt l y m p h oc y t osis 
( > 1 0, 0 0 0 cells/ µ L) ca n be s u bjecte d t o FI S H a nal ysis. 
6. 4. [ADDRESS_692745] wit h f ut ure de vel o p me nt of t his c o m p o u n d. 
6. 4. 1 4. Alter n ati ve A ntic a ncer Tre at me nt 
F or all patie nts i n pre -P D f o ll o w u p ( A p pe n di x A, A p pe n di x Ba n d A p pe n di x C)a n d 
A p pe n di x D, i de nt ificati o n of alter nat i ve a ntica ncer treat me nt, i ncl u di n g start date, reas o n, 
d urati o n ,a n d best o verall res p o nse ( B O R) will be rec or de d a n d assesse d at eac h visit acc or di n g 
t o t he visit sc he d ule o f assess me nts. 
F o ll o wi n g i m ple me ntati o n of Pr ot oc ol A me n d me nt 3, f or patie nts ra n d o mize d t o c hl ora m b ucil ,
i de nt ificat i o n of al ter nat i ve a nt ica ncer treat me nt will o nl y i ncl u de start date a n d reas o n. 
7. M AI N E F FI C A C Y E V A L U A TI O N S 
Di sease e val uat i o ns i ncl u de t he f o ll o wi n g: 
P h ysical e xa mi nat i o n ( w hic h will f oc us o n t he pre se nce/a bse nce of size i ncrease/ decrease i n 
l y m p h n o des, li ver, a n d s plee n) 
Di sease -relate d s y m pt o m s
H e m at ol o gi c para meters b y  C B C perf or m e d at a ce ntral  l a b orat or y
Ra di o gra p hic e val uat i o n ( C T or M RI sca n of t he nec k, c hest, a b d o me n, a n d pel vis) 
B o ne m arr o w as pi r at e a n d /or bi o ps y as a p pr o pri at e b y fl o w c y t o m etr y  i f t h ere is e vi de nce of 
C R i n t he ot her res p o nse para meters .
oPati e nts w h o ac hi e ve M R D -ne gati ve re missi o n i n t he b o ne marr o w m a y  t h e n be f o ll o w e d 
b y peri p heral bl o o d M R D a p pr o xi matel y e ver y  6 m o nt hs .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692746] of Heal t h  A ut h ori ti es, t h e data ma y be re vie we d b y a n I n de pe n de nt 
Re vie w Co m mittee (I R C) as well. 
7. 1. S us pecte d Dise ase Pr o gressi o n 
T he sc he d ules of assess me nts are pr o vi de d i n A p pe n di x A, A p pe n di x B,a n d A p pe n di x C. A n y 
s us pecte d case of disease pr o gressi o n will pr o m pt  pr oce d ures perf or me d i n a S u s pecte d -P D Visit 
(Secti o n 6. 3 ). Disease pr o gressi o n s h o ul d be c o nfir me d wit h a C T sca n ( or M RI, if C T is 
c o ntrai n dicate d) a n d s h o ul d be re p orte d t o t he S p o ns or wi t hi n 2 4 h o urs of di sc o ver y . If  disease 
pr o gressi o n is s us pecte d base d o n t he res ults of a si n gle e xa mi nat i o n (i ncl u di n g C T sca n) or a 
si n gle la b orat or y  para meter, t his fi n di n g s h o ul d be c o nfir me d b y a s u bse q ue nt e val uat i o n at l east 
[ADDRESS_692747] u d y -r el ate d pr oce d ures a n d assess me nts as descri be d i n A p pe n di x A,
A p pe n di x B,A p pe n di x Cor A p pe n di x Ds h o ul d be c o nti n ue d u nt il disease pr o gressi o n is 
deter mi ne d b y t he i n vest i gat or . W he n disease pr o gressi o n has bee n deter mi ne d b y t he 
i n vesti gat or, t he c urre nt st u d y  treat m e nt s h o ul d be di sc o nti n ue d. 
If ne w a nt ica ncer t hera p y is i nit iate d pri or t o pr o gressi ve disease, t he patie nt s h o ul d c o nt i n ue t o 
be f o ll o we d f or di sease p r o gressi o n as descri be d f or t he pre -P D f oll o w -u p p hase acc or di n g t o t he 
sc he d ule i n w hic h t he y  are e nr olle d (Secti o n 6. 3 ). 
Bl o o d tests perf or m e d l o call y  f or deter mi nat i o n of res p o nse or disease pr o gressi o n will nee d t o 
be re peate d b y  t he ce ntral  l a b orat or y  f or c o nfi r m at i o n of res ults. 
7. 2. G ui deli nes f or Dise ase E v al u ati o n 
O bject i ve res p o nse will be cate g orize d as C R , C R wi t h  i nc o m p lete b o ne marr o w rec o ver y ( CRi), 
n P R , P R , sta bl e disease, or P D —all base d u p o n I W C L L criteria ( Halle k 2 0 0 8 ). All res p o nses 
m u st be m ai ntai ne d f or at least [ADDRESS_692748] be c o nfir me d b y 
b o ne marr o w bi o ps y a n d /or as pi r at e . Res p o nse assess me nts will occ ur i n de pe n de nt of o n g oi n g 
t h era p y .
Detaile d defi nit i o ns of all cate g ories o f res p o nse are i n A p pe n di x E. Res p o nse criteria a n d 
cr it eria f or disease pr o gressi o n are descri be d i n A p pe n di x F. 
Gi ve n t he k n o w n mec ha nis m o f acti o n of  B C R -i n hi bit i n g a ge nts, i ncl u di n g i br uti ni b , a n d t he 
treat m e nt -relate d l y m p h oc y t osis fre q ue ntl y o bser ve d d uri n g treat me nt wit h i br ut i ni b , is ol ate d 
treat m e nt -relate d l y m p h oc y t osis (i n a bse nce of ot her cli nical, C T, or la b orat or y  e vi de nce of 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692749] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 3 di sease pr o gressi o n) will n ot be c o nsi dere d pr o gressi ve disease . T his a p pr oac h i s s u p p orte d b y  
b ot h t he a ut h ors of t he I W C L L 2 0 0 8 g ui deli nes (Halle k 2 0 1 2 , C hes o n 2 0 1 2 ) a n d t he N C C N. 
Ta ble 5o utli nes w hat is re q uire d f or eac h para meter at baseli ne t o be e val ua ble t hr o u g h o ut t he 
st u d y. 
T a ble 5: E v al u a ble P ar a meter Re q uire me nts 
P ar a meter Re q uire me nts t o be E v al u a ble f or Res p o nse 
Meas ura ble disease L y m p h n o de > 1. 5 c m 
S ple n o me gal y E nlar ge d s plee n 
He pat o me gal y E nlar ge d li ver 
L y m p h oc yte c o u nt > 4, 0 0 0/ L
Platelets < 1 0 0, 0 0 0/ L
A bs ol ute ne utr o p hil c o u nt < 1, 5 0 0/ L
He m o gl o bi n < 1 1. 0 g/ d L 
7. 3. S ust ai ne d He m at ol o gic al I m pr o ve me nt 
I n all pat ie nt s a n d t he s u bset of patie nts wit h c y t o pe nia(s) at baseli ne ( H g b ≤1 1 g/ d L, 
pl at el ets ≤1 0 0, 0 0 0 / μ L ), ti me t o i m pr o ve me nt i n bl o o d c o u nts a n d perce nta ge of patie nts wi t h  
i m pr o ve me nt (s ustai ne d i m pr o ve me nt, defi ne d as i m pr o ve me nt i n c y t o pe nia b y a n i ncrease of 
H g b le vels fr o m baseli ne b y  ≥2 g/ d L, or a n i ncrease of platelet c o u nts fr o m baseli ne b y  ≥5 0 %, 
wi t h  t he d urati o n of  i m pr o ve me nt last i n g f o r at least [ADDRESS_692750] ors) will be assesse d .
7. 4. Res ol uti o n of Pretre at me nt Dise ase -Rel ate d S y m pt o ms 
Res o l ut i o n of pretreat me nt c o nstit uti o nal s y m pt o ms i ncl u di n g fat i g ue, wei g ht l oss, a n ore xia, 
fe vers, ni g ht s weats, or s y m pt o ms o f s ple n o me gal y  wi ll be e val uate d. 
7. 5. Tre at me nt -Rel ate d Defi niti o ns 
Defi nit i o ns of meas ur a ble disease, treat me nt -relate d l y m p h oc yt osis, Ric hter’s tra nsf or mat i o n, 
M R D , a n d treat m e nt fail ure ca n be f o u n d i n A p pe n di x E.
7. 5. 1. C o m p ute d T o m o gr a p h y Sc a ns 
Ra di ol o gi c al  i ma gi n g b y C T wi t h  c o ntrast is re q ui re d if attai na ble, a n d it m ust i ncl u de t he pel vis, 
a b d o me n, c hest, a n d nec k . P ati e nts w h o are i nt ol era nt t o I V c o nt rast a ge nts will ha ve C T sca ns 
perf or m e d wi t h  or al  c o ntrast . W he n p ossi ble, all patie nts s h o ul d ha ve ra di o gra p hic t u m or 
meas ure me nts perf or me d at t he partici pati n g st u d y ce nter or a n acce pta ble alter nate i ma gi n g 
facilit y usi n g a n i de ntical  i ma gi n g pr ot o c ol  a n d si milar e q ui p me nt . T he sa me i ma gi n g e q ui p me nt 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692751] be perf or me d t o c o nfir m disease pr o gressi o n. 
U p t o 6 meas ura ble l y m p h n o des (tar get lesi o ns), clearl y  m eas ura ble i n 2 per pe n dic ular 
di me nsi o ns, will be f o ll o we d f or eac h pat ie nt . Meas ura ble sites of disease s h o ul d be c h ose n s uc h 
t h at t he y  are re prese ntati ve of t he patie nt’s disease . I n a d diti o n, select i o n of tar get lesi o ns s h o ul d 
be fr o m as dis parate re gi o ns of t he b o d y  as p ossi ble . If a d dit i o nal lesi o n s are prese nt b ut are n ot 
i ncl u de d i n t he tar get lesi o n assess me nt, t he y  ca n be a d de d as n o ntar get lesi o ns f o ll o we d 
t h r o u g h o ut t he st u d y .
T he l o n gest di a meter of t he s plee n a n d li ver will be assesse d at Scree ni n g a n d all s u bse q ue nt 
res p o nse e val uat i o ns. 
L y m p h n o des a n d s plee n will be e val uate d r a di o gra p hicall y , a n d ra di o gra p hic fi n di n gs will 
o verri de p h ysical e xa mi nat i o n assess me nt of t he sa me lesi o n. 
Sca ns will be rea d b y  a n in de pe n de nt l ocal ra di o l o gi st, a n d res ults will be i nter prete d b y  t he 
i n vesti gat or. 
7. 5. 2. B o ne M arr o w As pir ate a n d /or Bi o ps y a n d Mi ni m al Resi d u al Dise ase 
If t he patie nt’s p h ysical e xa mi nat i o n fi n di n gs, la b orat or y  e val uat i o ns, a n d ra di o gra p hic 
e val uat i o ns s u g gest t h at C R has bee n ac hie ve d, a b o ne marr o w as pi[INVESTIGATOR_337] a n d /or bi o ps y s h o ul d be 
o btai ne d t o c o nfir m t he C R or n P R . I n rare cases w here pr o gressi o n is o nl y s h o w n i n 
1para meter, a b o ne marr o w as pi[INVESTIGATOR_337] a n d/ or bi o ps y ca n be perf or me d t o c o nfir m c y t o pe nic 
pr o gressi o n a n d dist i n g uis h a ut oi m m u ne a n d treat me nt -relate d c y t o p e ni as. 
P eri p heral  bl o o d a n d b o ne marr o w as pi[INVESTIGATOR_533436] o ps y wit h fl o w c y t o m etr y  assess me nt(s) f or 
M R D s h o ul d be d o ne if t here is e vi de nce of C R i n all o f t h e res p o nse para meters . M R D is 
defi ne d as < [ADDRESS_692752] u d y , AEs are rec or de d as f o ll o ws: 
A E data c ollecte d f or patie nts o n first -li ne or sec o n d -li ne i br uti ni b wit hi n A E re p orti n g 
p eri o d defi ne d i n Sect i o n 8. 3. [ADDRESS_692753] u d y  visi ts i de ntifie d i n t he 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692754] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 5 sc he d ules of assess me nt f o r i br ut i ni b (A p pe n di x Ba n d A p pe n di x C), w he n v o l u nt eere d b y  
t h e pati e nt, a n d w he ne ver t he i n vest i gat or bec o mes a ware of a n e ve nt. 
If A E re p orte d as o n g oi n g at t h e ti m e of  cl os ure of t he pare nt st u d y , A E data will c o nti n ue t o 
be c o llecte d f or patie nt s ra n d o mize d t o c hl ora mb ucil . All A Es are rec or de d at t he st u d y  visi ts 
i de nt ifie d i n t he sc he d ule of assess me nt ( A p pe n di x A). 
A E data are n ot c ollecte d f or patie nts o n sec o n d -li ne t hera p y wit h a n alter nat i ve a nt ica ncer 
treat m e nt ot her t ha n i br uti ni b .
8. 1. S afet y M o nit ori n g Pl a n 
A P h ar m a c o vi gila nce C o m mittee will c o m par e AEs i n t he st u d y  wi t h  safet y  data fr o m  t he e nt ir e 
cli nical trial data base f or i br uti ni b . All e nr olle d patie nts will be e val uate d cli nicall y  a n d usi n g 
sta n dar d l a b orat or y  testi n g d uri n g t heir partici pati o n i n t his st u d y .
S af et y assess me nts will c o nsist of m o nit ori n g a n d rec or di n g AEs a n d S A Es; meas ure me nts of 
pr ot oc ol -s pecifie d he mat ol o g y , cli nical c he mistr y , a n d ot her l a b orat or y  v aria bles; meas ure me nt 
of  pr ot oc ol -s pecifie d vital si g ns; a n d ot her pr ot oc ol -s pecifie d tests t hat are dee me d crit ic al  t o t he 
saf et y e val uat i o n of t he st u d y  dr u g(s). 
8. 2. Defi niti o ns 
8. 2. 1. A d verse E ve nts 
A n A E i s a n y  u nt o war d m e dical occ urre nce i n a patie nt a d mi nistere d a p har mace ut ical pr o d uct 
a n d w hic h d oes n ot necessaril y ha ve a ca usal relat i o ns hi p wit h t hi s treat m e nt . A n A E ca n 
t h eref ore b e a n y  u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a cli nicall y si g nifica nt a b n or mal 
la b orat or y  f i n di n g, f or e xa m ple), s y m pt o m, or disease te m p orall y  ass ociate d wi t h  t he use of a n 
i n vesti gat i o nal st u d y  dr u g, w het her or n ot c o nsi dere d relate d t o t he st u d y  dr u g ( I C H -E 2 A 1 9 9 5 ). 
F or t he p ur p oses of t his cli nical st u d y , AEs i ncl u de e ve nts w hic h are eit her ne w or re prese nt 
detecta ble e xacer bati o ns of pre -e xist i n g c o n dit i o ns. 
Di sease pr o gressi o n is n ot a n A E ; rat her i t m a y be t he ca use of a n A E . A E s t hat occ ur d ue t o 
di sease pr o gressi o n m ust be re p orte d as all ot her treat me nt -e m er ge nt A E s. 
T he ter m  “ disease pr o gressi o n” s h o ul d n ot be re p orte d as a n A E ter m. As a n e xa m ple, 
" w orse ni n g of C L L/ S L L" or t he cli nica l dia g n osis t hat is ass ociate d wit h disease pr o gressi o n 
s h o ul d be re p orte d. 
A E s ma y  i ncl u de, b ut are n ot li mite d t o: 
S u bject i ve or o bject i ve s y m pt o ms s p o nta ne o usl y offere d b y t he pat ie nt  a n d/ or o bser ve d b y  
t h e i n vest i gat or or st u d y  staff i ncl u di n g la b orat o r y  a b n or m ali ti es of cli nical si g nifica nce. 
A n y AEs e x peri e nce d b y t he patie nt t hr o u g h t he c o m plet i o n of fi nal st u d y  pr oce d ures. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692755] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 6 AEs n ot pre vi o usl y o bser ve d i n t he patie nt t hat e mer ge d uri n g t he pr ot oc ol -s pecifie d A E 
re p orti n g peri o d, i ncl u di n g si g ns or s y m pt o ms ass ociate d wit h C L L/ S L L t hat were n ot 
prese nt bef ore t he A E re p orti n g peri o d (see Secti o n 8. 3. 1 ). 
C o m plicat i o ns t hat occ ur as a res ult of pr ot oc ol -ma n date d i nter ve nt i o ns ( e g, i n vasi ve 
pr oce d ures s uc h as bi o psies). 
T he f o ll o wi n g are N O T c o nsi dere d A Es: 
Pre -e xisti n g c o n dit i o n:   A pre -e xist i n g c o n dit i o n ( d oc u m e nte d o n t he me dical hist or y  C R F) 
is n ot c o nsi dere d a n A E u nless t he se verit y,  f re q ue nc y, or c haracter of t he e ve nt w orse ns 
d uri n g t he st u d y  p eri o d. 
Pre -pl a n ne d or electi ve h os pit aliz ati o n:   A h os pi[INVESTIGATOR_90730] i o n pla n ne d be f o re si g ni n g t he I C F 
is n ot c o nsi dere d a n S A E, b ut rat her a t hera pe utic i nter ve nt i o n. H o we ver, if d uri n g t he 
pre -pla n ne d h os pi[INVESTIGATOR_90730] i o n a n e ve nt occ urs, w hic h pr ol o n gs t he h os pi[INVESTIGATOR_90730] i o n or m eets a n y  
ot her S A E criteria, t he e ve nt will be c o nsi dere d a n S A E. S ur geri es or i nter ve nti o ns t hat were 
u n der c o nsi derat i o n, b ut n ot perf or me d bef ore e nr oll me nt i n t he st u d y , will n ot be c o nsi dere d 
seri o us if t he y are perf or me d after e nr oll me nt i n t he st u d y  f or a c o n di ti o n t hat has n ot 
c ha n ge d fr o m its baseli ne le vel . El ecti ve h os pi[INVESTIGATOR_1314] o ns f or s ocial reas o ns, s olel y f or t he 
a d mi nistrati o n of c he m ot hera p y , or d ue t o l o n g tra vel dista nces are als o n ot S A Es. 
Di a g n ostic testi n g a n d pr oce d ures:   Testi n g a n d pr oce d ures s h o ul d n ot t o be re p orte d as 
AEs or S A Es, b ut rat her t h e ca use f or t he test or pr oce d ure s h o ul d be re p orte d. 
8. 2. 2. Seri o us A d verse E ve nt 
N ote:  T he ter ms “ se vere ”a n d “seri o us” are n ot s y n o n y m o us . Se verit y ( or i nte nsi t y ) r ef ers t o t he 
gra de of a n A E (see bel o w) . “ Seri o us” is a re g ulat or y  defi ni ti o n .
A S A E (e x perie nce) or reacti o n is a n y u nt o war d me dical occ urre nce t hat at a n y  d ose: 
Res ults i n deat h (ie, t he A E act uall y  ca uses or l ea ds t o deat h). 
Is life -t h reate ni n g . Life -t h reate ni n g i s defi ne d as a n A E i n w hic h t he patie nt was at ris k of 
deat h at t he ti me of t he e v e nt . It d oes n ot refer t o a n e ve nt w hic h h y p ot heticall y mi g ht ha ve 
ca use d deat h if it were m ore se vere . If eit her t he i n vesti gat or or t he Sp o ns or belie ves t hat a n 
A E m eets t he defi nit i o n of life -t h reate ni n g, i t will be c o nsi dere d life -t h reate ni n g. 
Re q ui r es i n -pat ie nt  h os pi [INVESTIGATOR_90730] i o n > [ADDRESS_692756] i n g h os pi [INVESTIGATOR_90730] i o n. 
Res ults i n persiste nt or si g nifica nt disa bilit y/ i nca pacit y (ie, t h e A E res ults i n s u bsta nt ia l 
di sr u pt i o n of t he patie nt’s a bilit y t o c o n d uct n or mal life f u nct i o ns). 
Is a c o n ge nital a n o ma l y/ birt h -d ef ect .
Is a n i m p orta nt me dical e ve nt t hat ma y n ot res ult i n deat h, be i m me diatel y life -t h reate ni n g or 
re q ui re h os pi [INVESTIGATOR_1314] o n, b ut m a y  be c o nsi dere d a n S A E w he n, base d u p o n a p pr o priate me dical 
j u d g me nt, t he e ve nt ma y je o par dize t he pati e nt or pati e nt ma y  r e q ui re i nter ve nt i o n t o pre ve nt 
o ne of t he ot her o utc o mes liste d i n t his defi nit i o n. E xa m ples of s uc h e ve nts are i nte nsi ve 
treat m e nt i n a n e mer ge nc y  de part me nt  or at h o me f or aller gic br o nc h os pas m, bl o o d 
d y scrasias, or c o n v ulsi o n t ha t d oes n ot res ul t i n h os pi[INVESTIGATOR_1314] o n; or de vel o p me nt of dr u g 
de pe n de nc y  or dr u g a b use. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692757] i gat or ’s pers pecti ve ma y be i nf or me d b y ha vi n g act uall y o bser ve d t he e ve nt, 
a n d t he Sp o ns or is li kel y t o ha ve br oa der k n o wle d ge of t he dr u g a n d its effects t o i nf or m its 
e val uat i o n of t he si g nifica nce of t he e ve nt, if eit her t he Sp o ns or or t he i n vesti gat or belie ves t hat 
t h e e ve nt is seri o us, t he e ve nt will be c o nsi dere d seri o us. 
8. 2. 3. Se verit y 
Defi nit i o ns f o u n d i n t he C o m m o n Ter mi n o l o g y Cri t eri a f or A d verse E ve nts versi o n 4. 0 3 
(C T C A E v 4. 0 3 ) will be use d f or gra di n g t he se verit y  (i nte nsit y) of n o n he mat ol o gic AEs . Refer t o 
A p pe n di x If o r t he gra di n g of he mat ol o gic AEs . T he C T C A E v 4. 0 3 di s pla ys Gra des 1 t hr o u g h 5 
wi t h  u ni q ue cli nical descri pt i o ns of se verit y f o r eac h refere nce d A E . S h o ul d a pat ie nt e x perie nce 
a n y A E n ot liste d i n t he C T C A E v 4. 0 3 , t he f o ll o wi n g gra di n g s yste m s h o ul d be use d t o assess 
se verit y: 
Gra de 1 ( Mil d A E) –e x perie nces w hic h are us uall y tra nsie nt, re q uiri n g n o s pecial treat me nt, 
a n d n ot i nterferi n g wit h t h e patie nt’s dail y act i vit ies 
Gra de 2 ( M o derate A E) – e x perie nces w hic h i ntr o d uce s o me le vel of i nc o n ve nie nce or 
c o ncer n t o t he patie nt, a n d w hic h ma y i nterfere wit h dail y act i vit ies, b ut are us uall y  
a m eli orate d b y  si m ple t hera pe ut ic me as ures 
Gra de 3 ( Se vere A E) –e x perie nces w hic h are u nacce pta ble or i nt olera ble, si g nifica nt l y 
i nt err u pt t he patie nt’s us ual dail y  acti vi t y , a n d re q uire s yste mic dr u g t hera p y  or ot her 
treat m e nt 
Gra de 4 ( Life -t h reate ni n g or disa bli n g A E) –e x perie nces w hic h ca use t he patie nt t o be i n 
i m mi ne nt da n ger of deat h 
Gra de 5 ( Deat h relate d t o A E) – e x perie nces w hic h res ult i n patie nt deat h 
8. 2. 4. C a us alit y 
T he i n vest i gat or is t o assess t he ca usal relati o n (ie, w het her t here is a reas o na ble p ossi bilit y t h at 
t h e st u d y  dr u g ca use d t he e ve nt) usi n g t he f o ll o wi n g defi nit i o ns: 
N ot Rel ate d: A n ot her ca use of t he A E is m ore pla usi ble; a te m p oral se q ue nce ca n n ot 
be esta blis he d wit h t he o nset of t he A E a n d a d mi nistrati o n of t he 
i n vesti gat i o nal pr o d uct; or, a ca usal relati o ns hi p is c o nsi dere d 
bi o l o gicall y i m pla usi ble. 
U nli kel y: T he c urre nt k n o wle d ge or i nf or mati o n a b o ut t he A E i n dicates t hat a 
r el at i o ns hi p t o t he i n vest i gat i o nal pr o d uct is u nli kel y. 
P ossi bl y Relate d: T here i s a cli nicall y  pla usi ble t i me se q ue nce bet wee n o nset of t he A E 
a n d a d mi nistrati o n of  t he i n vest i gat i o nal pr o d uct, b ut t he A E c o ul d als o 
be attri b ute d t o c o nc urre nt or u n derl yi n g disease, or t he use of ot her 
dr u gs or pr oce d ures . P ossi bl y relate d s h o ul d be use d w he n t he 
i n vesti gat i o nal pr o d uct is o ne of se veral bi o l o gicall y  pla usi ble A E 
ca uses. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692758] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 8 Relate d: T he A E is clearl y relate d t o use of t he i n vest i gat i o nal pr o d uct. 
8. 2. 5. U ne x pecte d A d verse E ve nts 
A n “ u ne x pecte d” A E is a n A E t hat is n ot liste d i n t he I B/ pac ka ge i nsert or is n ot liste d at t he 
s pecificit y or se verit y t h at has bee n o bser ve d . F or e xa m ple, he patic necr osis w o ul d be 
“ u ne x pecte d” ( b y  vi rt u e of  greater se verit y)  i f t he I B referre d o nl y t o ele vate d he patic e nz y mes 
or he patit is . Si milarl y, cere bral t hr o m b oe m b o lis m a n d cere bral vasc ulit is w o ul d be “ u ne x pecte d” 
( b y  virt ue of greater s p ecificit y)  if  t he I B/ pac ka ge i nsert liste d o nl y cere bral  v asc ular acci de nts . 
“ U ne x pecte d” al s o refers t o AEs t hat are m e nt i o ne d i n t he I n vest i gat or's Br oc h ure as occ urri n g 
wi t h  a cl ass of dr u gs or as a ntici pate d fr o m t he p har mac ol o gical pr o perties of t he d r u g, b ut are 
n ot s pecificall y  m e nt i o ne d as occ urri n g wit h t he st u d y  dr u g u n der i n vest i gat i o n. 
8. 3. D oc u me nti n g a n d Re p orti n g of A d verse a n d Seri o us A d verse E ve nts b y 
I n vesti g at ors 
T he i n vest i gat or is res p o nsi ble f or e ns uri n g t hat all AEs a n d S A Es t hat are o bser ve d or re p orte d 
d uri n g t he st u d y , as o utli ne d i n t he pri or secti o ns, are rec or de d o n t he C R F . All AEs o n g oi n g at 
t h e ti me o f cl os ure of t he pare nt st u d y  m ust be f o ll o we d u p t o res ol ut i o n i n t he e xte nsi o n st u d y . 
All S A Es als o m ust be re p orte d o n t he S A E W or ks heet (see Secti o n 8. 3. 3 ). 
8. 3. 1. A d verse E ve nt Re p orti n g Peri o d 
F or patie nts ra n d o mize d t o i br uti ni b i n t he pare nt st u d y a n d c o nti n ui n g o n i br uti ni b the r a p y i n 
P C Y C - [ADDRESS_692759] t o f o ll o w- u p or wi t h dra ws 
c o nse nt . Res ol uti o n/sta ble mea ns t he patie nt has ret ur ne d t o baseli ne state of healt h or t he 
i n vesti gat or d oes n ot e x pect a n y f urt her i m pr o ve me nt or w orse ni n g of t he e ve nt. 
A n y S A E t hat occ urs m ore t ha n [ADDRESS_692760] be re p orte d t o t he S p o ns or . Res ol ut i o n i nf or mat i o n after 3 0 da ys s h o ul d 
be pr o vi de d. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692761] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 5 9 Pr o gressi ve disease s h o ul d n ot be re p orte d as a n e ve nt ter m, b ut i nstea d s y m pt o ms/cli nical si g ns 
of  di sease pr o gressi o n ma y  be re p orte d . All deat hs s h o ul d be re p orte d wit h t he pri mar y ca use of 
deat h as t he A E ter m, as deat h is t y p icall y t he o utc o me of t he e ve nt, n ot t he e ve nt itself . Aut o ps y  
a n d p ost m ort e m  re p orts m ust be f or war de d t o t he S p o ns or, or desi g nee, as o utli ne d a b o ve, if 
all o we d per l ocal re g ulat or y  g ui deli nes . If a deat h occ urs wit hi n [ADDRESS_692762] i gat or s will assess t he occ urre nce of A Es i ncl u di n g S A Es as descri be d i n t he sc he d ules of 
assess me nts f o r i br uti ni b (A p pe n di x Ba n d A p pe n di x C), rec or di n g e ve nts w he n v o l u nt eere d b y  
t h epati e nt , di sc o vere d b y  st u d y  pers o n nel d uri n g q uesti o ni n g, detecte d t hr o u g h p h ysical 
e xa mi nat i o n, cli nicall y si g nifica nt la b orat or y  test, or ot her m ea ns . E ve nts will be rec or de d i n t he 
pati e nt ’s me dical rec or d a n d o n t he A E C R F a n d, w he n a p plica ble, o n t he S A E W or ks heet. 
Eac h rec or de d A E or S A E will be descri be d b y it s d urati o n (i e, start a n d e n d dates), se verit y,  
re g ul at or y  s eri o us ness cri teria (if a p plica ble), s us pecte d relat i o ns hi p t o t he i n vest i gat i o nal 
pr o d uct, a n d a n y  act i o ns ta ke n. 
8. 3. 3. E x pe dite d Re p orti n g Re q uire me nts f or Seri o us A d verse E ve nts 
All S A Es (i nit ial a n d f o ll o w- u p i nf or m at i o n) will be re p orte d o n t he S A E W or ks heet a n d fa xe d 
t o P har m ac ycl ics Dr u g Safet y,  or desi g nee, wi t hi n [ADDRESS_692763] f o ll o w- u p a n d ot her a d dit i o nal i nf or mat i o n fr o m t h e 
i n vesti gat or (e g, h os pi[INVESTIGATOR_307] a d missi o n/ disc har ge n otes a n d la b orat or y  res ul ts) . T he c o nt act 
i nf or m at i o n ( p h o ne, fa x a n d e mail) f or t he dr u g safet y  ca n be f o u n d o n t he S A E W or ks heet f or m 
a n d i nstr ucti o ns. 
All deat hs s h o ul d be re p orte d wit h t he pri mar y  ca use of deat h as t he A E ter m, as deat h is 
t y pi[INVESTIGATOR_1306] y  t he o utc o m e of  t he e ve nt, n ot t he e ve nt it self . T he pri mar y  ca use of deat h o n t he 
a ut o ps y  re p ort or t he A E / S A E m ost pr o xi mal t o deat h s h o ul d be t he ter m re p orte d . A ut o ps y  a n d 
p ost m ort e m  re p orts m ust be f or war de d t o P har mac yclics Dr u g Safet y,  or desi g nee, as o utli ne d 
a b o ve. 
If st u d y  dr u g i s disc o nt i n ue d beca use of a n S A E, t his i nf or mat i o n m u st be i ncl u de d i n t he S A E 
re p ort. 
8. 3. 4. E ve nts of S peci al I nterest 
S pecific AEs, or gr o u ps of A E s, will be f o ll o we d as part of sta n dar d safet y m o nit ori n g act i vit ies 
b y t he Sp o ns or . T hese e ve nts will be re p orte d t o t h e Sp o ns or wit hi n 2 4 h o urs of a ware ness 
f o ll o wi n g t he pr oce d ure descri be d a b o ve f or S A Es ( Secti o n 8. 3. 3 ) a n d will re q uire e n ha nce d data 
c ollect i o n. H o we ver, a n E ve nt of S pecial I nterest will be c o nsi dere d a n S A E o nl y if it meets 1of  
t h e cri t eri a f or S A Es . All E ve nts of S pecial I nterest will be s u b mi tt e d wi t h o ut a seri o us cri t eri o n 
selecte d if n o ot her seri o us criteri o n is met. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692764] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 6 0 8. 3. 4. 1. M aj or He m orr h a ge 
Maj or h e m orr ha ge is defi ne d as a n y of t he f oll o wi n g: 
A n y treat me nt -e m er ge nt he m orr ha gic A Es of Gra de 3 or hi g her *. 
A n y treat me nt -e m er ge nt seri o us a d vers e e ve nts of blee di n g of a n y  gra de 
A n y treat me nt -e m er ge nt ce ntral ner v o us s yste m he m orr ha ge/ he mat o ma of a n y gra de 
* All he m orr ha gic e ve nts re q uiri n g tra nsf usi o n of re d bl o o d cells s h o ul d be re p orte d as Gra de [ADDRESS_692765] i m me diatel y i nf or m t he 
i n vesti gat or if t he patie nt’s part ner bec o me s pre g na nt fr o m t h e ti me of c o nse nt t o [ADDRESS_692766] d ose of i br uti ni b .T he i n vesti gat or s h o ul d c o u nsel t he pat ie nt , di sc ussi n g a n y  ris ks of 
c o nti n ui n g t he pre g na nc y a n d a n y p ossi ble effects o n t he fet us . 
Alt h o u g h pre g na nc y  i tself is n ot re gar de d as a n A E, t he o utc o me will nee d t o be d oc u me nte d . 
Re p ort a n y  pre g na nc y t hat occ urs i n a patie nt’s part ner fr o m t he ti me of c o nse nt t o [ADDRESS_692767] i ve ter mi nati o n o f t h e pre g na nc y , miscarria ge, or deli ver y  of  t he fet us . F or pre g na ncies wit h 
a n o utc o m e of  l i ve birt h, t he ne w b or n i nfa nt will be f o ll o we d u nt il 3 0 da ys ol d b y c o m p leti n g t he 
Pre g na nc y Re p ort F or m Part II . A n y c o n ge nital a n o mal y/ birt h defect n ote d i n t he i nfa nt m ust be 
re p orte d as a n S A E. 
8. 3. 6. E ye -Rel ate d A d verse E ve nts 
Ne w or w o rse ni n g e ye -relate d s y m pt o m s t hat are Gra de [ADDRESS_692768] u d y treat me nt a n d d uri n g a n y pr ot oc ol -
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692769] -pr o gressi o n f o ll o w- u p f or o verall s ur vi val i n all 
pati e nt s. 
8. 4. Re p orti n g of Seri o us A d verse E ve nts b y S p o ns or 
Re g ulat or y  A ut h ori ti es, I R Bs/ R E Bs/I E Cs, a n d i n vesti gat or s will be n otifie d of S A Es i n 
acc or da nce wit h a p plica ble re q uire me nts (e g, G o o d Cli nical Pract ices [ G C Ps], I C H g ui deli nes, 
nat i o nal re g ul at i o ns, a n d l ocal re q uire me nts). 
T he P har mac yclics P har mac o vi gila nce C o m mittee will re vie w a n d e val uate acc u m ulat i n g safet y 
data fr o m  t he e nt ir e cli nical  tri al  data base f or i br ut i ni b at a p pr o priate i nter vals (e g, q uarterl y) t o 
i de nt if y ne w safet y si g n als or i ncrease d fre q ue nc y of e ve nts . T his will i ncl u de a n a g gre gate 
re vie w a n d c o m paris o n t o a c o ntr ol gr o u p of S A Es fr o m pre vi o us st u dies t hat were dee me d as 
“ n ot s us pecte d” of bei n g ass ociate d wit h use of i br uti ni b beca use t he y  were li kel y  t o ha ve bee n 
ma nifestati o ns of u n derl yi n g disease or t hat c o m m o nl y  occ ur i n t he pati e nt p o p ul at i o n. 
8. 5. S peci al Re p orti n g Sit u ati o ns 
S peci al re p orti n g sit uat i o ns o n a S p o ns or st u d y  m a y  re q uire e x pe di te d re p orti n g a n d/ or safet y 
e val uat i o n w hic h i ncl u de, b ut are n ot li mite d t o: 
O ver d ose of a n y st u d y  dr u g 
S us pecte d a b use/ mis use of a st u d y  dr u g 
I na d verte nt or acci de ntal e x p os ure t o a st u d y  dr u g 
Me dicat i o n err or i n v o l vi n g a pr o d uct ( wit h or wit h o ut s u bject e x p os ure t o t he st u d y dr u g 
(e g, na m e c o nf usi o n )
Occ urre nce of a n y s pecial re p orti n g sit uat i o ns s h o ul d be rec or de d i n t he e C R F . If a n y s pecial 
re p orti n g sit uat i o n meets t he criteria of a n A E, it s h o ul d be rec or de d o n t he A Es e C R F . If t he A E 
is c o nsi dere d seri o us, it s h o ul d be rec or de d o n t he A Es e C R F as seri o us a n d s h o ul d be re p orte d 
o n t he Seri o us A d verse E ve nt Re p ort F or m . T he Seri o us A d verse E ve nt Re p ort F or m s h o ul d be 
se nt vi a e mail  or f a x t o P har m ac yclics Dr u g Safet y or desi g nee wit hi n [ADDRESS_692770] u d y  
o utc o m es at ris k. 
9. 1. Disc o nti n u ati o n of Tre at me nt 
Treat me nt will be disc o nt i n ue d i n t he e ve nt of a n y  of  t he f o ll o wi n g ci rc u msta nces: 
Pr o gressi ve disease 
U nacce pta ble t o xicit y: a n i nterc urre nt ill ness or a d verse e ve nt t hat pre ve nts f urt her i br ut i ni b 
a d mi nistrati o n 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692771] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 6 2 Wit h dra wal o f c o nse nt f or treat me nt b y  patie nt 
I n vest i gat or decisi o n (s uc h as c hr o nic n o nc o m p lia nce, si g nifica nt pr ot oc ol de viat i o n, or t he 
best i nterest of t he patie nt) 
C o m plet i o n of treat m e nt per Pr ot oc ol A me n d me nt 3 
St u d y  ter mi nat i o n b y S p o ns or 
P ati e n t b e c o m es pre g na nt 
All patie nt s, re gar dless of reas o n f or disc o nt i n uat i o n of st u d y  treat m e nt will  u n der g o a n 
E n d -of -Treat m e nt Visi t a n d be f oll o w e d f or pr o gressi o n  a n d s ur vi val. 
T he I n vesti gat or s h o ul d n otif y  t he S p o ns or wi t hi n 2 4 h o urs if a pat ie nt disc o nt i n ues i br ut i ni b 
thera p y d ue t o disease pr o gressi o n a n d s h o ul d pr o vi de d oc u me ntati o n of disease pr o gressi o n f or 
re vie w b y  t he S p o ns or’s Me dical M o nit or . If a patie nt s h o ws si g ns of disease pr o gressi o n o n 
p h ysical e xa mi nat i o n or l a b orat or y  assess me nt, t he pati e nt ma y c o nt i n ue st u d y  tr e a t m e nt u ntil 
di sease pr o gressi o n is c o nfir me d . T hese pat ie nt ss h o ul d st a y  i n t he st u d y  t o be f o ll o we d f or 
s ur vi val. 
9. 2. Wit h dr a w al fr o m t he St u d y 
Wit h dra wal fr o m t h e st u d y  (i ncl u di n g all f o ll o w- u p re q uire me nts) will occ ur u n der t he f o ll o wi n g 
ci rc u msta nces: 
Wit h dra wal o f c o nse nt f or f o ll o w- u p b y t he patie nt 
L ost t o f oll o w - u p 
C o m plet i o n of st u d y  u n der Pr ot oc ol  A me n d me nt 3 
St u d y  ter mi nat i o n b y Sp o ns or 
Deat h 
I n case a patie nt is l ost t o f oll o w -u p, e ver y p ossi ble eff ort m ust be ma de b y t he st u d y  si t e 
pers o n nel t o c o nt act t he patie nt a n d deter mi ne t he reas o n f or disc o nt i n uat i o n. T he m eas ures 
ta ke n t o f o ll o w- u p m ust be d oc u m e nte d i n t he patie nt’s rec or ds. 
W he n a pat ie nt  wi t h dra ws bef ore c o m plet i n g t he st u d y, t he reas o n f or wit h dra wal m ust be 
d oc u m e nte d i n t he s o urce d oc u me nts. 
[ADDRESS_692772] a n ( S A P). 
Data fr o m St u d y  P C Y C - [ADDRESS_692773] 
le vel f or safet y a n d efficac y  a n al yses. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692774] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 6 3 1 0. 1. E n d p oi nts 
P F S o n first -li ne t hera p y 
Pr o gressi o n Free S ur vi val after i nit iati o n o f s u bse q ue nt a nt ica ncer t hera p y ( P F S 2) 
O verall s ur vi val 
Ti m e t o ne xt treat m e nt 
O R R a n d D O R 
S af et y as m eas ure d b y all  A Es a n d S A Es 
Di sease o utc o m e f ol l o wi n g cessat i o n of i br ut i ni b thera p y af t er attai n me nt of mi ni mal 
resi d ual disease ( M R D)- ne gat i ve re missi o n i n t h ose patie nts recei vi n g i br uti ni b as sec o n d- 
li ne t h era p y 
[ADDRESS_692775] u d y  e n d p oi nts will be perf or me d p eri o di call y  as a p pr o pri ate. 
1 0. 5. A n al ysis P o p ul ati o ns 
1 0. 5. 1. I nte nt -t o -Tre at P o p ul ati o n 
T he i nt e nt -t o -treat ( I T T )p o p ulat i o n is defi ne d as all ra n d o mize d pat ie nt s i n St u d y  
P C Y C - [ADDRESS_692776] u d y  P C Y C - 1 1 1 5- C A, ei t h er c hl ora m b ucil or i br ut i ni b .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692777] u d y P C Y C -1 1 1 5 -C A .
P F S 2 will be a nal yze d f or I T T patie nts . It i s defi ne d as t h e ti me i nter val bet wee n t he date of 
ra n d o mizat i o n a n d date of e ve nt, w hic h is defi ne d as pr o gressi ve disease as assesse d b y 
i n vesti gat or t h at  occ urs aft er t he ne xt li ne of s u bse q ue nt a nt ica ncer t h era p y  (i n cl u di n g cr oss -o ver 
t o i br ut i ni b), deat h fr o m a n y ca use, or t he start of asec o n d s u bse q ue nt a nti ca ncer t h era p y  i f n o 
pr o gressi ve disease is rec or de d . T h ose w h o d o n ot recei ve s u bse q ue nt t hera p y or d o n ot 
e x perie nce t he e ve nt as s pecifie d a b o ve are ce ns ore d at t he last disease assess me nt wit h o ut 
sec o n d disease pr o gressi o n. 
T he a nal ysis f or P F S o n first -li ne t hera p y will f o ll o w t he pri mar y  m et h o d descri be d i n t h e 
P C Y C - [ADDRESS_692778] i mate of t he hazar d rati o a n d its c orres p o n di n g 9 5 % CI will be c o m p ute d 
usi n g a C o x pr o p or ti o nal  h azar d m o d el  stratifie d b y  t he ra n d o mizat i o n stratificat i o n fact ors ( Rai 
sta ge a n d E C O G perf or ma nce sc ore) . Me dia n P F S 2a n d its 9 5 % c o nfi de nce i nter val ( CI) will be 
esti mate d usi n g t he Ka pla n- Meier met h o d. 
[ADDRESS_692779] 9 5 % c o nfi de nce i nter val . A nal ysis detail will b e 
defi ne d i n t he statist ical a nal ysis pla n. 
[ADDRESS_692780] t he d urati o n o f ti me d uri n g w hic h pat ie nt s are e x perie nci n g t u m or 
re d ucti o n a n d si g nifica nt be nefit i n ter ms of disease c o ntr ol, D O R will be c o m p ute d f or t he 
res p o n ders s u bset base d o n t he res p o nse criteria ( Secti o n 1 0. 7. 2 ), a n d will i ncl u de d urati o n w he n 
a res p o n der ac hie ve sa P R wi t h  l y m p h oc y t osi s. He nce, D O R est i mate d b y t he Ka pla n -Meier 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692781] a n .
1 0. 7. 4. Dise ase O utc o me F oll o wi n g M R D- Ne g ati ve C R 
At  t he i n vesti gat or’s discret i o n, pati e nts recei vi n g sec o n d -li ne i br ut i ni b t h era p y  w h o ac hie ve a n d 
retai n M R D -ne gat i ve C R f or 6 c ycles ca n ha ve t heir i br uti ni b disc o nt i n ue d . If sec o n d -li ne 
i br uti ni b is disc o nt i n ue d, t he pati e nt will be f o ll o we d f or M R D rec urre nce . A 6 -m o nt h 
M R D -ne gat i ve C R rate per t h e sa me e val ua ble s u b gr o u p defi ne d f or O R R ( Secti o n 1 0. 7. 3 ) a n d 
t h e rec urre nce rate base d o n a s u bset of patie nts w h o ac hie ve a 6 -m o nt h M R D -ne gat i ve C R will 
be calc ulate d. 
M R D -ne gat i ve s u bjects w h o e x perie nce c o nfir me d M R D -p osi ti ve rela pse a n d/ or cli nical disease 
pr o gressi o n b y  I W C L L cri teria m a y re start i br uti ni b t hera p y. 
[ADDRESS_692782] baseli ne 
assess me nts/ visits will be ce ns ore d at t he date of ra n d o mizat i o n. S ur vi val rate at la n d mar k p oi nts 
will be s u m marize d b y  fi rst -li ne treat me nt ar m usi n g Ka pla n -Meier est i mates. 
[ADDRESS_692783] i vit ies ( Me d D R A) . AEs t hat starte d after t he first d ose of st u d y  
dr u g a n d u p t o [ADDRESS_692784] u g or i nit iat i o n of s u bse q ue nt t hera p y , w hic h 
occ urs earlier, are c o nsi dere d treat me nt e mer ge nt . All treat me nt -e m er ge nt AEs will be ta b ulate d 
usi n g sta n dar d met h o ds. 
All la b orat or y  val ues will be c o n verte d t o sta n dar d i nter nat i o nal u nits ( SI u nits) . He mat ol o gic 
t o xi ci t y  will be gra de d acc or di n g t o t he I W C L L criteria ( Halle k 2 0 0 8 ). All ot her gra da ble 
la b orat or y  para meters will be gra de d usi n g t he N CI C T C A E . Sta n dar d met h o ds f or s u m marizi n g 
la b orat or y  v aria bles will be use d, i ncl u di n g t he use of s u m mar y  st ati st ics a n d s hift ta bles. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692785] ices, wit h a p plica ble l ocal 
re g ul at i o ns (i ncl u di n g U S C o de of Fe deral Re g ulati o ns [ C F R] Ti tle [ADDRESS_692786] i ve 
2 0 0 1/ 2 0/ E C), a n d wit h t he et hical pri nci ples lai d d o w n i n t he Declarat i o n of Helsi n ki. 
1 1. 2. I nstit uti o n al Re vie w B o ar d (I R B), Rese arc h Et hics B o ar d ( R E B) a n d I n de pe n de nt 
Et hics C o m mittee (I E C) A p pr o v al 
T he i n vest i gat or will s u b mit t his pr ot oc ol, t he I C F, I B, a n d a n y ot her rele va nt s u p p orti n g 
i nf or m at i o n (e g, all a d vert is i n g materials or materials gi ve n t o t he patie nt d uri n g t he st u d y ) t o t he 
a p pr o priate I R B/ R E B/I E C f or re vie w a n d a p pr o val bef ore st u d y  i nit iat i o n. A me n d me nts t o t he 
pr ot oc ol  a n d I C F m ust al s o be a p pr o ve d b y  t he I R B/ R E B/I E C bef ore t he i m ple me ntati o n of 
c ha n ges i n t his st u d y .
T he i n vest i gat or is res p o nsi ble f or pr o vi di n g t he I R B/ R E B/I E C wit h a n y re q uire d i nf or mat i o n 
bef ore or d uri n g t he st u d y, s uc h as S A E e x pe dite d re p orts or st u d y pr o gress re p orts. 
T he I R B/ R E B/I E C m ust c o m pl y wit h c urre nt U nite d States ( U S) re g ulat i o ns ( § 2 1 C F R 5 6) as 
well as c o u ntr y -s pecific nat i o nal re g ulat i o ns a n d/ or l ocal la ws. 
T he f o ll o wi n g d oc u m e nts m us t be pr o vi de d t o P har m ac yclics or its a ut h orize d re prese ntati ve 
bef ore e nteri n g patie nts i n t his st u d y : ( 1) a c o p y  of t he I R B/ R E B/I E C letter t hat gra nts f or mal 
a p pr o val; a n d ( 2) a c o p y  of  t he I R B/ R E B/I E C -a p pr o ve d I C F. 
[ADDRESS_692787] y wit h t he U S re g ulat i o ns ( § 2 1 C F R Part 5 0) as well as c o u ntr y  
s pecific nat i o nal re g ulat i o ns a n d/ or l ocal la ws . T he I C F will d oc u me nt t he st u d y -s pecific 
i nf or m at i o n t he i n vesti gat or or hi s/ her desi g nee pr o vi des t o t he patie nt a n d t he patie nt’s 
agree m e nt t o parti ci pate. 
T he i n vest i gat or or desi g nee ( desi g nee m ust be liste d o n t he Dele gat i o n of A ut h orit y l o g), 
m ust e x plai n i n ter ms u n dersta n da ble t o t he patie nt t he p ur p ose a n d nat ure of t he st u d y , st u d y  
pr oce d ures, a ntici pate d be nefits, p ote ntial r is ks, p ossi ble AEs, a n d a n y disc o mf ort partici pat i o n 
i n t he st u d y  m a y  e n t ail . T his pr ocess m ust be d oc u me nte d i n t he patie nt’s s o urce rec or d . Eac h 
pati e nt m ust pr o vi de a si g ne d a n d date d I C F bef ore a n y  st u d y -r el ate d ( n o nsta n dar d of care) 
acti vit ies are per f o r me d . T he ori gi nal a n d a n y  a me n de d si g ne d a n d date d c o nse nt f or ms m ust 
r e m ai n i n eac h pat ie nt ’s st u d y  f ile at t he st u d y  si te a n d be a vaila ble f or verificati o n b y  st u d y  
m o nit ors at a n y  ti me . A c o p y  of  eac h si g ne d c o nse nt f or m  m ust be gi ve n t o t he patie nt at t he ti me 
t h at i t i s si g ne d b y t he pat ie nt .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692788] u d y  s hall  be c o n d ucte d i n 
acc or da nce wit h t he pr o visi o ns of t he Declarat i o n of Helsi n ki ( Oct o ber 2 0 0 8) a n d all re visi o ns 
t h ere of, a n d i n acc or da nce wit h F D A re g ulati o ns ( 2 1 C F R Parts 1 1, 5 0, 5 4, 5 6, a n d 3 1 2, 
S u b part D –Res p o nsi bilit ies of S p o ns ors a n d I n vesti gat ors) a n d wit h t he I C H g ui deli nes o n G C P 
(I C H E 6 ). 
[ADDRESS_692789] be pr o vi de d t o eac h patie nt as part of t he i nf or me d c o nse nt 
pr ocess (refer t o Secti o n 1 1. 3 ), ei t h er as part of t he I C F or as a se parate si g ne d d oc u me nt (f or 
e xa m ple, i n t he U S, a site -s pecific HI P A A c o nse nt ma y  b e use d) . T he i n vest i gat or or desi g nee 
m ust e x plai n t o eac h patie nt t ha t f or t he e val uat i o n of st u d y  res ul ts, t he pati e nt’s pr otecte d healt h 
i nf or m at i o n o btai ne d d uri n g t he st u d y  m a y  b e s hare d wi t h  P har mac yclics a n d its desi g nees, 
re g ul at or y  a ge ncies, a n d I R Bs/ R E Bs/I E Cs . As t he st u d y  S p o ns or , P har mac yclics will n ot use t he 
pa ti e nt’s pr otecte d healt h i nf or mat i o n or discl ose it  t o a t hir d part y  wi t h o ut a p plica ble pat ie nt  
a ut h ori zat i o n. It i s t he i n vest i gat or ’s or desi g nee’s res p o nsi bilit y t o o btai n writte n per missi o n t o 
use pr otecte d healt h i nf or mati o n fr o m eac h patie nt . If a pa ti e nt wi t h dra ws per missi o n t o use 
pr otecte d healt h i nf or mat i o n, i t is t he i n vest i gat or ’s res p o nsi bilit y t o o btai n t he wit h dra wal 
re q uest i n writ i n g fr o m t he patie nt a n d t o e ns ure t hat n o f urt her data will be c ollecte d fr o m t he 
pati e nt . A n y data c ollecte d o n t he patie nt bef ore wit h dra wal will be use d i n t he a nal ysis o f st u d y  
res ul ts. 
D uri n g t he re vie w of s o urce d oc u me nts b y  t h e m o ni t ors or a u di t ors, t he c o nfi de nt ia lit y of  t he 
pati e nt will be res pecte d wit h strict a d here nce t o pr ofessi o nal sta n dar ds a n d re g ul at i o ns. 
[ADDRESS_692790] kee p a rec or d t hat lists all pati e nts c o nsi dere d f or e nr oll me nt (i ncl u di n g 
t h ose w h o di d n ot u n der g o scree ni n g) i n t he st u d y . F or t h ose patie nts s u bse q ue nt l y e xcl u de d 
fr o m e nr oll me nt, t he reas o n(s) f or e xcl usi o n is t o be rec or de d. 
T he i n vest i gat or /st u d y staff m ust mai ntai n a de q uate a n d acc urate rec or ds t o e na ble t he c o n d uct 
of  t he st u d y  t o be f ull y d oc u m e nte d a n d t he st u d y  data t o be s u bse q ue nt l y verifie d . Esse nt ia l 
d oc u m e nt ati o n i ncl u des, b ut i s n ot li mite d t o, t he I B, si g ne d pr ot oc ols a n d a me n d me nts, 
I R B/ R E B/I E C a p pr o val letters ( date d), si g ne d F or m F D A 1 5 7 2 a n d Fi na ncial Discl o s ures, 
si g ne d I C Fs (i ncl u di n g pat ie nt  c o nfi de nt ia lit y i nf or mat i o n), dr u g di s pe nsi n g a n d acc o u nta bilit y 
rec or ds, s hi p pi n g rec or ds of i n vest i gat i o nal pr o d uct a n d st u d y -relate d materi als, si g ne d 
( el e ctr o ni call y ), date d a n d c o m plete d C R Fs, a n d d oc u me ntati o n of C R F c orrecti o ns, S A E f or ms 
tra ns mitte d t o P har mac yclics a n d n otificat i o n of S A Es a n d relate d re p orts, s o urce 
d oc u m e nt ati o n, n or m al  l a b orat or y  val ues, dec o di n g pr oce d ures f or bli n de d st u dies, c urric ula 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692791] u g f or t he i n dicati o n f or w hic h it is bei n g 
i n vesti gate d a n d u nt il t here are n o pe n di n g or c o nte m plate d mar keti n g a p plicat i o ns; or, if n o 
a p plicat i o n is t o be file d or if t he a p plicati o n is n ot a p pr o ve d f or s uc h i n dicati o n, u nt il [ADDRESS_692792] u d y  d o c u m e nts or i ma ges ( e g, sca n, ra di o gra p h, E C G traci n g) at 
a n y ti me . S h o ul d a n i n vest i gat or wis h t o assi g n t he st u d y  rec or ds t o a n ot her part y  or m o ve t he m  
t o a n ot her l ocati o n, a d va nce writte n n otice will be gi ve n t o P har mac yclics . P har mac yc lics will 
i nf or m  t he i n vesti gat or of  t he date t hat st u d y  rec or ds m a y be destr o ye d or ret ur ne d t o 
P har mac yclics. 
P har mac yclics m ust be n otifie d i n a d va nce of, a n d P har mac yclics m ust pr o vi de e x press writte n 
a p pr o val  of , a n y c ha n ge i n t he mai nte na nce of t he f ore g oi n g d oc u m e nts if t he i n vest i gat or wis hes 
t o m o ve st u d y  rec or ds t o a n ot her l ocati o n or assi g n res p o nsi bilit y f o r rec or d rete nti o n t o a n ot her 
part y . If t he i n vesti gat or ca n n ot g uara ntee t he arc hi vi n g re q uire me nts set f ort h herei n at his or her 
st u d y  si te f or all  s uc h d oc u m e nts, s pecial  arra n ge me nts m ust be ma de bet wee n t he i n vest i gat or 
a n d P har mac yclics t o st ore s uc h d oc u me nts i n seale d c o ntai ners a wa y fr o m t h e st u d y  si te s o t hat 
t h e y  ca n be ret ur ne d seale d t o t he i n vest i gat or f o r a u di t p ur p oses. 
[ADDRESS_692793] u d y  data acc uratel y rec or de d s uc h t hat t he i nf or mat i o n mat c hes t he 
data c o ntai ne d i n me dical rec or ds ( e g, p h ysicia ns’ n otes, n urses’ n otes, cli nic c harts a n d ot her 
st u d y -s pecific s o urce d oc u me nts) . A ut h orize d st u d y site pers o n nel ( ie, liste d o n t he Dele gat i o n of 
A ut h ori t y  l o g) will  c o m plete C R Fs desi g ne d f or t his st u d y  acc or di n g t o t he c o m plet i o n 
g ui deli n es t hat will be pr o vi de d . T he i n vest i gat or will e ns ure t hat t he C R Fs are acc urate, 
c o m plete, l e gi ble, a n d c o m plete d wi t hi n 5 da ys of eac h patie nt’s visit . At  all t i mes, t he 
i n vesti gat or has fi nal res p o nsi bilit y f o r t he acc urac y  a n d a ut he nt icit y of all cli nical data. 
T he C R Fs e xists wit hi n a n electr o nic data ca pt ure ( E D C) s yste m wit h c o ntr olle d access ma na ge d 
b y P har mac yclics or its a ut h orize d re prese ntati ve f or t his st u d y . St u d y  staff wi ll be a p pr o priatel y 
trai ne d i n t he use of C R Fs a n d a p plicat i o n of electr o nic si g nat ures bef ore t he start of t he st u d y 
a n d bef ore bei n g gi ve n access t o t he E D C s y st e m . Ori gi nal  data a n d a n y  c ha n ges of data will be 
rec or de d usi n g t he E D C s y st e m , wi t h  all c ha n ges trac ke d b y  t he s yste m  a n d rec or de d i n a n 
el e ctr o ni c a u di t tr ail . T he i n vest i gat or attests t hat t he i nf or mat i o n c o ntai ne d i n t he C R Fs is tr ue 
b y pr o vi di n g electr o nic si g nat ure wit hi n t he E D C s yste m . After data base l oc k, t he i n vest i gat or 
will recei ve a c o p y  of  t he pati e nt data (e g, pa per, C D, or ot her a p pr o priate me dia) f or arc hi vi n g 
at t he st u d y  si t e. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692794] u d y M o nit ori n g/ A u dit Re q uire me nts 
Re prese ntati ves of P har mac yclics or its desi g nee will m o nit or t hi s st u d y  u ntil c o m plet i o n. 
M o ni t ori n g will be c o n d ucte d t hr o u g h pers o nal visits wit h t he i n vest i gat or a n d site staff, re m ote 
m o nit ori n g, as well as a n y a p pr o priate c o m m u nicati o ns b y  m ail, f a x, e m ail , or t el e p h o ne . T he 
p ur p ose of m o nit ori n g is t o e ns ure t hat t he st u d y  i s c o n d ucte d i n c o m p lia nce wit h t he pr ot oc ol, 
sta n dar d o perati n g pr oce d ures ( S O Ps), a n d ot her writte n i nstr ucti o n s a n d re g ul at or y  g ui deli nes, 
a n d t o e ns ure t he q ualit y a n d i nte gri t y  of  t he data . T his st u d y  is als o patie nt t o re vie ws or a u dits. 
T o ass ure t he acc urac y  of  data c ollecte d i n t he C R Fs, it is ma n dat or y  t hat t he m o ni t or/ a u di t or 
ha ve access t o all ori gi nal s o urce d oc u m e nts, i ncl u di n g all electr o ni c m e dical  rec or ds ( E M R) at 
reas o na ble ti mes a n d u p o n reas o na ble n otice . D uri n g t he re vie w of s o urce d oc u me nts, e ver y 
eff ort will be ma de t o mai ntai n t he a n o n y mit y a n d c o nfi de nt ia lit y of  all pat ie nt s d uri n g t his 
cli nic al st u d y . H o we ver, beca use o f t h e e x peri me ntal nat ure of t his treat me nt, t he i n vesti gat or 
a grees t o all o w t he I R B/ R E B/I E C, re prese ntati ves of P har mac yclics, its desi g nate d a ge nts a n d 
a ut h ori ze d e m pl o y ees of t he a p pr o priate Re g ulat or y  A ut h ori t y  t o i ns pect t he facilit ies use d i n 
t hi s st u d y  a n d, f or p ur p oses of verificati o n, all o w direct access t o t he h os pi[INVESTIGATOR_533437] e nr olle d i nt o t his st u d y . A state me nt t o t his effect will be i ncl u de d i n t he i nf or me d 
c o nse nt a n d per missi o n f o r m  a ut h ori zi n g t he use of pr otecte d healt h i nf or mati o n. 
P har mac yclics or its a ut h orize d re prese ntati ve ma y perf or m a n a u dit at a n y  ti me d uri n g or after 
c o m plet i o n of t his st u d y . All st u d y -relate d d oc u m e nt ati o n m ust b e m a de a vaila ble t o t he 
desi g nate d a u dit or . I n a d dit i o n, a re prese ntati ve of t he F D A or ot her Re g ulat or y  A ge ncies ma y  
c h o ose t o i ns pect a st u d y  si t e at a n y  ti me bef ore, d uri n g, or after c o m plet i o n of t he cli nical st u d y . 
I n t he e ve nt of s uc h a n i ns pect i o n, P har mac yclics will be a vaila ble t o assist i n t h e pre parati o n . 
All perti ne nt st u d y  data s h o ul d be ma de a vaila ble as re q ueste d t o t he Re g ulat or y  A ut h ori t y  f or 
verificati o n, a u dit, or i ns pect i o n p ur p oses. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692795] u d y  
acc or di n g t o t he c urre nt pr ot oc ol; will rea d a n d u n dersta n d t he I B; will o btai n I R B/ R E B/I E C 
a p pr o val  t o c o n d uct t he st u d y; will o btai n i nf or me d c o nse nt fr o m eac h st u d y  p arti ci pa nt; will 
mai ntai n a n d s u p pl y t o t he Sp o ns or or desi g nee, a u di t ors a n d re g ul at or y  a ge ncies a de q uate a n d 
acc urate rec or ds of st u d y  act i vit y a n d dr u g acc o u nta bilit y f o r st u d y -relate d m o ni t ori n g, a u di ts, 
I R B/ R E B/I E C re vie ws a n d re g ulat or y  i ns pecti o ns; will  re p ort S A Es t o t he Sp o ns or or desi g nee 
a n d I R B/ R E B/I E C acc or di n g t o t he s pecifics o utli ne d i n t his pr ot oc o l; will pers o nall y c o n d uct or 
s u per vise t he st u d y; a n d will e ns ure t hat c ollea g ues partici pat i n g i n t he st u d y are i nf or me d a b o ut 
t h ei r o bli gat i o ns i n meet i n g t he a b o ve c o m mit me nts. 
[ADDRESS_692796] i gat i o nal pla n a n d pr ot oc ols a n d pr o m pt l y i nf or m 
i n vesti gat or s, healt h a n d re g ulat or y  a ge ncies/a ut h ori ties as a p pr o priate of si g nifica nt ne w a d vers e 
effects or ris ks wit h res pect t o t he dr u g. 
[ADDRESS_692797] i gat or (as desi g nate d o n t he F or m F D A 1 5 7 2) will 
pr o vi de a si g ne d Fi na ncial Discl os ure F or m i n acc or da nce wit h § [ADDRESS_692798] or i nj ur y, a p pr o priate me dical care as deter mi ne d b y t he 
i n vesti gat or / desi g nee will be pr o vi de d. 
T he I C F will i ncl u de a descri pt i o n of tr e at m e nt i n t he e ve nt of a st u d y  r el ate d i nj ur y a n d 
ha n dli n g of t he c osts ass ociate d t here wit h, i nc or p orati n g c o u ntr y -s pecific nati o nal re g ulat i o ns 
a n d/ or l ocal la ws . Fi na ncial c o m pe nsat i o n f o r l ost wa ges, di sa bili t y  or di sc o mf o rt d ue t o t he 
st u d y  i s n ot a vaila ble. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692799] u d y  i nit iat i o n. 
1 1. 1 4. Pr ot oc ol A me n d me nts 
P har mac yclics will i nit iate a n y  c ha n ge t o t he pr ot oc ol  i n a pr ot oc ol a me n d me nt d oc u me nt . T he 
a m e n d me nt will be s u b mitte d t o t he re g ulat or y  a ut h ori ti es a n d / or I R B/ R E B/I E C t o get her wit h, if 
a p plica ble, a re vise d m o del I C F . Wr it te n d oc u me ntati o n of  re g ul at or y  a ut h ori ti es, I R B/ R E B/I E C 
a n d re q uire d site a p pr o val , as a p plica ble, m ust be recei ve d b y P har mac yclics bef ore t he 
a m e n d me nt m a y  ta ke effect at eac h site . A d dit i o nall y ,u n der t hi s circ u msta nce, i nf or mat i o n o n 
t h e i ncrease d ris k a n d/ or c ha n ge i n sc o pe m ust be pr o vi de d t o patie nts alrea d y  acti vel y 
parti ci pat i n g i n t he st u d y, a n d t he y m ust rea d, u n dersta n d a n d si g n a n y re vise d I C F c o nfir mi n g 
willi n g ness t o re mai n i n t he tri al. 
N o ot her si g nifica nt or c o nsiste nt c ha n ge i n t he st u d y pr oce d ures, e xce pt t o eli mi nate a n 
i m me diate hazar d, s hall be effecte d wi t h o ut t he m ut ual a gree me nt of t he i n vest i gat or a n d 
P har mac yclics. 
[ADDRESS_692800] or a n d/ or l ea d statisticia n ma y als o be i ncl u de d i n t he list of a ut h ors . T hi s c ust o m  ca n be 
a dj uste d u p o n m ut u al  a gree me nt of t he a ut h ors a n d P har mac yclics. 
[ADDRESS_692801] i gat or will ass ure t hat a de q uate c o nsi derat i o n is gi ve n t o t he 
pr otecti o n of  t he pati e nts’ i nterests. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692802] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7 2 1 2. R E F E R E N C E S 
Bre n ner H, G o n d os A, P ulte D . Tre n ds i n l o n g -t e r m  s ur vi val of patie nts wit h c hr o nic l y m p h oc ytic le u ke mia 
fr o m t he 1 9 8 0s t o t he earl y 2 1s t ce nt ur y . Bl o o d 2 0 0 8; 1 1 1( 1 0): 4 9 1 6 - 4 9 2 1. 
B ur ger J A, O' Brie n S, F o wler N, et al . T he Br ut o n's t yr osi ne ki nase i n hi bit or, P CI -3 2 7 6 5, is well t olerate d 
a n d de m o nstrate d pr o misi n g cli nical acti vit y i n c hr o nic l y m p h oc ytic le u ke mia ( C L L) a n d s m all 
l y m p h oc ytic l y m p h o ma ( S L L): A n u p date o n o n g oi n g P hase 1 st u d ies . Bl o o d 2 0 1 0; 1 1 6: A bstract 5 7. 
C a m p o E, S wer dl o w S H, Harris N L, et al . T he 2 0 0 8 W H O classificati o n of l y m p h oi d ne o plas ms a n d 
be y o n d: e v ol vi n g c o nce pts a n d practical a p plicati o ns . Bl o o d 2 0 1 1; 1 1 7: [ADDRESS_692803] u g A d mi nistrati o n a p pr o val: Rit u xi ma b i n 
c o m bi nati o n wit h fl u dara bi ne a n d c ycl o p h os p ha mi de f or t he treat me nt of patie nts wit h c hr o nic l y m p h oc ytic 
le u ke mia . T he O nc ol o gist 2 0 1 1; 1 6: [ADDRESS_692804] us c ycl o p h os p ha mi de f or patie nts 
wit h c hr o nic l y m p h oc ytic le u kae mia (t he L R F C L L 4 Trial): a ra n d o mize d c o ntr olle d trial . La ncet 
2 0 0 7; 3 7 0: 2 3 0 - 3 9. 
Cella D, Lai J, C ha n g C, et al . Fati g ue i n ca ncer patie nts c o m pare d wit h fati g ue i n t he ge neral U nite d States 
p o p ulati o n . Ca ncer 2 0 0 2; 9 4: 5 2 8 -3 8. 
C hil d C G, T urc otte J G. “ S ur ger y a n d p ortal h y perte nsi o n”. I n C hil d C G. T he li ver a n d p ortal h y perte nsi o n. 
P hila del p hia: Sa u n ders . 1 9 6 4. p p. 5 0- 6 4. 
C ha n g B Y, Fra ncesc o M, De R o oij M F, et al. E gress of C D 1 9 + C D 5 + cells i nt o peri p heral bl o o d f oll o wi n g 
treat me nt wit h t h e  B r ut o n t y r osi ne ki nase i n hi bit or i br uti ni b i n ma nt le cell l y m p h o ma patie nts. Bl o o d. 
2 0 1 3a; 1 2 2: 2 4 1 2 - 2 4. 
C ha n g B Y, Fra ncesc o M, Ste g ger da S, et al. I br uti ni b I n hi bits Mali g na nt Cell A d hesi o n a n d Mi grati o n a n d 
Re d uces T u m or B ur de n i n L y m p h N o de a n d B o ne Marr o w i n a M uri ne M o del of Ma ntle C ell 
Disse mi nati o n a n d Pr o gressi o n. 2 0 1 3 b A A C R: A bstract 9 2 3. 
C ha n g B Y, Ma ga dala P, H ua n g, M M, et al. E gress of C D 1 9 + C D 5 + cells i nt o t he Peri p heral Bl o o d 
f oll o wi n g Tr e at me nt wit h Br ut o n T yr osi ne Ki nase I n hi bit or, P CI -3 2 7 6 5, i n Ma ntle Cell L y m p h o ma 
Patie nts, Bl o o d 2 0 1 1; 1 1 8: A bstract 9 5 4. 
C hes o n B D, B yr d J C, Rai K R, et al . N o vel tar gete d a ge nts a n d t he nee d t o  r ef i ne cli nical e n d p oi nts i n 
c hr o nic l y m p h oc ytic le u ke mia . J Cli n O nc ol 2 0 1 2; 2 3: 2 8 2 0 - 2 2. 
C hes o n B D, R u m mel MJ . Be n da m usti ne: re birt h of a n ol d dr u g. J Cli n O nc ol 2 0 0 9; 2 7: 1 4 9 2 – 1 5 0 1. 
C hi orazzi N, Rai K R, Ferrari ni M. C hr o nic l y m p h oc ytic le u ke mia . N E n gl J Me d 2 0 0 5; 3 5 2: 8 0 4 – 8 1 5. 
C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts ( C T C A E), Versi o n 4. 0 3. P u blis he d J u ne 1 4, 2 0 1 0 
Di n g W, Z e nt C S. Dia g n osis a n d ma na ge me nt of a ut oi m m u ne c o m plicati o ns of c hr o nic l y m p h oc ytic 
le u ke mia/ s mall l y m p h oc ytic l y m p h o ma. Cli n A d v He mat ol O nc ol. 2 0 0 7; 5: [ADDRESS_692805] -li ne t hera p y of y o u n ger patie nts wit h c hr o nic l y m p h oc ytic le u ke mia. Bl o o d 2 0 0 6; 1 0 7: 8 8 5 –[ADDRESS_692806] -li ne t h e ra p y wit h fl u dara bi ne c o m pare d wit h 
c hl ora m b ucil d oes n ot r e s ult i n a ma j or be nefit f or el derl y patie nts wit h a d va nce d c hr o nic l y m p h oc ytic 
le u ke mia . Bl o o d 2 0 0 9; 1 1 4: 3 3 8 2 –3 3 9 1. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692807] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7 3 E ur o Q ol Gr o u p. E ur o Q ol -A ne w facilit y f or t he meas ure me nt of healt h -r e late d q ualit y of li f e . Hea lt h 
P olic y. 1 9 9 0; 1 6: 1 9 9 – 2 0 8. 
Fisc her K, Cra m ber P, B usc h R, et al . Be n da m usti ne c o m bi ne d wit h rit u xi ma b i n patie nts wit h rela pse d 
a n d/ or r e fract or y c hr o nic l y m p h oc ytic le u ke mia: a m ultice nter p hase II trial of t he G e r m a n C hr o nic 
L y m p h oc ytic Le u ke m ia St u d y Gr o u p . J Cli n O nc ol. 2 0 1 1; 2 9: [ADDRESS_692808] us c ycl o p h os p ha mi de c o m pare d 
wit h fl u dara bi ne f or patie nts wit h pre vi o usl y u ntreate d c hr o nic l y m p h oc ytic le u ke mia: U S I nter gr o u p Trial 
E 2 9 9 7. J Cli n O nc ol 2 0 0 7; 2 5: 7 9 3 –7 9 8. 
Fli n n I W, B yr d J C, M orris o n C, et al. Fl u dara bi ne a n d c ycl o p h os p ha mi de wit h fil grasti m s u p p ort i n patie nts 
wit h pre vi o usl y u ntreate d i n d ole nt l y m p h oi d mali g na ncies. Bl o o d. 2 0 0 0; 9 6: 7 1 -5. 
Frie d ber g J W, S har ma n J, Sc hae f e r- C utill o J, et al. F osta mati ni b dis o di u m ( F os D), a n oral i n hi bit or of S y k, 
is well -t olerate d a n d has si g nifica nt cli nical acti vit y i n diff use lar ge B -cell l y m p h o ma ( D L B C L) a n d c hr o nic 
l y m p h oc ytic le u ke mia ( S L L/ C L L). Bl o o d. 2 0 0 8; 1 1 2( 1 1). A bstract 3. 
F ur m a n R R, B yr d J C, Br o w n J R, et al. C A L -[ADDRESS_692809] or y c hr o nic l y m p h oc ytic le u ke mia. Bl o o d. 2 0 1 0; 1 1 6 ( 2 1). A bstract 5 5 a n d oral prese ntati o n at: 
A mer ica n S ociet y of He mat ol o g y A n n ual Meeti n g; Dece m ber 4 -7, 2 0 1 0; Orla n d o, F L. 
Gri b be n J G, O’ Brie n S. U p date of t hera p y of c hr o nic l y m p h oc ytic le u ke mia . J Cli n O nc ol 2 0 1 1: 2 9: 5 4 4 –
5 5 0. 
Halle k M. Si g nali n g t h e  e nd of c hr o nic l y m p h oc ytic le u ke mia: ne w fr o ntli ne treat me nt strate gies. Bl o o d. 
2 0 1 3; 1 2 2: 3 7 2 3 - 3 4. 
Halle k M, C hes o n B D, Cat o vs k y D, et al . Res p o nse assess me nt i n c hr o nic l y m p h oc ytic le u ke mia treate d 
wit h n o vel a ge nts ca usi n g a n i ncr ease of p e ri p heral bl o o d ly m p h oc ytes. Bl o o d 2 0 1 2 (letter; p u blis he d 4 
J u ne 2 0 1 2). htt p:// bl o o dj o ur na l. he mat ol o g yli brar y. or g/c o nte nt/ 1 1 1/ 1 2/ 5 4 4 6/re pl y # bl o o dj o ur nal _el _ [ADDRESS_692810] 2 0 1 2 
Halle k M, Fisc her K, Fi n gerle -R o ws o n G, et al. A d diti o n of rit u xi ma b t o fl u dara bi ne a n d c ycl o p h os p ha mi de 
i n patie nts wit h c hr o nic l y m p h oc ytic le u kae mia: A ra n d o mise d, o pe n -la bel, p hase 3 trial. La ncet 2 0 1 0; 3 7 6: 
1 1 6 4 – 1 1 7 4. 
Halle k M, C hes o n B D, Cat o vs k y D, et al . G ui deli nes f or t he dia g n osis a n d treat me nt of c hr o nic l y m p h oc ytic 
le u ke mia: a re p ort fr o m t he I nter nati o nal W or ks h o p o n C hr o nic L y m p h oc ytic L e u ke mia u p dati n g t he 
Nati o nal Ca ncer I nstit ute -W or ki n g Gr o u p 1 9 9 6 g ui deli ne. Bl o o d 2 0 0 8; 1 1 1: 5 4 4 6 –5 4 5 6. 
Her ma n S E, G or d o n A L, Hertlei n E, et al. Br ut o n t yr osi ne ki nase re prese nts a pr o misi n g t hera pe utic tar get 
f or treat me nt of c hr o nic l y m p h oc ytic le u ke mia a n d is effecti vel y tar gete d b y P CI -3 2 7 6 5. Bl o o d. 2 0 1 1; 
1 1 7: [ADDRESS_692811] -li ne t hera p y 
f or c hr o nic l y m p h oc ytic le u ke mia . J Cli n O nc ol 2 0 0 7; 2 5: 5 6 1 6 –5 6 2 3. 
I nter nati o nal C o nfere nce o n Har m o nisati o n (I C H) of Tec h nical Re q uire me nts f or Re gistrati o n of 
P har mace uticals f or H u ma n Us e: I C H Har m o nise d Tri partite G ui deli ne: G ui da nce f or G o o d Cli nical 
Practice (I C H - E 6) ( R 1). J u ne 1 9 9 6 . 
I nter nati o nal C o nfere nce o n Har m o nizati o n (I C H) G ui deli ne f or I n d ustr y: Cli nical Safet y Data 
Ma na ge me nt: Defi niti o ns a n d Sta n dar ds f or E x pe dite d Re p orti n g (I C H -E 2 A). Marc h 1 9 9 5. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692812] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7 4 I n vesti gat o r's Br oc h ure. I br uti ni b. P har mac yclics L L C; Ja nsse n Researc h & De vel o p me nt, L L C. 
K na uf W U, Lissic h k o v T, Al da o u d A, et al. P hase III ra n d o mize d st u d y of be n da m usti ne c o m pare d wit h 
c hl ora m b ucil i n pre vi o usl y u ntreate d patie nts wit h c hr o nic l y m p h oc ytic le u ke mia. J Cli n O nc ol. 2 0 0 9; 2 7: 
4 3 7 8- 8 4. 
L oza ns ki G, Heere ma N A, Fli n n I W, et al . Ale mt uz u ma b is a n effecti ve t hera p y f or c hr o nic l y m p h oc ytic 
le u ke mia wit h p 5 3 m utati o ns a n d deleti o ns . Bl o o d . 2 0 0 4; 1 0 3: 3 2 7 8 - 8 1. 
Nati o nal C o m pre he nsi ve Ca ncer Net w or k ( N C C N). N C C N Cli nical Practice G ui d eli nes i n O nc ol o g y 
( N C C N G ui deli nes) N o n -H o d g ki n’s L y m p h o mas. Versi o n 3. 2 0 1 6. N C C N. or g 
O' Brie n S M, Ka ntarjia n H M, C ortes J, et al. Res ults of t he fl u dara bi ne a n d c ycl o p h os p ha mi de c o m bi nati o n 
re gi me n i n c hr o nic l y m p h oc ytic le u ke mia. J Cli n O nc ol. 2 0 0 1; 1 9: 1 4 1 4- 2 0. 
O’ Brie n S G, G uil h ot F, Lars o n R A, et al . I mati ni b c o m pare d wit h i nterfer o n a n d l o w -d ose c ytara bi ne f or  
ne wl y dia g n ose d c hr o nic -p hase c hr o nic m yel oi d le u ke mia . Ne w E n gl J Me d 2 0 0 3; 3 4 8( 1 1): 9 9 4 –1 0 0 4. 
O' Brie n S, B ur ger J A, Bl u m K A, et al . T he Br ut o n's t yr osi ne ki nase ( B T K) i n hi bit or P CI -[ADDRESS_692813] or y ( R/ R) c hr o nic l y m p h oc ytic le u ke mia/s mall l y m p h oc ytic 
l y m p h o ma ( C L L/ S L L): F oll o w -u p of a P hase I b/II st u d y . Bl o o d 2 0 1 1; 1 1 8: A bstract 9 8 3. 
O ke n, M M, Creec h, R H, T o r me y, D C, et al . T o xicit y a n d r e s p o nse criteria of t he easter n c o o perati ve 
o nc ol o g y gr o u p. A m J Cli n O nc ol 1 9 8 2; 5: 6 4 9 - 6 5 5. 
Pa n Z, Sc heere ns H, Li SJ, et al . Disc o ver y of selecti ve irre versi ble i n hi bit ors f or Br ut o n's t yr osi ne ki nase . 
C he m Me d C he m 2 0 0 7; 2: 5 8 – [ADDRESS_692814] or y B-cell N o n -H o d g ki n L y m p h o ma a n d Us e of a N o vel Fl u or esce nt Pr o be 
P har mac o d y na mic Assa y. Bl o o d ( A S H A n n ual Meeti n g A bst racts) 2 0 0 9; 1 1 4( 2 2): 3 7 1 3. 
P o na n der S, C he n S S, B u g g y J, et al. T he Br ut o n t yr osi ne ki nase i n hi bit or P CI -3 2 7 6 5 t h warts c hr o nic 
l y m p h oc ytic le u ke mia cell s ur vi val a n d tiss ue h o mi n g i n vitr o a n d i n vi v o. Bl o o d 2 0 1 2; 1 1 9: 1 1 8 2 –1 1 8 9. 
P u g h R N, M urra y -L y o n I M, Da ws o n L, et al. “ Tra nsecti o n of t he oes o p ha g us f or blee di n g oes o p ha geal 
varices”. T he Britis h j o ur nal of s ur ger y. 1 9 7 3; 6 0: 6 4 6 -9. 
Rai K R, Peters o n B, A p pel ba u m F R, et al. Fl u dara bi ne c o m pare d wit h c hl ora m b ucil as pri mar y t hera p y f or 
c hr o nic l y m p h oc ytic le u ke mia. N E n gl J Me d 2 0 0 0; 3 4 3: 1 7 5 0 – [ADDRESS_692815] us fl u dara bi ne pr ol o n gs pr o gressi o n -free 
s ur vi val c o m pare d wit h fl u dara bi ne a n d c ycl o p h os p ha mi de al o ne i n pre vi o usl y treate d c hr o nic l y m p h oc ytic 
le u ke mia . J Cli n O nc ol 2 0 1 0; 2 8: 1 7 5 6 – [ADDRESS_692816] ors: A n e vi de nce -base d cli nical practice g ui deli ne 2 0 0 6; 2 4: 3 1 8 7 - 3 2 0 5. 
Ste ve ns o n F K, Kr ys o v S, Da vies AJ, et al. B- cell r e ce pt or si g nali n g i n c hr o nic l y m p h oc ytic le u ke mia. 
Bl o o d 2 0 1 1; 1 1 8: 4 3 1 3 - 4 3 2 0. 
S ur veilla nce E pi [INVESTIGATOR_32450] o g y a n d E n d Res ults ( S E E R), N CI, U S Nati o nal I nstit utes of H e alt h, F ast Stats; 
Statistics Stratifie d b y Ca ncer Site, 2 0 1 0. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692817] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7 5 Yelle n S B, Cell a D F, We bster K, et al . Meas uri n g fati g ue a n d ot her a ne mia -r e late d s y m pt o ms wit h t he 
F u ncti o nal Assess me nt of Ca ncer T hera p y ( F A C T) meas ure me nt s y ste m . J Pai n S y m pt o m Ma na ge. 
1 9 9 7; 1 3: 6 3 - 7 4. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692818] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7 6 1 3. A P P E N DI C E S 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692819] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 7 8 c. Bo ne marr o w bi o ps y a n d /or  as pi[INVESTIGATOR_337] s h o ul d be perf or me d t o c o nfir m c o m plete res p o nse (C R ) or n P R , w he n a p pr o priate, t o e val uate c yt o pe nia . Marr o w 
c ollecte d t o c o nfir m C R s h o ul d ha ve mi ni mal resi d ual disease (M R D) assesse d b y fl o w c yt o metr y o n t he as pi[INVESTIGATOR_337]; patie nts c o nfir me d as M R D -ne gati ve i n 
t he marr o w s h o ul d be f oll o we d a p pr o xi matel y e ver y 6 m o nt hs f or M R D b y peri p heral fl o w c yt o metr y (Secti o n 6. 4. 1 1. 2). Patie nts w h o ha ve M R D -p ositi ve 
stat us i n t he b o ne marr o w, ca n als o be f oll o we d wit h peri p heral bl o o d M R D assess me nts e ver y 4 t o 6 m o nt hs , h o we ver, o nce t he patie nt bec o mes M R D -
ne gati ve i n t he peri p heral bl o o d, t his res ult s h o ul d be s u bse q ue ntl y c o nfir me d wit h a b o ne marr o w M R D assess me nt. 
d. To be c o m plete d bef ore a n y ot her pr oce d ures or p h ysicia n i nteracti o ns; i ncl u des E Q - 5 D- 5 L a n d F A Ci T -Fati g ue i nstr u me nts 
e. O nl y a d verse e ve nts a n d c o nc o mita nt m e dicati o ns o n g oi n g at t he e n d of A E/c o nc o mita nt me dicati o ns re p orti n g peri o d will be f oll o we d -u p t o res ol uti o n. 
f. Patie nts disc o nti n ui n g I P f or reas o ns ot her t ha n P D m ust be m o nit ore d f or alter nati ve a nti -ca ncer treat me nt i ncl u di n g start date a n d reas o n .
g. E ver y 1 2 m o nt hs or earlier if P D is s us pecte d. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692820] u d y, t he f oll o wi n g assess me nts occ ur o n Da y 1 of e ver y 4t h c ycle (ie, C ycles 13, [ADDRESS_692821] u d y ); fr o m C ycle 3 0 o n war d s, t he assess me nts t he n occ ur e ver y 1 2 c ycles (e ver y 1 2 m o nt hs f or pr e -P D f oll o w -
u p) u ntil t he patie n t e x perie nces P D or t he st u d y is cl os e d b y  t he S p o ns or .
c. A d verse e ve nts are rec or de d at desi g nate d st u d y visits, w he n v ol u nteere d b y t he patie nt, a n d w he ne ver t he i n vesti gat or bec o mes a ware of a n e ve nt . All ne w 
mali g na nt t u m ors i ncl u di n g s oli d t u m ors, s ki n mali g na ncies a n d he mat ol o gic mali g na ncies are t o be re p orte d f o r t h e  d urati o n of st u d y treat me nt a n d d uri n g 
a n y  pr ot oc ol -s pecifie d f oll o w -u p peri o ds i ncl u di n g p ost -pr o gressi o n f oll o w -u p f or o verall s ur vi val. 
d. If P D is c o nfir me d a n d t he I W C L L treat me nt g ui deli nes i n dicate t hat ne w a ntica ncer t hera p y is i n dicate d , sec o n d -li ne treat me nt pla n is esta blis he d a n d 
s u bse q ue nt assess me nts are as descri be d i n A p pe n di x D. If P D is n ot c o nfir me d, s u bse q ue nt assess me nts are deter mi ne d b y w het her patie nt is still recei vi n g 
i br uti ni b : 
If t h e  patie nt is still recei vi n g i br uti ni b at t he ti me of t he S us pecte d -P D Visit, s u bse q ue nt assess me nts are descri be d u n der “ Desi g nate d C ycles / D a y 1” 
If t h e  patie nt is n o l o n ger recei vi n g i br uti ni b at t he ti me of t he S us pecte d -P D Visit, s u bse q ue nt assess me nts are descri be d u n der “ Pre -P D F oll o w - u p 
Visits.” i br uti ni b is n ot t o be restarte d i n t hese patie nts. 
e. Visit t hat f oll o ws t he e n d of ra n d o mize d i br uti ni b t hera p y 
f. T his visit pr o vi des f oll o w -u p f or patie nts i n w h o m P D is n ot c o nfir me d b ut w h o were n o l o n ger recei vi n g i b r uti ni b at t he ti me of t he S us pecte d -P D Visit 
(e g, i b r uti ni b was st o p pe d b y t he i n vesti gat or w he n P D was s us pecte d) . U n til [ADDRESS_692822] u d y , pr e- P D F oll o w - u p 
Visits occ ur e ver y  4 m o nt hs after t he E n d -of -Treat me nt Visit f or patie nts w h o( 1) ha d n ot e x perie nce d P D a n d ( 2) ha d i br uti ni b t h e r a p y disc o nti n ue d bef ore 
t he S us pecte d -P D Visit . Starti n g fr o m m o nt h [ADDRESS_692823] u d y cl os ure (i br uti ni b t hera p y is n ot t o 
be restarte d i n t hese patie n ts ). 
g. B o ne marr o w bi o ps y a n d /or  as pi[INVESTIGATOR_337] s h o ul d be perf or me d t o c o nfir m c o m plete res p o nse ( C R) or n P R , w he n a p pr o priate, t o e val uate c yt o pe nia. Marr o w 
c ollecte d t o c o nfir m C R s h o ul d ha ve mi ni mal resi d ual disease ( M R D) assesse d b y fl o w c yt o metr y o n t he as pi[INVESTIGATOR_337]; patie nts c o nfir me d as M R D -ne gati ve i n 
t he marr o w s h o ul d be f oll o we d a p pr o xi matel y e ver y 6c y cles f or  M R D b y peri p heral fl o w c yt o metr y (see Secti o n 6. 4. 1 1. 2 ). Patie nts w h o ha ve M R D -
p ositi ve stat us i n t he b o ne marr o w, ca n als o be f oll o we d wit h p eri p heral bl o o d M R D assess me nts e ver y 4 t o 6 c y cles , h o we ver, o nce t he patie nt bec o mes 
M R D -ne gati ve i n t he peri p heral bl o o d, t his res ult s h o ul d be s u bse q ue ntl y c o nfir me d wit h a b o ne marr o w M R D assess me nt. 
h. T o be c o m plete d bef ore a n y ot her pr oce d ures or p h ys icia n i nteracti o ns; i ncl u des E Q - 5 D- 5 L a n d F A Ci T -Fati g ue i nstr u me nts .
i. I ncl u des f oc use d oc ular q uesti o ns ( n ot re q uire d f or pre -P D) .
j. Patie nts disc o nti n ui n g I P f or reas o ns ot her t ha n P D m ust be m o nit ore d f or alter nati ve a nti -ca ncer treat me nt i ncl u di n g start date, reas o n, d ur ati o n ,a n d 
res p o nse .
k. O nl y a d verse e ve nts a n d c o nc o mita nt me dicati o ns o n g oi n g at t he e n d of A E/c o nc o mita nt me dicati o ns re p orti n g peri o d will be f oll o we d -u p t o res ol uti o n. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692824] be m o nit ore d f or alter nati ve a nti -ca ncer treat me nt i ncl u di n g d urati o n a n d res p o nse .
p. O nl y a d verse e ve nts a n d c o nc o mita nt me dicati o ns o n g oi n g at t he e n d of A E/c o nc o mita nt me dicati o ns re p orti n g peri o d will be f oll o we d -u p t o res ol uti o n. 
After i m ple me ntati o n of Pr ot oc ol A me n d me nt [ADDRESS_692825] u d y (ie, ot her t ha n St u d y P C Y C - 1 1 1 6- C A) ma de a vaila ble f or acti ve patie nts w h o c h o ose t o c o nti n ue o n 
i br uti ni b o n a cli nical pr ot oc ol w he n access t o c o m mercial i br uti ni b is n ot feasi ble. 
I n or der t o mi ni mize or a v oi d treat me nt i nterr u pti o ns, t he patie nts o n sec o n d -li ne i br uti ni b o pti n g t o m o ve t o a n ot her l o n g -ter m e xte nsi o n st u d y, ma y be all o we d 
t o c o nti n ue treat me nt wit hi n t his st u d y f or a li mite d ti me bef ore tra nsiti o ni n g t o t he ot her st u d y. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692826] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 8 5 A p pe n di x E. Defi niti o ns of Res p o nse (H alle k 2 0 0 8 )
C o m plete Res p o nse ( C R) 
All o f t h e f ol l o wi n g are re q uire d f or a C R: 
N o si g nifica nt l y m p ha de n o pat h y  ( > 1. 5 c m ) b y C T or pal pa ble o n e xa mi nat i o n (if n ot 
sca n na ble) 
N o he pat os ple n o me g al y  b y C T 
N o c o nstit uti o nal s y m pt o ms ,defi ne d as: n o fe ver > 3 8º C f or ≥ [ADDRESS_692827] i o n, n o u ni nte nt i o nal ≥ 1 0 % b o d y  wei g ht l oss wi t hi n last 6 m o nt hs, n o ni g ht s weats f or 
> [ADDRESS_692828] i o n, a n d n o fati g ue ( E C O G perf or m a nce sc ore ≥ 2) 
i nt erf eri n g wi t h  w or k or us ual  acti vit ies 
A N C > 1 5 0 0/ L, pl at el ets > 1 0 0, 0 0 0/ L, a n d he m o gl o bi n > 1 1. 0 g/ d L 
L y m p h oc y te c o u nt <4. 0 x 1 0 9/ L 
Marr o w as pi[INVESTIGATOR_337] a n d / or bi o ps y m ust be perf or me d after all ot her criteria meet t he defi nit i o n o f 
C R . T o defi ne a C R, t he marr o w sa m ple m ust be at least n or m ocell ular f or a ge, wit h < 3 0 % of 
n ucleate d cells bei n g l y m p h oc y t es . B- l y m p h o i d n o d ules s h o ul d be a bse nt . I n a d dit i o n, i n pat ie nt s 
w h o meet t he C R criteria, M R D b y fl o w c yt o met r y s h o ul d be perf or me d t o e val uate M R D stat us. 
C o m plete Res p o nse wit h a n I nc o m plete M arr o w Rec o ver y ( C Ri) 
C Ri  i s defi ne d as a C R wit h a n i nc o m p lete r ec o ver y o f t h e pati e nt’s b o ne marr o w . B o ne marr o w 
m ust be h y p ocell ular . Patie nts w h o ha ve a C Ri f ulfill criteria f or a C R, b ut c o nti n ue t o ha ve 
persiste nt a ne mia, t hr o m b oc y t o p e ni a, or ne utr o pe nia d ue t o dr u g t o xi ci t y  i n t he b o ne marr o w a n d 
n ot d ue t o a n y  e vi de nce of C L L. 
N o d ul ar P arti al Res p o nse ( n P R) 
N o d ul ar parti al res p o nse ( n P R) is a res p o nse w here patie nts meet criteria f or a C R, b ut t he b o ne 
marr o w bi o ps y  s h o ws t hat t here are still B -l y m p h oi d n o d ules prese nt . T hese n o d ules are resi d ual 
di sease a n d t her ef ore t he pati e nt is ter m e d a n n P R. 
P arti al Res p o nse ( P R) 
At  least t w o of t he Cate g or y  A  para m et ers m ust be met; wi t h  o ne e xce pt i o n: s u bjects w h o o nl y  
ha ve a b n or m al  l y m p h n o des at baseli ne. F or t his e xce pt i o n, s u bjects will o nl y  n e e d t o m eet t he 
l y m p h n o de res p o nse criteria. 
≥ 5 0 % decrease i n t he s u m pr o d ucts of u p t o 6 l y m p h n o des, b y C T or, if o nl y o ne 
meas ura ble l y m p h n o de at baseli ne, a ≥ 5 0 % decrease i n t he l o n gest dia meter of t he si n gle 
l y m p h n o de b y C T A N D n o i ncrease i n a n y  ot her l y m p h n o de b y C T . N ote: I n a s mall l y m p h 
n o de < 2 c m, a n i ncrease o f < 2 5 % i s n ot c o nsi dere d t o be si g nifica nt. 
N o ne w e nlar ge d l y m p h n o des b y C T or p h ysical e xa mi nat i o n 
≥ 5 0 % decrease i n t he e nlar ge me nt of s plee n a n d/ or li ver size fr o m baseli ne or n or malizat i o n 
b y C T 
If a b n or m al  at baseli ne, a ≥ 5 0 % dr o p i n l y m p h oc yte c o u nt fr o m baseli ne or ≤ 4. 0 x 1 0 9/ L 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692829] or s u p p ort or 
tra nsf usi o n * If all criteria are n or mal at baseli ne, t he y m ust re mai n n or mal t o be c o nsi dere d a 
P R: 
A N C > 1 5 0 0/ μ L, or ≥ 5 0 % i m pr o ve me nt o ver baseli ne 
Pl at el ets > 1 0 0, 0 0 0/ μ L, or ≥ 5 0 % i m pr o ve me nt o ver baseli ne 
H e m o gl o bi n > 1 1. 0 g/ d L ,or ≥ 5 0 % i m pr o ve me nt o ver baseli ne 
* N ote: F or a criteri o n t o be c o nsi dere d a res p o nse, it m ust ha ve bee n e val ua ble at baseli ne. 
P R wit h L y m p h oc yt osis 
If a b n or m al  l y m p h oc y te c o u nt at baseli ne a n d res p o nse crit eria ( ≥ 5 0 % dr o p i n l y m p h oc y te c o u nt 
fr o m baseli ne or ≤ 4. 0 x 1 0 9/ L) has n ot bee n met a n d patie nt res p o n ds i n o nl y o ne ot her 
Cate g or y . A para meter bel o w, t he n t he res p o nse is c o nsi dere d P R L. 
≥ 5 0 % decrease i n t he s u m pr o d ucts of u p t o 6 l y m p h n o des b y C T or, if o nl y o ne meas ura ble 
l y m p h n o de at baseli ne, a ≥ 5 0 % decrease i n t he l o n gest dia meter of t he si n gle l y m p h n o de 
b y C T A N D n o i ncrease i n a n y  ot her l y m p h n o de b y  C T. N ote: I n a s m all l y m p h n o de 
< 2 c m, a n i ncrease of < 2 5 % is n ot c o nsi dere d t o be si g ni fica nt. 
N o ne w e nlar ge d l y m p h n o des b y C T or p h ysical e xa mi nat i o n. 
≥ 5 0 % decrease i n t he e nlar ge me nt of li ver a n d/ or s plee n size fr o m  baseli ne or n or malizat i o n 
b y C T. 
Pl us a res p o nse i n at least o ne of  t h e f ol l o wi n g cri t eri a i n de pe n de nt of gr o wt h fact or s u p p ort or 
tra nsf usi o n. * If all criteria are n or mal at baseli ne, t he y  m ust r e m ai n n or m al t o be c o nsi dere d a 
P R: 
A N C > 1 5 0 0/ μ L or ≥ 5 0 % i m pr o ve me nt o ver baseli ne 
Pl at el ets > 1 0 0, 0 0 0/ μ L or ≥ 5 0 % i m pr o ve me nt o ver baseli ne 
H e m o gl o bi n > 1 1. 0 g/ d L ,or ≥ 5 0 % i m pr o ve m e nt o ver baseli ne 
* N ote: F or a criteri o n t o be c o nsi dere d a res p o nse, it m ust ha ve bee n e val ua ble at baseli ne .
St a ble Dise ase 
N ot meet i n g criteria f or C R, C Ri, n P R, P R, P R wit h l y m p h oc yt osis, or pr o gressi ve disease 
Pr o gressi ve Dise ase 
At  least O N E of  f ol l o wi n g: 
Ne w e nlar ge d n o des > 1. [ADDRESS_692830] e n o me gal y 
≥ 5 0 % i ncrease fr o m na dir i n e xist i n g l y m p h n o de ( m ust reac h > 1. [ADDRESS_692831] 
di a meter) or ≥ 5 0 % i ncrease fr o m na dir i n s u m of pr o d uct of dia meters of m ult i ple n o des 
≥ 5 0 % i ncrease fr o m na dir i n e nlar ge me nt of li ver or s plee n 
≥5 0 % i ncrease fr o m t he na dir c o u nt if c o nfir me d b y ce ntral la b o n ≥2 seri al  assess me nts if 
t h e A L C i s ≥3 0, 0 0 0/ µ L a n d l y m p h oc y te d o u bli n g ti me is ra pi d, u nless c o nsi dere d treat me nt 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692832] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 8 7 r el ate d l y m p h oc yt osi s Ne w c y t o pe nia ( he m o gl o bi n or pl at el ets) attri b uta ble t o C L L . T he 
pr o gressi o n of a n y c y t o pe nia ( u nrelate d t o a ut oi m m u ne c y t o pe nia or blee di n g), as 
d oc u m e nte d b y  a decrease of he m o gl o bi n le vels fr o m  baseli ne b y m o re t ha n 2 g/ dL or t o 
<1 0. 0 g/ dL, or b y a decrease o f pl at el et c o u nts fr o m baseli ne b y m o re t ha n 5 0 % or t o 
<1 0 0 , 0 0 0/ Li n t he prese nce of acti ve C L L defi nes di sease pr o gressi o n . W he n a p plica ble, a 
marr o w bi o ps y  s h o ul d d e m o n strate a n i nfiltrate of cl o nal C L L cells. 
U ne q ui v ocal pr o gressi o n f or n o n- tar get lesi o ns 
Tra nsf or mat i o n t o a m ore a g gressi ve hist ol o g y  ( e g, Ri c hter's S y n dr o me) . W he ne ver p ossi ble, 
t hi s dia g n osis s h o ul d be esta blis he d b y l y m p h n o de bi o ps y. 
S us pecte d pr o gressi ve disease m ust be c o nfir me d b y a serial e xa mi nat i o n at l east [ADDRESS_692833] i ve 
e vi de nce of disease t hat is i de ntifie d b y  r a di ol o gi c al  i ma gi n g, p h ysical e xa mi nat i o n, or ot her 
pr oce d ures, as a p pr o priate, i ncl u di n g peri p heral bl o o d c o u nts. 
Tre at me nt -rel at ed L y m p h oc yt osis 
Treat me nt -relate d l y m p h oc yt osis is defi ne d as a n ele vat i o n i n bl o o d l y m p h oc y te c o u nt of ≥5 0 % 
c o m pare d wi t h  b aseli ne t hat occ urs i n t he setti n g of u ne q ui v ocal i m pr o ve me nt i n at least 1ot her 
di sease -relate d para meter i ncl u di n g l y m p h n o de size, s plee n size, he mat ol o gic para meters 
( he m o gl o bi n a n d platelet c o u nt), or disease -relate d s y m pt o m s. Treat m e nt -relate d l y m p h oc yt osis 
is is o lat e d l y m p h oc y t osi s occ urri n g w he n n o ot her criteria f or pr o gressi ve disease are met . I n t his 
parti c ular st u d y , i t will n ot be c o nsi dere d pr o gressi ve disease . T his is s u p p orte d b y  t h e m ost 
rece nt versi o n of t he N C C N N H L 2 0 1 6g ui deli nes. 
Ric hter’s Tr a nsf or m ati o n 
Ri c hter's s y n dr o m e is l y m p h o mat o us tra nsf or m at i o n t o a m o re a g gressi ve hist ol o g y i n a pat ie nt  
wi t h  C L L or S L L a n d is m ost ofte n c haracterize d b y  t he de vel o p m e nt of  hi g h -gra de N H L or 
H o d g ki n’s disease . S y m pt o ms of Ric hter’s tra nsf or mat i o n ca n i ncl u de ne w or pr o gressi ve 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692834] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 8 8 l y m p ha de n o pat h y  or or ga n o m e gal y , fe ver, l oss of wei g ht a n d m uscle m ass, a n d ot her healt h 
pr o bl e ms . Ri c hter's tra nsf or m ati o n ca n be s u g geste d b y  a C T/ P E T sca n, b ut m ust be c o nfir me d 
wi t h  a bi o ps y (ie, l y m p h n o de) de m o nstrati n g t he hist ol o gic tra nsf or mat i o n. 
Mi ni m al Resi d u al Dise ase ( M R D) 
M R D is de fi ne d as < 1 C L L cell per 1 0, 0 0 0 le u k oc y tes, as assesse d b y  fl o w c y t o m etr y  of  a b o ne 
marr o w as pi[INVESTIGATOR_337] a n d /or bi o ps y or peri p heral bl o o d sa m ple . Patie nts w h o ac hie ve a c o m plete 
res p o nse ( C R) s h o ul d be e val uate d f or era diat i o n of disease cells as deter mi ne d b y fl o w 
c y t o m etr y  o n t he b o ne m arr o w as pi [INVESTIGATOR_20325] i o n w he n a vaila ble . P ati e nts w h o ac hie ve M R D -ne gati ve 
re missi o n i n t he b o ne marr o w ma y  t he n be f oll o w e d b y  peri p heral  bl o o d M R D a p pr o xi matel y  
e ver y 6c y cles de pe n di n g o n t heir visit sc he d ule . P ati e nts w h o ha ve M R D -p osi ti ve stat us i n t he 
b o ne marr o w, ca n als o be f o ll o we d wi t h  p eri p heral bl o o d M R D assess me nts, h o we ver, o nce t he 
pati e nt bec o m es M R D -ne gat i ve i n t he peri p heral bl o o d, t his res ult s h o ul d be s u bse q ue nt l y 
c o nfir me d wit h a m arr o w M R D assess me nt .
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692835] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 8 9 A p pe n di x F. Criteri a f or Res p o nse C ate g ories 
P ar a meter C R P R P D 
Gr o u p A 
L y m p ha de n o pat h y aN o ne; ≤ 1. 5c m Decrease ≥ 5 0 % i ncr ease ≥ 5 0 % 
He pat o me gal y N o ne Decrease ≥ 5 0 % i ncr ease ≥ 5 0 % or ne w 
he pat o me gal y 
S ple n o me gal y N o ne Decrease ≥ 5 0 % i ncr ease ≥ 5 0 % or ne w 
s ple n o me gal y 
Bl o o d l y m p h oc ytes < 4 0 0 0/ µ L Decrease ≥ 5 0 % fr o m 
baseli ne i ncr ease ≥ 5 0 % o ver 
baseli ne c
Marr o w bN or m ocell ular, 
< 3 0 % l y m p h oc ytes, 
n o B l y m p h oi d n o d ules. 
H y p ocell ular defi nes C Ri 
Gr o u p B 
Platelet c o u nt > 1 0 0, 0 0 0/ µ L > 1 0 0, 0 0 0/ µ L or i ncrease 
≥ 5 0 % o ver baseli ne Decrease of ≥ 5 0 % fr o m 
baseli ne sec o n dar y t o 
C L L 
He m o gl o bi n > 1 1 g/ d L > 1 1 g/ d L or i ncrease 
≥ 5 0 % o ver baseli ne Decrease of > 2 g/ d L fr o m 
baseli ne sec o n dar y t o 
C L L 
Ne utr o p hils > 1 5 0 0/ µ L > 1 5 0 0/ µ L or i ncrease 
≥ 5 0 % o ver baseli ne N/ A 
aS u m of t he pr o d ucts of m u lti ple l y m p h n o des (as e val uate d b y C T sca ns) or t he l o n gest dia meter of o ne 
tar get l y m p h n o de 
bT his para meter is n ot rele va nt f or t he P D cate g or y u nless c o nfir mi n g c yt o pe nic pr o gressi o n. 
cS u bjects wit h treat me nt -r e late d l y m p h oc yt osis s h o ul d re mai n o n st u d y treat me nt i n t he a bse nce of ot her 
criteria f or pr o gressi ve disease (see S e cti o n 7. 2 ). F or s u bjects wit h o ut treat me nt -r e late d l y m p h oc yt osis, 
P D b y l y m p h oc yte c o u nt ca n be c o nsi dere d base d o n ≥5 0 % i ncrease fr o m t he na dir c o u nt if c o nfir me d 
b y ce ntral la b o n ≥2 serial assess me n ts if t he A L C is ≥3 0, 0 0 0 / µ L a n d l y m p h oc yte d o u bli n g ti me is 
ra pi d. 
N ote: Gr o u p A defi nes t he t u m or l oa d a n d Gr o u p B defi nes t he f u ncti o n of t he he mat o p oietic s yste m .
C R: all of t he criteria nee d t o be met a n d s u bjects ha ve t o lac k disease relate d c o nstit ut i o nal s y m pt o ms. 
B o ne ma rr o w a n d as pi[INVESTIGATOR_533438] q uire d t o c o nfir m C R. 
P R: At least t w o of t he Gr o u p A para meters m ust be met; wit h t w o e xce pti o ns: 1) s u bjects w h o o nl y ha ve 
a b n or ma l l y m p h n o des at baseli ne, or 2) s u bjects w h o ha ve o nl y a b n or mal l y m p h n o de a n d a b n or mal 
l y m p h oc yte c o u nt ( A L C) at baseli ne. F or t hese t w o e xce pti o ns, s u bjects will o nl y nee d t o meet t he l y m p h 
n o de res p o nse criteria. 
I n a d diti o n t o t he Gr o u p A criteria, all s u bjects m ust als o ha ve a res p o nse i n at least o ne of t he Gr o u p B 
criteria. 
S D: t he a bse nce of P D a n d t he fail ure t o ac hie ve a res p o nse. 
P D: at least [ADDRESS_692836] ol o g y .
Cr oss refere nce:  Halle k 2 0 0 8 , Halle k 2 0 1 2 , Halle k 2 0 1 3 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692837] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 0 A p pe n di x G. I n hi bit ors a n d I n d ucers of C Y P 3 A 
I n hi bit ors a n d i n d ucers of C Y P 3 A are defi ne d as f oll o ws . Refer t o Secti o n 5. 5. 2. 1 o n i nstr ucti o ns f or 
c o nc o mita nt use of C Y P 3 A i n hi bit ors or i n d ucers wit h i br uti ni b .F urt her i nf or m ati o n ca n be f o u n d at t he 
f oll o wi n g we bsite: htt p:// me dici ne.i u p ui.e d u/cli n p har m / d dis/ m ai n -ta ble/. 
I n hi bit ors of C Y P 3 A I n d ucers of C Y P 3 A 
Str o n g i n hi bit ors: car ba maze pi [INVESTIGATOR_050] 
i n di na vir efa vire nz 
nelfi na vir ne vira pi [INVESTIGATOR_533439] o na vir bar bit urates 
clarit hr o m yci n gl uc oc ortic oi ds 
itrac o naz ole m o dafi nil 
ket oc o naz ole o xcar barze pi [INVESTIGATOR_533440] o d o ne p he n o bar bital 
sa q ui na vir p he n y t oi n 
s u b o x o ne pi o glitaz o ne 
telit hr o m yci n rifa b uti n 
c o bicistat rifa m pi n 
b oce pre vir St. J o h n’s W ort 
mi befra dil tr o glitaz o ne 
tela pre vir 
tr olea n d o m yci n 
p osac o naz ole a
M o der ate i n hi bit ors: 
a pre pi[INVESTIGATOR_55501] 
a m pre na vir 
a mi o dar o ne 
ataza na vir 
ci pr ofl o xaci n 
criz oti ni b 
dar u na vir 
dr o ne dar o ne 
er yt hr o m yci n 
diltiaze m 
fl uc o naz ole 
f osa m pre na vir 
gra pefr uit j uice 
Se ville ora n ge j uice 
vera pa mil 
v oric o naz ole b
i mati ni b 
We a k i n hi bit ors: 
ci meti di ne 
fl u v o xa mi ne 
All ot her i n hi bit ors: 
c hl ora m p he nic ol 
dela viri di ne 
diet h yl -dit hi ocar ba mate 
gest o de ne 
mife prist o ne 
n orfl o xaci n 
n orfl u o xeti ne 
star fr uit 
aBase d o n P B P K si m ulati o ns, u p t o 9. 7- f ol d i ncrease i n A U C a n d 6. [ADDRESS_692838] u d y, if i br uti ni b nee ds t o be a d mi nistere d wit h v oric o naz ole, 1 4 0 
m g i br uti ni b will be d ose d. 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692839] at us E aster n C o o per ati ve O nc ol o g y Gr o u p ( E C O G) Perf or m a nce St at us a
0 F ull y  acti ve, a ble t o carr y o n all pre -disease perf or ma nce wit h o ut restricti o n. 
1Restricte d i n p h ysicall y stre n u o us acti vit y b ut a m b ulat or y a n d a ble t o carr y o ut w or k of a li g ht or se de ntar y 
nat ure, e g, li g ht h o use w or k, office w or k. 
2A m b ulat or y a n d ca pa ble of all self -care, b ut u na ble t o carr y o ut a n y w or k acti vities . U p a n d a b o ut m ore t ha n 
5 0 % of wa ki n g h o urs. 
3 Ca pa ble of o nl y li mite d self -care, c o nfi ne d t o be d or c hair m ore t ha n 5 0 % of wa ki n g h o urs. 
4 C o m pletel y disa ble d . Ca n n ot carr y o n a n y self -care . T otall y c o nfi ne d t o be d or c hair. 
5 Dea d. 
aO ke n, M M, Creec h, R H, T or me y, D C, et al . T o xicit y a n d res p o nse criteria of t he easter n c o o perati ve o nc ol o g y gr o u p. 
A m J Cli n O nc ol 1 9 8 2; 5: 6 4 9 - 6 5 5. 
S o urce : htt p:// w w w.ec o g. or g/ ge neral/ perf _stat ht ml ; a ccesse d 0 4 Ja n uar y 2 0 0 8 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692840] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 2 A p pe n di x I. H e m at ol o gic A d verse E ve nt Gr a di n g Sc he me ( H alle k 2 0 0 8 )
A n e val uat i o n of t he he mat ol o gic t o xicit y i n pat ie nts wi t h  a d va nce d C L L/ S L L m ust c o nsi der t he 
hi g h fre q ue nc y of marr o w i n v o l ve me nt a n d pre vi o us e x p os ure t o c he m ot hera p y  wi t h  c o nse q ue nt 
me d ullar y  c o m pr o mise at t he i nit iati o n of  t hera p y . T he sta n dar d he mat ol o gic gra di n g s yste m f or 
s oli d t u m ors ca n n ot, t heref ore, be direct l y a p plie d . A s u bsta ntial pr o p orti o n of pat ie nt s w o ul d be 
c o nsi dere d t o ha ve Gra de 2 t o 4 he mat ol o gic t o xicit y  b ef ore a n y  t hera p y is gi ve n . T heref ore, t he 
f o ll o wi n g m o difie d sc he ma will be use d t o q ua ntitate he mat ol o gic deteri orati o n i n pat ie nt s wi t h  
C L L/ S L L. 
He m at ol o gic Gr a di n g Sc he me 
Decre ase i n Pl atelets or H g b ( N a dir) fr o m 
Pre -tre at me nt V al ue, % A N C/ μ L ( n a dir) cT o xicit y Gr a de 
0 -1 0 % a≥ 2 0 0 0 0
1 1 -2 4 % a, b ≥ 1 5 0 0 a n d < 2 0 0 0 1
2 5 -4 9 % a, b ≥ 1 0 0 0 a n d < 1 5 0 0 2
5 0 -7 4 % a, b ≥ 5 0 0 a n d < 1 0 0 0 3
7 5 % a, b < 5 0 0 4
a. If at a n y  le vel of decrease, t he platelet c o u nt falls bel o w 2 0 x 1 0 9/ L, t o xicit y will be c o nsi dere d Gra de 4. If t he 
baseli ne platelet c o u nt is < 2 0 x 1 0 9/ L, platelet t o xicit y ca n n ot be e val uate d. 
b. Baseli ne a n d s u bse q ue nt H g b val ues m ust be deter mi ne d t he da y of a n y  gi ve n tra nsf usi o n. 
c. If t he A N C was < 1 0 0 0/ µ L bef ore t hera p y, t he patie nt is n ot e val ua ble f or t o xicit y refera ble t o t he A N C 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692841] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 3 A p pe n di x J. E Q - 5 D- 5 L 
 
 
     
            
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692842] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 4               
 
       
       
       
       
      
 
        
        
        
        
        
        
    
        
        
        
        
        
  
      
      
      
      
      
  
      
      
      
      
      
 
                 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692843] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 5              
 
        
         
        
              
             
  
    
 
                   
   
 
   
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692844] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 6 A p pe n di x K. F A Ci T - F ati g ue 
       
                        
                   
      
        
        
       
             
                
     
           
           
          
            
                      
 
                    
  
    
  
 
 
 
 
 
 
 
 
 
 
 
 
    
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
I M B R U VI C A ®(i br uti ni b) Pr ot oc ol P C Y C - [ADDRESS_692845] 2 0 2 2 
FI N A L 
P har mac yclics L L C Pr o prietar y a n d C o nfi de ntial Pa ge 9 7 A p pe n di x L. C hil d -P u g h  Sc ore f or S u bjects wit h Li ver I m p air me nt *
( * C hil d - P u g h Sc ore t o be use d o nly i n s u bjects wit h c hr o nic liver dise ase) 
Me as ure 1 p oi nt 2 p oi nts 3 p oi nts 
T otal bilir u bi n, μ m ol/ L ( m g/ d L) < 3 4 ( < 2) 3 4- 5 0 ( 2 -3) > 5 0 ( > 3) 
Ser u m al b u mi n, g/ L ( g/ d L) > 3 5 ( > 3. 5) 2 8- 3 5 ( 2. 8 -3. 5) < 2 8 ( < 2. 8) 
P T/I N R < 1. 7 1. 7 1- 2. 3 0 > 2. 3 0 
Ascites N o ne Mil d M o derate t o Se vere 
He patic e nce p hal o pat h y N o ne Gra de I -II ( or s u p presse d 
wit h me dicati o n) Gra de III -I V 
( or refract or y) 
P oi nts Cl ass 
5- 6 A
7- 9 B
1 0- 1 5 C
S o urce: 
1. C hil d C G, T urc otte J G. “ S ur ger y a n d p ortal h y perte nsi o n”. I n C hil d C G. T he li ver a n d p ortal h y perte nsi o n. 
P hila del p hia: Sa u n ders . 1 9 6 4. p p. 5 0 - 6 4 . 
2. P u g h R N, M urra y -L y o n I M, Da ws o n L, et al. “ Tra nsecti o n of t he oes o p ha g us f or blee di n g oes o p ha geal 
varices” . T he Britis h j o ur nal of s ur ger y, 1 9 7 3; 6 0: 6 4 6 - 9. 
‡N ote: sec o n d -li ne i br uti ni b is n ot a p plic a ble after i m ple me nt ati o n of Pr ot oc ol A me n d me nt 3 .
 
 
Pr ot oc ol/ Pr ot oc ol A me n d me nt A p pr o v al F or m F or m N o.: F O R M- 0 3 4 5. 2 
Effecti ve D ate:  2 5 J a n 2 0 1 9 
G o ver ni n g D oc:  WI- 0 1 3 9 
P a ge:  1 of 2 
C o nfi de nti al  T his i nf or mati o n is c o nfi de ntial t o P har mac yclics, a n A b b Vie C o m pa n y  T he user is r es p o nsi ble f or usi n g t he a p pr o priate re visi o n of t his d oc u me nt  Pr ot oc ol/ Pr ot oc ol A me n d m e nt A p pr o v al F or m 
D ate circ ul ate d f or re vie w :  1 6- Se p- 2 0 2 2  
 
P ur p ose :  Pr ot oc ol A m e n d me nt  
 
St u d y N u m ber :  P C Y C- 1 1 1 6 -C A 
Pr ot oc ol Versi o n d ate ( D D M M M Y Y Y Y):  [ADDRESS_692846] o ber 2 0 2 2 
  Ori gi n al 
  A me n d me nt – Versi o n # 4 
Pr ot oc ol Title:  A n O p e n-la bel E xte nsi o n St u d y i n Patie nts 6 5 Years or Ol der wit h C hr o nic L y m p h oc ytic Le u ke mia ( C L L) or S mall 
L y m p h oc ytic L y m p h o ma ( S L L) W h o Partici pate d i n St u d y P C Y C- 1 1 1 5- C A (I br uti ni b v ers us C hl ora m b ucil)  
Ple ase i n dic ate t h at y o u h a ve re vie we d a n d a p pr o ve t he d oc u me nt liste d a b o ve b y si g ni n g a n d d ati n g bel o w.  
A p pr o v al Si g n at ures 
N a me Si g n at ure A p pr o v al D ate 
Cli nic al Scie nce  N A 
 
   
Cli nic al O per ati o ns   N A 
 
   
Dr u g S afety & P h ar m ac ovi gil a nce  N A 
 
   
Bi o metrics   N A 
 
   
1 0/ 1 0/ 2 2  
   
 
 
Pr ot oc ol/ Pr ot oc ol A me n d me nt A p pr o v al F or m F or m N o.: F O R M- 0 3 4 5. 2 
Effecti ve D ate:  2 5 J a n 2 0 1 9 
G o ver ni n g D oc:  WI- 0 1 3 9 
P a ge:  2 of 2 
C o nfi de nti al  T his i nf or mati o n is c o nfi de ntial t o P har mac yclics, a n A b b Vie C o m pa n y  T he user is r es p o nsi ble f or usi n g t he a p pr o priate re visi o n of t his d oc u me nt  A p pr o v al Si g n at ures 
N a me Si g n at ure A p pr o v al D ate 
Re g ul at ory Aff airs   N A 
 
    
Rese arc h   N A 
 
        
Cli nic al P h ar m ac ol o gy   N A 
 
        
P R C C h air m a n   N A 
 
        
  
   
 
 
Pr ot oc ol/ Pr ot oc ol A me n d me nt A p pr o v al F or m F or m N o.: F O R M- 0 3 4 5. 2 
Effecti ve D ate:  2 5 J a n 2 0 1 9 
G o ver ni n g D oc:  WI- 0 1 3 9 
P a ge:  [ADDRESS_692847] or y 
D C R Re v C h a n ge Descri pti o n 
9 8 4 8 0 Ne w F or m. 
1 0 4 6 3 1 A d diti o n of Pr ot oc ol date a n d versi o n. 
2 1 4 1 1 2 Ref or mat si g nat ure ta ble t o ma ke r o o m f or D oc u Si g n electr o nic si g nat ure c o nfir mati o ns. 
  
   